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Abstract
Two innovative radiotherapy (RT) approaches are under development at the ID17 Biomed-
ical Beamline of the European Synchrotron Radiation Facility (ESRF): microbeam radiation
therapy (MRT) and minibeam radiation therapy (MBRT). The two main distinct character-
istics with respect to conventional RT are the use of submillimetric field sizes and spatial
fractionation of the dose. This PhD work deals with different features related to small-field
dosimetry involved in these techniques. Monte Carlo (MC) calculations and several experi-
mental methods are used with this aim in mind. The core of this PhD Thesis consisted of the
development and benchmarking of an MC-based computation engine for a treatment plan-
ning system devoted to MRT within the framework of the preparation of forthcoming MRT
clinical trials. Additional achievements were the definition of safe MRT irradiation protocols,
the assessment of scatter factors in MRT, the further improvement of the MRT therapeutic
index by injecting a contrast agent into the tumour and the definition of a dosimetry protocol
for preclinical trials in MBRT.
Keywords: microbeam radiation therapy, minibeam radiation therapy, small-
field dosimetry, Monte Carlo simulation, treatment planning system, dosimetry
protocols, clinical trials, synchrotron radiation
Immaculada Martínez-Rovira
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Preface
Radiotherapy (RT) is the use of ionising radiation to treat cancer or other types of benign
lesions. Along with surgery and chemotherapy, RT is one of the most effective methods for
cancer treatment. Furthermore, around 70% of all cancer patients will receive RT at some
stage during the course of their illness [IAEA-TRS-461 2008]. Since radiation does not attack
cancer cells specifically, it also produces deleterious effects in the surrounding healthy tissue.
Despite intensive research and development during the last few decades, there are still some
radioresistant tumours for which radical treatment is not feasible at hospitals. In the quest
for ways to improve the therapeutic index for such tumours, new approaches have been
explored. Intensity-modulated radiation therapy (IMRT), hadrontherapy and synchrotron
radiation therapies are some examples.
Within this context, three new RT techniques are under development at the ID17 Biomedi-
cal Beamline of the European Synchrotron Radiation Facility (ESRF): synchrotron stereotactic
radiation therapy (SSRT), microbeam radiation therapy (MRT) and, more recently, minibeam
radiation therapy (MBRT). The last two techniques possess very distinct features with respect
to conventional RT methods. They combine submillimetric field sizes and spatial fractiona-
tion of the dose. The resulting biological effects appear to challenge many of the current
paradigms in RT. Remarkable healthy tissue resistance to very high doses in one fraction was
observed in several MRT biological investigations performed during the last two decades. In
addition, MRT rendered significant tumour growth delay and, in some cases, complete tu-
mour ablation. The success of the preclinical studies has paved the way for clinical trials,
which are currently in preparation at the ESRF. The first step includes the treatment of large
animals as a milestone before implementation in human beings.
Thin microbeams (and their associated small beam spacing) demand high dose rates,
which are nowadays only available at synchrotrons. Since microbeams are closely packed,
it is important that the patient does not move during irradiation. Even cardiosynchronous
motion effects might be an issue. The therapeutic dose should thus be delivered in a fraction
of a second. The thicker beams employed in MBRT might represent a compromise between
having high tissue sparing and the ease of implementing this technique with cost-effective
equipment at hospitals. For this reason, a new method to produce minibeam patterns was
recently developed and tested at the ESRF Biomedical Beamline. The different beam widths
and spacings used in MRT and MBRT might lead to a dissimilar biological response. In the
light of the advantages of MBRT over MRT, preclinical trials in MBRT need to be performed
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in order to evaluate the healthy tissue sparing capability of MBRT and (possible) distinct
biological effects.
This PhD thesis is framed within medical physics developments aimed at the preparation
of forthcoming clinical trials in MRT and preclinical studies in MBRT. To this end, both Monte
Carlo (MC) simulations and experimental dosimetry studies were performed for the dose
assessment of the micrometre-sized fields used in these two innovative techniques.
The dissertation is divided into three parts: i) the first part provides an introduction of the
main topics to be addressed in this thesis, i.e., the use of RT to treat cancer and its limitations,
fundamentals of synchrotron radiation and third-generation sources, such as the ESRF, and
the basis of spatially fractionated synchrotron RT techniques from the biological and physical
point of view; ii) the second part contains a compendium of several original investigations
reported in six papers published in (or submitted to) peer-reviewed journals. In the first
paper, safe irradiation protocols for forthcoming MRT clinical trials are defined. The second
article assesses how much the MRT therapeutic index can be further improved by enhancing
dose deposition in the tumour when loading it with high-atomic-number contrast agents.
The third and fourth papers report the development and commissioning of the MC-based
calculation engine for a dedicated treatment planning system (TPS) in MRT. In line with
this, the fifth article deals with one of the most challenging issues in MRT: the assessment of
absolute dose in such extremely small field sizes by means of scatter factors. The sixth paper
consists of the development of a dosimetry protocol to guide preclinical trials in MBRT; iii)
finally, the main conclusions of this work and some reflections on future developments are
presented.
viii
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1.1 Radiotherapy
1.1.1 Cancer incidence and treatment
Cancer is a large group of diseases characterised by uncontrolled growth of abnormal cells,
which leads to the formation of malignant tumours. Cancerous cells can invade nearby tissue
and spread out to distant parts of the body through the bloodstream and lymphatic system.
Both external factors (tobacco, infectious organisms, chemicals and radiation) and internal
factors (inherited mutations or mutations generated from metabolism, immune conditions
and hormones) can initiate carcinogenesis [ACS 2011].
Cancer is considered to be responsible for one out of four deaths in Europe. In particular,
it is the cause of approximately 40% of deaths of people between the age of 45 and 74
[Niederlaender 2006]. The incidence and mortality of different types of cancer (in Europe)
is represented in figure 1.1. More details on cancer epidemiology worldwide can be found
elsewhere [Ferlay 2010, ACS 2011, CBTRUS 2011].
The 5-year survival rate for all cancers diagnosed in 1999–2006 was 68% [ACS 2011].
This value has been largely improved with respect to the value of 50% in the period 1975–
1977 due to advances in early diagnosis and cancer treatment [ACS 2011].
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Figure 1.1: Age-standarised rate (ASR) for world (W) standard population on incidence and mortality
of different types of cancer in Europe in 2008 (both sexes, all ages). Extracted from [Ferlay 2010].
However, despite the great improvements in the treatment of cancer, the outcome of
some tumours remains unsatisfactory [Niyazi 2011]. This is the case of high-grade gliomas
(glioblastomas), a cancer of glial cells, which is the most frequent and aggressive type of
brain tumour. The median survival time of these patients is approximately one year and the
survival rate five years after treatment is only about 5% [CBTRUS 2011]. Although the an-
nual incidence of malignant primary brain and central nervous system tumours is low, these
cancers entail extremely high morbidity and mortality. This is especially dramatic in chil-
dren, as brain tumours are the second most common paediatrics malignancy, after leukaemia
[ACS 2011], and the treatment options are very limited due to the high risk of complications
in the development of the central nervous system.
Cancer treatment highly depends on tumour type, location and stage. Surgery, radio-
therapy (RT) and chemotherapy are the most frequent options. It is common to combine all
or several of these techniques. Among them, RT has a key role since a high percentage of
patients (about 70%) will receive RT at some point during their illness [IAEA-TRS-461 2008].
1.1.2 Radiotherapy: concept and brief history
Radiotherapy is the medical use of ionising radiation (IR) to treat tumours and some benign
lesions such as nodules, vascular problems, etc. IR is able to damage cells either by direct
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break-up of DNA chains, or indirectly, as a result of the free radicals generated from the
ionisation of water followed by DNA oxidation. The latter process is the dominant in con-
ventional RT. The basis of RT lies in the fact that, compared to healthy cells, cancerous cells
possess a reduced capability to repair DNA [Joiner 2009].
The first RT treatment was performed less than a year after W. C. Roentgen discovered the
x-rays in 1895; E. H. Grubbe irradiated a patient that was suffering postoperative recurrence
of breast cancer with x-rays. Despite the fact that first attempts were limited by primitive
available x-ray generators, the therapeutic use of x-rays became widespread very quickly and
3134 cases of malignancies were treated from 1896 to 1909 [Kazem 1995].
In parallel, the discovery of radioactivity by H. Becquerel in 1986 and of polonium and
radium in 1898 by M. Curie and P. Curie remarkably advanced the methods used for the treat-
ment of cancer. Radium was initially used in several ways to treat different types of tumours
until 1950, when cobalt-60 units started to come into use. This last step represented a big
boost in the quest for higher photon energies for the treatment of deep-seated tumours. Ad-
ditionally, the discovery of new isotopes and improved techniques for dose delivery expanded
the idea of shrinking tumours through direct exposure to radioactive materials.
Thus, RT was soon split into two main divisions: external beam RT and brachytherapy
[Khan 2010]. In the first case, the radiation source is external to the patient and radiation
is delivered to the tumour in a non-invasive way. At present, this modality, which is mainly
based on linear accelerators (also named linacs), accounts for almost 90% percent of RT treat-
ments [Gerber 2008]. Instead, in brachytherapy, the radiation source (usually contained in
radioactive seeds, rods or liquid) is located inside the patient in direct contact with the tu-
mour. Hereafter, we will only refer to external beam RT. More information on brachytherapy
can be found elsewhere [Thomadsen 2005, Polgár 2009, Crook 2011].
Cobalt therapy units have been at the forefront of external RT for a number of years.
However, the reliability, flexibility, accuracy and the possibility of reaching higher energies
given by linacs partially supplanted cobalt therapy as a treatment tool. Nevertheless, cobalt-
60 is still in use for certain tumour sites. Both gamma and electron RT beams are produced
by modern linacs, which accelerate electrons to kinetic energies from 2 to 25 MeV using
microwave radio-frequency (RF) fields. Thanks to their characteristic dose fall-off in depth,
direct electron beams are used to treat tumours that are not very deep. They are also em-
ployed to boost photon treatments to increase the dose deposited in the tumour while sparing
nearby healthy tissue. Photon beams (6–18 MV) are produced by the rapid deceleration of
electrons in a high-density target (bremsstrahlung). See figure 1.2 for a schematic representa-
tion of a linac. More details about their working principle can be found in [Podgorsak 2005].
Superficial and orthovoltage units (50–500 keV x-rays) are also employed for treatment of
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superficial cancers [Amdur 1992]. Other accelerators such as microtrons have also been
explored as electron accelerators for medical applications due to their reduced dimensions
[Brahme 1981].
Figure 1.2: A block diagram of a typical medical linear accelerator (top) and schematic images showing
the basic components of the head of a modern linac for x-ray (A) and electron (B) therapy (bottom).
Extracted from [Khan 2010].
A series of technological advances have improved the targeting of external beam RT by
moving from 2D rectangular treatment fields to four-dimensional conformal RT (4D-CRT)
techniques. In particular, advanced imaging technologies such as computer tomography (CT),
magnetic resonance imaging (MRI) and positron emission tomography (PET) have enabled
the direct 3D visualisation, definition and characterisation of the tumour and surrounding
healthy tissue. This, along with the use of an increased number of fields and multi-leaf
collimators (MLC) allowed high, homogeneous and conformed doses to be delivered to the
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tumour with minimal irradiation of normal tissue. Intensity-modulated radiation therapy
(IMRT) is the most modern and sophisticated high-precision 3D-CRT, with the ability to fit
complex shapes in treatment volumes. This is obtained by modulating the number of fields,
their shape and intensity distribution of each beam, which is constituted by multiple small
and adjustable ‘beamlets’ [Elith 2011, IMRTGroup 2001]. The high level of dose conformity
encouraged the development of new imaging capabilities in real time or during the course
of the treatment in order to improve precision on dose delivery (4D-CRT or image-guided
radiation therapies, IGRT [Dawson 2006]).
Historically, fractionation of the dose in small daily doses of radiation (1.8–4 Gy) over sev-
eral weeks has been applied in order to permit healthy cells to recover between sessions while
causing cumulative damage to the tumor cells [Coutard 1934]. The high precision delivery
methods mentioned above and advances in radiobiology enabled a move towards different
dose-escalation schemes for some types of tumours [Papiez 2008]. For instance, stereotactic
radiosurgery (SRS) delivers a high radiation dose to the tumour in one or a few fractions by
converging multiple radiation beams on an intracranial lesion [Phillips 1994]; or stereotactic
body radiation therapy (SBRT), which also uses hypo-fractionated scheme, employs robotic
guidance technologies [Martin 2010]. As a result, the impact of tumour cell repopulation is
diminished. Both techniques can be delivered by using adapted linacs or specialised systems
such as the Gamma Knife R© [ELEKTA R© 2012] or CyberKnife R© [ACCURAY R© 2012].
There are other RT methods available or in development nowadays. For instance, hadron-
therapy, which is an advanced external RT technique that uses charged particles such as pro-
tons, alphas, C, Ne, etc. [Brahme 2004]; or boron neutron capture therapy (BNCT), where
the patient is exposed to neutron irradiation which causes the activation of boron compounds
(previously injected and mostly concentrated in tumour cells) to emit alpha particles and
lithium nuclei from the disintegration of 11B, which deposit the dose locally within the tu-
mour [Barth 2005]. The combination of enhanced radiobiological properties and localised
dose deposition of such particles have overcome some of the inherent dosimetric and bio-
logical shortcomings of photons and electrons [Halperin 2006]. Additionally, new delivery
and dose deposition methods are being explored by synchrotron RT techniques, which will
be thoroughly explained in the following sections.
1.1.3 The therapeutic index
IR induces cell damage both in the tumour and in adjacent normal tissue. The rationale of
RT lies in the fact that, in general, healthy tissue presents a higher recovery capability than
tumour tissue. In addition, the tumour control probability (TCP) follows a sigmoid curve in
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function of dose. As the radiation dose is increased, the TCP rapidly escalates until a plateau
is reached. The same is true for the probability of inducing deleterious effects in normal
tissue, which is represented by the normal tissue complication probability (NTCP) curve. The
balance between the TCP and NTCP is a measure of the therapeutic index of the treatment
[Joiner 2009]. This concept was introduced in 1936 by H. Holthusen [Holthusen 1936] and
is illustrated in figure 1.3. The term therapeutic window corresponds to the range of doses
for which TCP is much higher than NTCP, that is to say, a tumour can be effectively treated
while staying within the safety range for healthy tissue.
TCP NTCP
TCP*(1-NTCP)
Figure 1.3: Illustration of the therapeutic index concept. TCP curve represents the probability of
tumour control and NTCP indicates the normal tissue complication probability. TCP*(1-NTCP)
is the probability of cure without deleterious effects in terms of the dose deposited to the tumour
(arbitrary units). Extracted from [Holthusen 1936].
The dose-response curves lie in close proximity for very radioresistant tumours such as
gliomas. In these cases, the risk of serious damage to normal tissue is not compatible with
the possibility of reaching curative doses. In order to widen the therapeutic window, either
the effect on the tumour needs to be increased (for example, by achieving a higher gradient
in TCP) or the dose received by the healthy tissue is reduced (the NTCP curve needs to shift
to the right) or both [Joiner 2009].
The beam type (photons, electrons, protons, etc.), beam quality, dose delivery methods
(temporal fractionation scheme, dose rate, spatial distribution, etc.) have a direct impact
on the therapeutic index [Willers 2006, Kim 2008, Joiner 2009]. Thus, the modification of
any of these parameters implies a different biological response. This might lead to a shift of
the NTCP dose-response curve to higher doses, opening the therapeutic window for highly
aggressive tumours.
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The response of gliomas to variations of some of these parameters has been already ex-
plored [Combs 2005, Fuller 2007, Wen 2008, Yamamoto 2008], as well as biological opti-
misation by using chemotherapy drugs (concomitant and adjuvant temozolomide) together
with RT [Stupp 2005, Stupp 2009]. Despite the fact that a significant prolongation of the
survival probability was observed in the latter case, tumour recurrence is still important
[Niyazi 2011]. This is the reason behind the interest in prospecting new RT approaches.
1.1.4 Exploring new paths in RT at the ESRF: synchrotron RT techniques
The application of synchrotron radiation in RT at the European Synchrotron Radiation Facil-
ity (ESRF) was first suggested by Larsson [Larsson 1983]. Nowadays, the quest for a curative
treatment of gliomas is at the origin of the development of three RT techniques at the ID17
Biomedical Beamline of the ESRF: contrast-enhanced synchrotron stereotactic radiation ther-
apy (SSRT), microbeam radiation therapy (MRT) and minibeam radiation therapy (MBRT).
Contrast-enhanced SSRT consists of loading the brain tumour with a high-atomic-number
(Z) element, such as iodinated contrast media, and irradiating it with monochromatic x-
rays from a synchrotron source (tuned at an optimal energy) in stereotactic conditions. The
highly conformal irradiation geometry and the increase in the photoelectric cross section
produce localised dose enhancement in the tumour. This leads to improved dose distribu-
tions when compared to conventional high energy RT treatments [Mesa 1999, Boudou 2005,
Adam 2008].
The other two techniques, i.e., MRT and MBRT, are the most exotic ones. Both approaches
combine submillimetric field sizes (25–100 µm and 500–700 µm-wide beams in MRT and
MBRT, respectively) with the spatial fractionation of the dose (interbeam separation of 200–
400 µm in MRT and 1200 µm in MBRT). At present, they are restricted to synchrotrons,
despite the fact that MBRT has the potential to be extended to hospitals with cost-effective
equipment. Further details on these techniques will be given in sections 1.4, 1.5 and 1.6.
1.2 Synchrotron radiation and third-generation sources
In this section, the fundamentals of SR will be presented. Afterwards, a brief overview of the
different components of third-generation synchrotrons, such as the ESRF, will be described,
with especial emphasis on insertion devices used to generate SR.
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1.2.1 Synchrotron radiation
Charged particles emit electromagnetic radiation when accelerated [Jackson 1998]. In par-
ticular, synchrotron radiation (SR) is generated when a charge moving at a relativistic speed
follows a curved trajectory. A non-relativistic particle produces radiation with the character-
istic pattern shown in figure 1.4 (left). The relativistic speed changes the observed frequency
by the Lorentz factor, γ = 1 + E/(mc2), where E is the kinetic energy of the electron, m is
the rest mass of the electron and c is the speed of light in vacuum. In particular, the radiation
pattern is distorted from an isotropic dipole into an extremely narrow cone of radiation with
an opening angle equal to 2γ−1 (in rad). See figure 1.4 (right). A higher electron energy
implies a smaller opening radiation angle, and thus, brighter SR [Wille 2001].
Figure 1.4: Angular distribution of the radiation emitted by non-relativistic (left) and relativistic (right)
charged particles following a curved trajectory. Extracted from [Wille 2001].
SR can be generated by astronomical structures or in specialised particle accelerators. In
the latter case, SR can occur as an undesired energy loss or produced on purpose for certain
applications. The widespread usefulness of SR in material science, biology, etc. has led to the
building of special facilities devoted to SR generation, which are named synchrotrons. These
facilities accelerate charged particles (typically, electrons) and confine them in a circular
orbit by means of electromagnetic fields. Figure 1.5 shows a scheme of the different parts
constituting a synchrotron (left) and a storage ring (right).
Electrons are generated by heating a cathode (typically made of tungsten) and then they
are pulled out by a strong electric field through a hole at the end of a gun. These electrons are
first accelerated in a linear accelerator. Subsequently, bunches of electrons are transmitted
into a circular accelerator (booster), where they are speeded up to operational energies. At
8
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Figure 1.5: Scheme of the different parts constituting a synchrotron (left) and a storage ring (right).
Extracted from [Barnes 2012].
this point, electrons are injected into a large storage ring, where they circulate in vacuum for
many hours.
Storage rings comprise both straight and curved sections under ultra-high vacuum (less
than 10−8 mbar). Dipole magnets (bending magnets) are located in the curved sections to
bend the electrons trajectory in order to maintain them in a closed orbit and/or produce SR
with a continuous spectrum. The electron beam is steered and focused by quadrupoles and
sextupoles in order to keep the beam within a defined orbit.
In third-generation synchrotron radiation sources, specialised devices called insertion de-
vices (ID) are located in the straight sections, between dipole magnets. They consist of an
array of magnets which are used to generate a spatially periodic magnetic field along the
electron beam path (see figure 1.6). There are two types of IDs at synchrotron facilities:
wigglers and undulators. They both produce significantly higher brightness SR than bending
magnets. Details on the properties of the SR emitted by an ID will be given in section 1.2.2.
RF cavities compensate the energy loss of the electrons on their trip along the storage
ring. The presence of RF accelerating fields and radiation damping result in variations in the
electron beam dimension and in the angular divergence with respect to the ideal position. Let
us denote the standard deviation of the dimensions of the electron beam in the horizontal and
vertical directions by σx and σz, respectively. Similarly, the divergence of the electron beam
is expressed as σ′x and σ′z. See the coordinate system in figure 1.6 (right). The deviation
of the electron beam position and angle are correlated by the emittances, εx = σxσ′x and
εz = σzσ′z, which remain invariant (Liouville’s theorem). Beam size and emittance are related
9
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Figure 1.6: Electron beam crossing a bending magnet (left) and an ID (right). Both systems are used to
produce extremely bright SR. IDs (undulators and wigglers) are present in third-generation synchrotron
sources and they consist of periodic magnetic structures. Extracted from [Wille 2001].
through the beta parameters, defined as βx = σx2εx and βz = σz2εz. Low β sections of the
synchrotron correspond to a small source size and a high divergent beam while a high β
section corresponds to the opposite situation [Wille 2001].
As has been explained, the SR is generated in the storage ring and it is channelled into
the beamlines through the front-end sections. A beamline is composed of several parts: the
optical hutch(es), the experimental hutch(es) and the control room(s). The first part is de-
voted to tuning the photon beam to the desired characteristics by means of monochromators,
slits, filters, etc. The second part is where the experiment is carried out. Several photon beam
modifiers, detectors and sample holders are also present in this hutch. The final part is where
scientists control the experiment remotely and acquire data.
The final characteristics of the photon beam depend on the device used to generate the
SR and on the beam modifiers interposed in the beam path. Key features of SR are:
• Wide energy range, ranging from infrared to hard x-rays. Experiments can be con-
ducted with white radiation or with monochromatic beams.
• The beam has a small angular divergence (of the order of a few mrad) and possesses
a low emittance, i.e., the product of the source cross section and the solid angle of
emission is small.
• High intensity and brightness. This enables measurements to be conducted at a high
speed and with better statistics.
• Highly tunable due to the small natural divergence and the high beam intensity (mono-
chromators, optical systems, filters, etc.).
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• High linear polarisation degree in the plane of the electron orbit. Above and below this
plane, the beam is elliptically polarised. This is of particular interest in the study of
magnetic systems.
• Pulsed light emission (pulse durations of or below one nanosecond), that can be ef-
fectively used for research applications that are highly demanding in terms of time
resolution.
• High temporal coherence (it is possible to have a small relative bandwidth by using
undulators or/and monochromators) and spatial coherence (low emittance). These
properties are used, for instance, in synchrotron imaging techniques.
1.2.2 Insertion devices
The two types of ID, i.e., wigglers and undulators, are distinguished by the deflection param-
eter (K), which characterises the electron motion inside the ID. For a sinusoidal magnetic
field, this dimensionless parameter is related to the deflection angle for half a wiggler pole
(δ) as K = γδ. In practical units, K is expressed as
K = 0.934B[T]λu[cm], (1.1)
where B is the peak magnetic field (in T), which depends on the wiggler gap (g), and λu is
the magnetic field period (in cm) [Als-Nielsen 2001].
If K ≤1, the flight of the electron beam is inferior or equal to the natural opening angle
of SR (2γ−1). Moreover, SR from different periods interfere coherently and the resulting
spectrum is constituted by quasi-monochromatic peaks at specific harmonics. The on-axis
brightness increases as N2, where N is the number of magnetic periods. In this regime, the
device is called an undulator [Brown 1983].
In the particular case of spatially fractionated techniques, the photon source is generated
by a wiggler. For these IDs, K is large (typically from 10–60). Thus, the horizontal beam
divergence (2Kγ−1) is much larger than the natural opening angle of SR and the radiation
produced at each pole adds incoherently. The spectrum of photons exiting a wiggler is es-
sentially emitted in a continuum of energies from the infrared to the x-ray region and it is
characterised by the critical energy εc, for which the radiated power is divided into two equal
parts. This energy is given by
εc(θ) = εc,max
√
1− (θ/δ)2, (1.2)
where θ is the observation angle in the horizontal plane and εc,max is
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εc,max[keV] = 0.665B2[T2]E2[GeV2]. (1.3)
From equations (1.2) and (1.3), it can be derived that high energy photons are concentrated
on the central part of the beam.
Interference effects are still present in wigglers, especially at long wavelengths and in de-
vices with many periods. Since wigglers are typically used at short wavelengths, these effects
produce small variations about the normal continuous spectrum and the SR generated by a
wiggler approximates the superposition of the SR from 2N bending magnets of alternating
curvature. However, this enhancement depends on the design of the wiggler and on the
emittance of the electron beam [Brown 1983].
More information on the physical properties of SR generated by IDs can be found else-
where [Brown 1983, Als-Nielsen 2001, Clarke 2004, Thompson 2009].
1.3 The ESRF and the ID17 Biomedical Beamline
A general overview of the ESRF is presented in this section, with special emphasis on the
technical description of the ID17 Biomedical Beamline. In particular, the characteristics of the
beam modifiers used for spatially fractionated synchrotron RT techniques will be described.
1.3.1 European Synchrotron Radiation Facility (ESRF)
The ESRF [ESRF 2012] is one of the largest and most powerful synchrotrons in the world.
It was founded in 1988 in Grenoble (France) and, nowadays, the ESRF is the result of an
international consortium of nineteen countries devoted to cutting-edge science with photons.
Figure 1.7 shows a satellite view of the ESRF (left) and a photograph taken inside the storage
ring (right).
The ESRF is a third-generation synchrotron composed of: i) a linac that accelerates elec-
trons up to 200 MeV; ii) a booster with a circumference of 300 m and a repetition rate of
10 Hz; and iii) a 6.04 GeV electron storage ring (844.4 m of perimeter). The beam is guided
by 64 bending magnets and focused by 320 quadrupoles and 224 sextupoles [ESRF 2012].
The main features of the machine are listed in table 1.1.
The 40 beamlines available at the ESRF are used for a wide variety of scientific topics:
material science, structural biology, extreme conditions science, x-ray imaging, etc. In partic-
ular, ID17 is one of the few synchrotron beamlines in the world entirely used for biomedical
research.
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Figure 1.7: Satellite view of the ESRF, from Google Maps (left), and a photograph of the ESRF storage
ring (right).
Table 1.1: ESRF storage ring electron beam parameters (*RMS: Root Mean Square) [ESRF 2012].
ESRF electron beam parameters
Electron energy E 6.04 GeV
Maximum intensity Imax 0.2 A
Horizontal emittance εx 3.9 nm
Vertical emittance εz 0.039 nm
Revolution frequency 355 kHz
Number of bunches 1 to 992
Time between bunches 2816 to 2.82 ns
Lifetime (992 bunches) 75 hours
RMS* bunch length (0.2 A) 20 ps
RMS* energy spread (0.2 A) 0.11%
1.3.2 ID17 Biomedical Beamline
ID17 is one of the two longest beamlines at the ESRF. The three main working areas are
medical imaging, radiation biology and radiation therapy [Suortti 2003, Thomlinson 2005,
Baruchel 2008, Bravin 2011]. Nowadays, large efforts are focused on RT programs, espe-
cially on the preparation of clinical trials in MRT and SSRT [Renier 2008, Requardt 2010,
Adam 2011].
ID17 possesses two experimental hutches and their corresponding optical hutches (see
figure 1.8). The first one, named the ‘MRT hutch’, is located at around 40 m from the wig-
13
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gler source and is used for spatially fractionated RT techniques (MRT and MBRT) and brain
microsurgery. In this case, the irradiations are performed with the white-beam coming from
the wiggler after some filtering. The second station is located at about 150 m from the source
and it uses monochromatic x-rays for SSRT [Adam 2011] or for medical imaging (absorption,
time-resolved, K-edge subtraction, phase contrast, analyzer-based and diffraction-enhanced
modes) [Baruchel 2008].
The photon source at ID17 is composed of two planar wigglers with periods of 15 cm
(named w150) and 12.5 cm (w125). In spatially fractionated synchrotron RT techniques,
only the first wiggler (w150) is used. The second wiggler (w125) was constructed to further
increase the photon beam flux in other applications such as SSRT.
Figure 1.8: ID17 Biomedical Beamline layout. Extracted from [ESRF 2012].
After exiting the wiggler, the beam is directed to the front-end sections and then to
the optical hutches, where it will encounter a series of beam modifiers that will tune the
beam following the particular requirements of each experiment. Specific details of the set-
up used in spatial-fractionated RT techniques (MRT and MBRT) will be given in following
sections. Additional information on the other parts of the beamline can be found elsewhere
[Elleaume 1999].
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1.3.3 ID17 w150 wiggler
The main characteristics of the ID17 w150 wiggler are listed in table 1.2. This wiggler is
located in a low β section (small source size and a high divergent electron beam) and it
is composed of 21 poles. The magnetic field and the deflection parameter depend on the
wiggler gap in a complex way, as represented in figure 1.9. The maximum magnetic field
is approximately 1.6 T for the minimum permitted gap of 2.48 cm. This corresponds to a
maximum total power of approximately 19.3 kW.
Table 1.2: ID17 wiggler (w150) characteristics (*RMS: Root Mean Square) [ESRF 2012].
ESRF electron beam parameters at the ID17 wiggler position
RMS* horizontal source size 57 µm
RMS* vertical source size 10.3 µm
ID17 wiggler parameters
Magnetic field period λu 15 cm
Number of poles 21 total, 19 equivalent
Number of periods N 11
Gap g (for the MRT irradiation conditions) 2.48 cm
Peak magnetic field B(g = 2.48 cm) 1.592 T
Deflection parameter K(g = 2.48 cm) 22.30
Critical energy εc(g = 2.48 cm) 38.6 keV
The full width at half maximum (FWHM) of the spatial distributions of photons at the
wiggler exit along the horizontal and vertical axis are 0.280 and 0.018 cm, respectively. The
vertical divergence corresponds to the natural opening angle of SR, 2γ−1=0.17 mrad, while
the horizontal divergence is equal to 2Kγ−1=3.77 mrad. Photons are emitted in a continuum
of energies with a critical energy (εc) of 38.6 keV for MRT and MBRT irradiation conditions
(g=2.48 cm). The emitted SR is linearly polarised in the orbital plane. Above and below
this plane, elliptical polarisation is observed. Since photons emitted by successive poles have
opposite sense of helicity, the net helicity is zero and the resulting beam is partially (linearly)
polarised. In particular, the total degree of linear polarisation of the SR emitted by the ID17
wiggler is 0.660 [Martínez-Rovira 2012a].
Detailed information on the phase-space distributions (position, direction of flight, spec-
trum and polarisation state) of the beam was assessed in this work and it will be presented in
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Figure 1.9: Peak magnetic field (B) versus wiggler gap (g) for the w150 wiggler. The curve follows a
complex trend: B = 2.78e−0.02535g + 0.8425e−0.07538g − 0.087e−0.081g − 0.487e−0.16g. The dependence
between both magnitudes has been measured experimentally and then fitted by a sum of exponential
curves (courtesy of J. Chavanne, ESRF).
section 2.5. Results were obtained with the SHADOW code [Lai 1986, Sánchez del Río 2011].
1.3.3.1 ID17 wiggler modelling: the SHADOW code
SHADOW is a widely used synchrotron radiation ray-tracing program [Lai 1986, Lai 1988,
Chapman 1989, Sánchez del Río 2011]. It is able to model synchrotron sources (bending
magnets, undulators and wigglers) and to trace the generated SR beam along complex optical
systems based on a phase ray-tracing approach.
SHADOW considers wigglers as a series of pseudo-bending magnets with no interference
effects between the different bends in the trajectory [Lai 1988]. Wiggler modelling involves
the calculation of the electron trajectory and the generation of the photon source by using
MC methods. Firstly, the electron trajectories in a sinusoidal magnetic field perpendicular
to the wiggler axis are calculated [Chapman 1989]. The resulting electron motion is also
sinusoidal and lies on the horizontal plane. Secondly, the total emitted number of photons
at each point of the trajectory is computed [Jackson 1998]. Most photons are produced
in regions of high curvature and only few of them in the region between the poles. The
distribution probability of photon emission is used to select the point (and its associated
radius of curvature ρ) where the photon is generated. Subsequently, the source is treated as
a conventional bending magnet with a radius of curvature ρ.
The divergence and position of electrons are computed by taking into account their emit-
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tances, i.e., the fact that the electrons are not all moving on the ideal central orbit but rather
distributed around two double-Gaussian distributions in the phase-space. Since the photon
emission is aligned to the electron direction, the photon energy and angle can be generated
independently from the electron direction [Green 1976, Chapman 1989]. The final photon
direction is then computed by shifting the emission angles along the real orbit of the electron.
SHADOW describes the state of polarisation of electromagnetic radiation by means of the
Stokes parameters [Fano 1954]. They are calculated from the electric field of the propagating
wavefront and the phase difference between the parallel and perpendicular (to the plane of
incidence) components [Hetch 2001].
1.3.4 Front-end section and MRT optical hutch
The beam exiting the wiggler travels in vacuum inside a long stainless steel pipe. Several
valves and Be windows (300–500 µm-thick) allow isolation between different vacuum sec-
tions. Along the way, ionisation chambers (IC) are used to monitor the beam.
In its path, the beam encounters several beam modifiers. Firstly, some diaphragms limit
the beam aperture to reduce the heat load in the downstream optical elements. The di-
aphragm that effectively limits the maximum irradiation field size is located at 21.6 m from
the wiggler centre, in the so-called front-end section. It is made of oxygen-free high conduc-
tivity (OFHC) copper and its horizontal (H) × vertical (V) apertures are 2.4×0.15 cm2. This
leads to a fixed maximum H and V dimensions at the patient position of 4.1 cm and 0.25 cm,
respectively.
The beam is directed towards the first optical hutch, whose layout is shown in figure 1.10.
After traversing an additional diaphragm, the beam finds a Kr gas filter (at a pressure of
85 mbar without the beam and of about 160 mbar for the maximum electron beam current).
This filter helps to further attenuate the beam intensity in order to protect the downstream
components in case of failure. The field size at the patient position is then defined by the
aperture of the primary slits. They consist of four motorised blocks of OFHC Cu (left, right,
up and down). Five water-cooled attenuators (1.42 mm of C, 0.28 + 1.24 mm of Al and 0.35
+ 0.69 mm of Cu), which are located after the primary slits, progressively eliminate the low
energy part of the spectrum.
The ‘fast shutter’ and the photon absorber are key elements since they are responsible for
stopping the radiation in less than 5 ms, after the irradiation process has been completed.
The fast shutter consists of two 15-mm-thick tungsten carbide blades coupled to two actuator
magnets. During the closing time of the ‘fast shutter’, the beam is absorbed by the photon
absorber (cooled 40-mm-thick Cu block), which has a longer reaction time (about 1 s). More
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Figure 1.10: MRT optical hutch layout (extracted from [ESRF 2012]). The photographs are taken at
several points in the optical hutch: at the monochromator, at the attenuators and at the gas filter position
(from left to right).
information on this system can be found in the work of Renier et al. [Renier 2002].
There are other elements placed out of the beam path in RT experiments or not used
nowadays. For instance, the double-Si (111) crystal Laue-type monochromator (energy
range: 30 to 80 keV), which is used to perform CT imaging prior to irradiation to ensure
good positioning, or the MRT slits, which consist of a couple of additional slits that were
used to further define the field size at the patient position.
1.3.5 MRT experimental hutch
The beam leaves the vacuum when it crosses the final Be window, which constitutes the
boundary with the experimental area. An Al foil acts as a separator between vacuum and air.
Figure 1.11 shows a schematic representation and a picture of the beam modifiers present in
the experimental hutch. An IC is located just after the vacuum section in order to monitor
the beam. The next three elements are out of the beam path in RT experiments and they are
only used for specific purposes. For instance, the plexiglass blocks act as photon absorbers
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during imaging, the rotary shutter is employed for some radiobiology MRT experiments and
the horizontal slit is only used for beamline alignment. The vertical slit (V slit) is present in
all MRT irradiations. It consists of a small aperture made of tungsten carbide and has several
available sizes (50, 100, 500 or 800 µm). Its function is very important since it allows only
the homogeneous central part of the beam to be selected for the irradiation.
Figure 1.11: Scheme and picture of the beam modifiers in the MRT experimental hutch (scheme courtesy
of M. Renier, ESRF).
Additional patient safety systems have been added to the set-up for forthcoming MRT clin-
ical trials. They prevent an overdose of the patient in case of failure by using lead shielding
blocks that limit the maximum irradiation dimensions [Berkvens 2011, Renier 2011].
Targets (patients or phantoms) are placed on a 3-axis Kappa-type high-precision goniome-
ter (Huber, Germany). The mechanical accuracy of this device is in the order of 5–10 µm.
The vertical dimensions of the beam at the goniometer position are very small since they are
defined by the V slit aperture. In order to fill in the required vertical field size, targets are
vertically scanned at constant speed (in the range of 10 to 100 mm/s). The chosen speed
depends on the desired dose, beam current and vertical slit size. This scanning method is
equivalent to homogeneous irradiation [Prezado 2011b].
The spatial fractionation of the beam is achieved by using two additional instruments:
either a multislit collimator (MSLC) in microbeam radiation therapy (MRT), or a chopper in
minibeam radiation therapy (MBRT). Thanks to the specific beam properties and these two
devices, ID17 offers an ideal environment for the exploration of RT approaches based on
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distinct dose delivery methods. In particular, those involving the use of intense micrometre-
sized beams.
In MRT, the beam is spatially fractionated along the horizontal direction by means of
a MSLC [Bräuer-Krisch 2009]. It consists of a unique 8-mm-thick block, mostly composed
of tungsten carbide (86.8%, weight percentage) and Cu (12.0%). The MSLC to be used
in the clinical trials will consist of a series of 50-µm-wide slits with a centre-to-centre (c-t-
c) separation of 400 µm. Details on other MSLCs used in MRT, which allowed additional
beam widths and c-t-c distances, can be found in the literature [Slatkin 1995a, Archer 1998,
Bräuer-Krisch 2005a].
The MSLC cooling system consists of a direct flow of N2 and a water-cooled Cu block
support. The whole system is enclosed in a box with one entrance and one exit 500-µm-
thick Al windows. Figure 1.12 shows a top view of the MSLC box (left) and a graphical
representation of the MSLC (right).
Figure 1.12: Top view of the MSLC whole block (left) used for MRT. The slits of the MSLC can not be
seen. On the right, a graphical representation of the MSLC (extracted from [Bräuer-Krisch 2009]).
In MBRT, the vertical spatial fractionation of the beam is achieved by using a special
device called white-beam chopper [Renier 2005], instead of a collimation block system. The
chopper is composed of ten tungsten carbide blades. See figure 1.13.
The rotational speed of the chopper is synchronised with the vertical motion of the target.
In this way, each opening of the chopper generates a horizontal beam print. The duty cycle
is fixed at 50%, and thus, the time the beam is on is exactly equal to the time when it is off.
For interlaced beams, the duty cycle is set to 53% in order to ensure maximum homogeneity
in the interlaced region. This innovative method was preferred over a static MSLC since it
offers excellent reliability and reproducibility [Prezado 2009b].
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Figure 1.13: Photograph of the white-beam chopper used for MBRT.
1.4 Basic principles of spatially fractionated synchrotron RT tech-
niques
As has been explained in section 1.1.3, differences in dose delivery methods (fractionation
scheme, dose rate, spatial distribution, etc.) have an impact on the therapeutic index of
RT treatments. This idea is the basis for the development of MRT and MBRT, whose main
features in terms of beam characteristics, exploration of the dose-volume effect and potential
advantages with respect to conventional methods will be explained in the following sections.
1.4.1 Beam characteristics at the patient position
MRT and MBRT irradiations present very distinct features with respect to conventional RT
techniques. The x-ray source differs from medical accelerators in the method for photon
generation, type and dimensions of the beam modifiers, beam intensity, energy range, etc.
See figure 1.2 and section 1.3. A summary of the main MRT and MBRT beam characteristics
at the patient position is:
• Submillimetric field sizes are used. The beam widths range from 25 to 100 µm in the
case of MRT and from 500 to 700 µm in MBRT.
• The beam is spatially fractionated. The irradiation is performed with an array of intense
quasi-parallel beams. The c-t-c distance is 200–400 µm in the case of MRT and 1200 µm
in MBRT.
• The energy spectrum ranges from 27 to 600 keV with a mean energy of 99 keV. The frac-
tion of photons with energies higher than 300 keV is very small (0.1%) [Siegbahn 2006,
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Martínez-Rovira 2012a].
• Beam divergence is approximately 0.5 mrad in the horizontal direction and 0.02 mrad
in the vertical one. These values are significantly lower than in a conventional linear
accelerator (around 35 mrad).
• The spectral flux at the patient position is several orders of magnitude higher than
any conventional x-ray generator. This leads to extremely high dose rates, which pro-
vide fast irradiations and minimise cardiosynchronous motion effects in the patient
[Poncelet 1992]. In particular, the dose rate is approximately 13.4 kGy/s for the max-
imum electron current and a 50 µm V slit size (for a 2×2 cm2 whole irradiation field
size at 2 cm-depth in water). This, along with the low energy spectrum and the small
beam divergence, allows production of sharply defined beam edges.
• The beam is highly linearly polarised in the plane of the electron orbit at the patient
position (the total degree of linear polarisation equals 0.994 [Martínez-Rovira 2012a]).
The resulting dose profiles consist of a pattern of peaks and valleys, i.e., with high doses
along the microbeam path and low doses in the spaces between them. The minimum dose
in the central region between two microbeams is named the valley dose and the dose at the
centre of the microbeam is the peak dose. The ratio between the peak dose and the valley
dose (peak-to-valley dose ratio, PVDR) is an important dosimetric parameter in spatially frac-
tioned techniques, since it plays an important role in biological response [Dilmanian 2002].
The MRT dosimetric parameters depend on the incident x-ray beam energy, beam width, c-
t-c distance, irradiation field size and tissue composition. Figure 1.14 shows an example of
lateral dose profile. The peak and valley regions and the c-t-c distance, which refers to the
separation between the centres of two consecutive peaks, are represented.
1.4.2 Exploring the limits of dose-volume effect
The use of submillimetric field sizes allows the limits of the dose-volume effect to be explored:
the smaller the field size is, the higher the tolerance of the healthy tissue. This phenomenon
has been known since the 50s, when Zeman and collaborators investigated the possible haz-
ards of heavy cosmic rays in the brain of astronauts [Zeman 1959, Zeman 1961, Curtis 1967].
To this end, they irradiated mice brains with 22.5 MeV deuteron beams of several field sizes.
They evaluated the threshold dose to produce necrotic lesions along the first half of the
beam path (1.5 mm) within 24 days. The reconstruction of the results is represented in
figure 1.15 [Zeman 1959, Zeman 1961]. The tolerance doses remain almost constant for
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Figure 1.14: Example of MRT dose pattern.
field sizes larger than approximately 0.1 mm; below this value, the tolerance dose increases
dramatically.
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Figure 1.15: Tolerance doses (Gy) of mice brains to irradiation with 22.5 MeV deuteron beams of several
widths (mm). There is an inverse relationship between radiosensitivity and volume of tissue exposed for
small volumes. This is known as the dose-volume effect [Zeman 1959, Zeman 1961, Curtis 1967].
Figure 1.16 shows histology images of mice brains irradiated with 22.5 MeV deuteron
beams with a diameter of 1 mm (entrance dose of 280 Gy) and 25 µm (4000 Gy). The results
clearly indicate that there is an inverse relationship for small volumes between radiosensi-
tivity and volume of tissue exposed. This phenomenon was also observed a few years later
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in x-ray beams [Straile 1963] and, subsequently, for high-energy photons [Hopewell 2000,
Lawrence 2010].
The dose-volume effect might be explained by the stem cell depletion hypothesis: for each
organ, there is a critical volume that can be repopulated by a single survival stem cell that
migrates from the nearby tissue to recover the tissue damaged by the radiation [Yaes 1988].
Thus, the combination of submillimetric field sizes and spatial fractionation of the dose pro-
vides a further gain in tissue sparing due to the biological repair of the microscopic lesions
by the minimally irradiated contiguous cells. This leads to a shift of the NTCP curve towards
higher doses, widening the therapeutic window for gliomas, as indicated by the biological
studies performed so far (see section 1.5).
Figure 1.16: Histology images of mice brains illustrating the dose-volume effect. On the left, complete
tissue destruction is observed after irradiation with a 22.5 MeV deuteron beam of 1 mm of diameter and
an entrance dose of 280 Gy. On the right, the tissue is well preserved after irradiation with a 25-µm-wide
beam and an entrance dose of 4000 Gy. Extracted from [Zeman 1961].
1.4.3 Potential advantages of MRT and MBRT with respect to conventional RT
methods
Possible improvements of MRT and MBRT over the existing clinical RT and radiosurgery
techniques might include:
• Superior normal tissue tolerances, allowing the use of higher and potentially curative
doses.
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• Small penumbras (10–40 µm) in comparison with several millimetres in radiosurgery.
Hence, they are a perfect candidate for the treatment of tumours close to an organ
at risk or for the treatment of illnesses such as epilepsy, Parkinson’s disease, etc. with
negligible secondary effects.
• A potentially more effective combination with tumour-dose enhancement agents based
on high-Z elements due to the larger photoelectric cross section in the energy range of
MRT and MBRT.
• MRT and MBRT might also produce a temporary disruption of the blood-brain bar-
rier (brain capillaries that protect the central nervous system by strictly regulating the
entrance of molecules from the extracellular fluid) for selective delivery of a chemother-
apy drug to small areas in the brain, which can be exploited for improving the thera-
peutic index in an exponential way.
1.5 Microbeam radiation therapy (MRT)
MRT was conceived at the Brookhaven National Laboratory (BNL) at the National Syn-
chrotron Light Source (NSLS), in Upton (USA) in 1992 [Slatkin 1992]. For two decades,
numerous experiments have been carried out at the NSLS and, subsequently, at the ESRF,
with the aim of assessing the therapeutic effectiveness of MRT. Nowadays, the use of MRT has
spread to other synchrotrons around the world (Spring 8 in Japan, Canadian Light Source,
Australian Synchrotron, etc.). This section will provide details on MRT preclinical trials and
related Monte Carlo and experimental dosimetric studies performed up to now.
1.5.1 MRT preclinical trials
1.5.1.1 Assessment of the MRT therapeutic index
The first MRT biological experiment took place at the BNL in 1995 [Slatkin 1995b]. Synchro-
tron-generated 20 and 37 µm microbeams (spaced by 75 and 200 µm, respectively; 48.5 keV
critical energy) were delivered to rat brains in a single exposure. No brain damage was
observed in the histology for entrance doses inferior to 625 Gy.
In 1998, the technique was applied to 9L gliosarcoma-bearing rats [Laissue 1998]. This
type of tumour, which is immunologically compatible with rats, is extremely radioresistant
compared to other models [Barth 1998, Bencokova 2008]. The irradiation was performed
with 25-µm-wide unidirectional and bidirectional arrays of microbeams (spaced by 100 µm;
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312.5 and 625 Gy skin entrance doses). The results showed that MRT protocols signifi-
cantly increased the survival of the animals, which was accompanied by a reduction in tu-
mour growth after irradiation (see figure 1.17). The longest survival was observed for the
625 Gy bidirectional group, with 50% of the animals alive at day 115 (control rats died within
31 days). Furthermore, the complete ablation of the tumour was also observed in more than
half of the rats. This suggested the possibility of a differential effect between healthy and
tumour tissue after MRT irradiations.
Figure 1.17: Survival curves of 9L gliosarcoma-bearing rats after irradiation with different MRT pro-
tocols: bidirectional irradiation with entrance doses of 312.5 (named 312-2) and 625 Gy (625-2), and
unidirectional irradiation with an entrance dose of 625 Gy (625-1). Extracted from [Laissue 1998].
A series of preclinical studies continued at the NSLS and started at the ESRF [Laissue 1999]
for more than 20 years. Several experiments confirmed the healthy tissue sparing capability
of MRT irradiation in hindbrains of weanling piglets [Laissue 2001], rat leg skin [Zhong 2003]
and in very immature tissues such as suckling rat hindbrains [Laissue 2001] or duck embryo
brains in ovo [Dilmanian 2001]. Figure 1.18 shows a histological section of a piglet cerebel-
lum 15 months after an MRT irradiation with an entrance dose of 300 Gy (20–30 µm-wide
microbeams spaced by 200 µm). Despite the fact that some cells were killed in the beam path,
no tissue destruction, haemorrhage, demyelination or locomotion problem was observed for
entrance doses up to 600 Gy.
The biological basis of the healthy tissue sparing after MRT irradiations is not well under-
stood. As has been mentioned, this effect was attributed to hyperplasia and migration of min-
imally irradiated endothelium and glial cells between the irradiated slices [Slatkin 1995b].
The initiation of migration, proliferation and differentiation of the progenitor glial cells could
be assisted by distant bystander effects from the dying cells [Dilmanian 2007b, Kashino 2009].
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Figure 1.18: Horizontal section of the cerebellum of a piglet 15 months after an MRT irradiation with
an entrance dose of 300 Gy (20–30 µm-wide microbeams spaced by 200 µm). The beam paths are clearly
visible in the histology images, but no tissue destruction is observed. Extracted from [Laissue 2001,
Laissue 2007].
Dilmanian et al. discovered that this sparing effect (measured by the onset of the appearance
of white matter necrosis) vanishes when the valley dose approaches the tissue tolerance to
seamless beams. Therefore, the brain damage threshold from MRT seemed to depend mostly
on the valley dose [Dilmanian 2002].
The fast regeneration of healthy vasculature may also play a role in normal tissue re-
covery after an MRT irradiation. Several experiments confirmed no changes in blood vol-
ume and vascular density in normal vasculature at very high entrance doses [Serduc 2006,
van der Sanden 2010]. In addition, no disruption of the blood brain barrier or significant
oedema was observed and only a transient increase in the blood-barrier permeability was
detected [Serduc 2006, Serduc 2008b]. The absence of important oedema may represent an
important advantage of MRT with respect to other RT treatments.
The high therapeutic index of MRT has been exhaustively confirmed by the significant
increase in survival time, and in some cases, tumour ablation in different kinds of tumours in
rodents, such as 9L rat gliosarcoma [Laissue 1998, Dilmanian 2002, Serduc 2008a], subcu-
taneous murine EMT-6 carcinoma [Dilmanian 2003b], subcutaneous human squamous-cell
SCCVII carcinoma [Miura 2006] and C6 and F98 gliomas [Schültke 2008]. In the latter case,
object recognition tests were performed on the animals after irradiation. MRT did not seem
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to affect the memory capability of the rats.
Tumour cells are not so effective in terms of a repair response to MRT irradiations as
normal cells [Crosbie 2010]. However, Dilmanian et al. showed that the tumoricidal ef-
fect of MRT is not completely attributed to direct tumour cell lethality since 2% of clono-
genic cells survived 5 min after the irradiation of 9L gliosarcoma-bearing rats (with doses
that had ablated about 50% of the tumours) [Dilmanian 2002]. It was hypothesised that
some other mechanisms might be the preferential effect on immature tumour vessels with
respect to differentiated normal vasculature, which would result in ischemic necrosis of the
tumour [Dilmanian 2002]. This was confirmed by irradiation of chick chorioallantoic mem-
branes ex ovo containing immature fast growing vessels. Results showed massive damage to
the microvascular plexus traversed by microbeams, while minor and reversible alterations,
and thus, an uninterrupted blood flow, was observed in larger vessels [Blattmann 2005,
Sabatasso 2011].
Posterior in vivo studies did not show any important damage to tumour vessels after MRT
irradiation in 9L gliosarcoma-bearing nude mices (by using two orthogonal arrays of 25-µm-
wide microbeams). In this case, the increased survival time was attributed to cytoreduction
rather than early direct effects of IR on tumour vessels [Serduc 2008a]. However, recent
studies with 50-µm-wide microbeams revealed loss of tumour vessel endothelia and a sig-
nificant decrease in blood volume from 8 to 15 days after irradiation, with a subsequent
reduction in tumour volume. The extracellular matrix and lack of endothelia could cause
initial temporary irrigation to the tumours. These results confirmed the differential effect
between tumour and healthy blood vessels for 50-µm-wide microbeams [Bouchet 2010].
The promising results obtained in preclinical studies have opened the door to the prepa-
ration of MRT clinical trials. The work performed on different medical physics features will
be explained in sections 1.5.2 and 1.5.3.
The remarkable MRT therapeutic index shown in the preclinical trials can be further
improved by optimising irradiation ballistics or by using drugs or high-Z contrast agents in
combination with MRT. Both improvements have been experimentally tested and they will
be described in the following subsections.
1.5.1.2 Optimisation of the MRT irradiation ballistics
Several studies were performed with the aim of finding the best balance between healthy
tissue sparing and tumour control in function of microbeam parameters (microbeam width,
c-t-c distance and irradiation modality).
The first work that evaluated MRT therapeutic index in function of the spacing of the
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microbeams was performed by Dilmanian et al. [Dilmanian 2002]. In this study, the bio-
logical effects of irradiations with 27-µm-wide microbeams spaced by 50, 75 and 100 µm
were assessed. These beam spacings turned out to be too small, given the observed tox-
icity in the normal brain. Subsequent studies revealed that a 200 µm spacing provided a
higher therapeutic index than 100 µm for a single array of 25-µm-wide microbeams in 9L
gliosarcoma-bearing rats [Régnard 2008b].
The effect of the microbeam width was evaluated by Serduc et al. [Serduc 2009a], who
concluded that 50-µm-wide microbeams (spaced by 211 µm) provide the best compromise
between tumour control and normal brain toxicity compared to 25 or 75 µm-wide microbeams,
for the same valley doses at the centre of the tumour of 9L gliosarcoma-bearing rats. Follow-
ing these observations, the irradiation conditions for forthcoming clinical trials were fixed to
50-µm-wide microbeams spaced by 400 µm. The c-t-c distance was chosen to maintain the
ratio of beam spacing to beam thickness from conclusions extracted in smaller beam sizes
[Régnard 2008b]. Some preclinical studies have already been performed in this configura-
tion [Bouchet 2010, van der Sanden 2010].
In addition, new irradiation configurations were explored. Some of the first MRT ex-
periments used two orthogonally crossed arrays of microbeams [Laissue 1998]. A further
improvement of this method consisted of the crossfire of two orthogonal microbeam ar-
rays. In this case, the microbeam spacing at the centre of the tumour is divided by two
but the healthy tissue remains exposed to unidirectional irradiation [Bräuer-Krisch 2005b,
Bräuer-Krisch 2005c]. High-precision irradiation methods using several entrance ports guided
by synchrotron imaging methods have also been developed [Serduc 2010a, Serduc 2010b].
In parallel, preliminary work pointed at a possible advantage of using a ‘temporal’ fractiona-
tion of the dose [Serduc 2009b].
1.5.1.3 MRT in combination with drugs
The exploration of other methods to further improve the MRT therapeutic index include,
for instance, the combination of MRT with immunotherapy. The subcoutaneous inocula-
tion of antigenically-enhanced radiation-disabled gliosarcoma cells grown in vitro showed
a significant increase in the survival time in 9L gliosarcoma-bearing rats [Smilowitz 2002,
Smilowitz 2006]. Additionally, MRT was also successfully used in combination with drugs
that produce a cytotoxic effect [Régnard 2008a] or an increase in the radiosensitivity [Schültke 2008]
of tumour cells.
The latest efforts are mainly directed to an enhancement of dose deposition in the tu-
mour by the combination of MRT with high-Z labelled-compounds. These can be selec-
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tively accumulated within the tumour prior to any irradiation protocol. This idea was first
proposed by Dilmanian et al. [Dilmanian 2007a] and applied experimentally by Régnard et
al. [Régnard 2008a]. The injection of gadolinium compounds Gd-DTPA (resulting from the
union of Gd with diethylene triamide pentaacetic acid, DTPA) in the tumour prior to MRT ir-
radiation improved the life span of rats by a factor greater than two. This is because the prob-
ability of undergoing a photoelectric interaction increases significantly for the energy range
of the MRT spectrum in the presence of high-Z contrast agents. Therefore, a localised dose
enhancement in the tumour is achieved. Similar results were obtained with Au@DTDTPA-Gd.
The combination of Gd and Au with a dithiolated derivative of DTPA (DTDTPA) permitted
both the follow up by x-ray imaging and MRI [Alric 2008].
The use of other lanthanides with chemical properties similar to those of Gd (Z=64) can
also be found in a biocompatible formulation with DTPA: holmium (Z=67), erbium (Z=68),
ytterbium (Z=70) and lutetium (Z=71). Some these approaches have already been used
and commercialised for medical applications [Koudelková 2003, Nawroth 2008, Yasui 2008].
Gold (Z=79) and iodine (Z=53) were also successfully used as dose enhancers in preclinical
trials with kilovoltage x-rays [Adam 2005, Hainfeld 2010]. Some new nanoparticles based
on Hf (Z=72), which preclude the metabolism of living organisms due to their structure,
have been recently developed [NANOBIOTIX R© 2012]. Finally, thallium (Z=81) is also a
good candidate due to its high-Z; it has already been employed for experimental treatment
of glioma-bearing rats [Ljunggren 2004].
1.5.2 Previous MC dosimetric studies in MRT
Several Monte Carlo (MC) dosimetric studies were performed to guide the aforementioned
biological research. Table 1.3 shows some of the most relevant MC studies in MRT (in chrono-
logical order). The main features of the microbeams and the phantoms used for the simula-
tions are also detailed; the studies marked in bold are related to this PhD work and they will
be presented in chapter 2.
The first MC dosimetric study in MRT was performed by Slatkin et al. [Slatkin 1992].
Despite the fact that the importance of including electron transport was recognised in this
work, dose distributions were initially computed by partially considering charged particle in-
teractions (INHOM, EGS4 + CPE codes). Subsequently, similar simulations were repeated
by other authors who used sophisticated codes which included more accurate cross sections
and a single-collision electron transport approach (PSI-GEANT [Stepanek 2000]) or a mixed
approach (PENELOPE [Siegbahn 2005, Siegbahn 2006] and GEANT4 [Spiga 2007] codes).
Differences in PVDR values were of the order of 10–20% with respect to the first MRT MC
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study [Slatkin 1992]. The impact on the lateral dose profiles for the different type of inter-
actions is represented in figure 1.19.
Figure 1.19: Impact on the lateral dose profiles of suppressing different types of interactions: the pho-
toelectric effect, Compton scattering and electron transport. The microbeam size corresponds to 25 µm.
Extracted from [Siegbahn 2006].
The important role of the low-energy physics models implemented in MC codes has been
emphasised in different works [Siegbahn 2006, Spiga 2007]. In particular, significant differ-
ences were observed in the dose profiles and PVDR values obtained with GEANT4 and with
PENELOPE. Deviations were mainly attributed to the cross sections and to the algorithms
for tracking secondary interactions used in the GEANT4 code [Torres 2004, Spiga 2007].
Two early works (with the EGS4 code) included the real spectrum and polarisation state
of the synchrotron beam in the simulations [Orion 2000, Felici 2005a], while other studies
considered non-polarised monochromatic beams. A very interesting publication of De Felici
et al. showed that the polarisation of the beam had a non-negligible effect on the dose cal-
culations away from the centre of the microbeam array [Felici 2005a]. Since the scattering
of polarised photons is now considered in the PENELOPE code (version 2008), recent MRT
studies also include this feature [Martínez-Rovira 2012a, Martínez-Rovira 2012b].
The simplification of the real irradiation source geometry was a common practice among
authors of theoretical MRT studies (see table 1.3). Indeed, identical, parallel, perfectly rect-
angular microbeams were usually considered. The dose of a single microbeam was simulated
and a superposition algorithm was used to generate the dose profile of the complete array.
These simplifications failed to account for the source size and shape, the beam divergence
along the distance from the synchrotron source to the patient position or any geometrical
and scattering effect arising from the radiation transport through the beamline.
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Nettelbeck et al. showed, by using simple models, that these approximations could lead to
inaccuracies in the valley doses, penumbral regions of dose profiles and in the PVDR values.
If beam divergence was included, an increase of 26% in the penumbra region and 10% in
the valley doses was observed. Furthermore, modelling of a synchrotron-distributed source
rather than a point source resulted in almost 30% larger penumbral doses [Nettelbeck 2009].
See figure 1.20. Additionally, De Felici et al. reported that the effects induced by the fine
structure of biological tissues were important for the microbeam dose deposition assessment
[Felici 2005b, Felici 2007].
Figure 1.20: Influence of the beam divergence (top) and source model (bottom) for a single microbeam
scored between a depth of 1 and 2 cm in water. Extracted from [Nettelbeck 2009].
All aforementioned works were performed on a water phantom. The first realistic dosi-
metric study of MRT dose distributions in a human head phantom was performed by Orion
et al. [Orion 2000]. The posterior study of Prezado et al. [Prezado 2009a] was also de-
voted to the dose assessment in a human head phantom but with particular interest in the
dose enhancement obtained in a Gd-loaded tumour. Other studies considered heterogeneous
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phantoms for lung cancer applications [Company 1998]. It is important to point out that the
use of realistic geometries is essential for correct dose assessment. For example, the valley
dose in a centrally located tumour in a water phantom is around 2.8 times higher than that
of a head phantom. The difference is mainly ascribed to the presence of bone. Thus, MC
studies performed in this PhD considered both a realistic source model and phantom.
1.5.3 Previous experimental dosimetric studies in MRT
In parallel, several experiments based on different dosimetric systems were performed. The
main challenge lies in developing a detector with a very high spatial resolution that is able to
cope with the high dose rates and high doses used in MRT.
Among the different approaches, solid state detectors were the first to be explored. Rosen-
feld et al. used a metaloxide-semiconductor field-effect transistor (MOSFET) in ‘edge on’
mode scanned through the beam and compared it with other experimental detector sys-
tems. The study showed the superiority of the MOSFET when mapping narrow radiation
beams since the spatial resolution was mainly determined by the sensitive gate-oxide layer
(1 µm in this case) [Rosenfeld 1996, Rosenfeld 1999, Kaplan 2000]. Orion et al. compared
experimental results with MC data and they found relatively good agreement in the lat-
eral dose fall-off of a single microbeam [Orion 2000]. Subsequent works measured ex-
perimental absolute peak and valley doses in a PMMA phantom by using a similar MOS-
FET; they found that experimental doses were 20% smaller than the expected MC values
[Rosenfeld 2001, Bräuer-Krisch 2003]. A study of Siegbahn et al. found that MC simula-
tions estimated PVDR values up to 50% higher than experimental data. The main sources
of discrepancies were attributed to the energy dependence response of the MOSFET detector
[Siegbahn 2009] and to the impact of the microbeams on the elements of the detector set-up,
which had a high average atomic number [Rosenfeld 2005].
Thermoluminescence (TL) systems have also been used in MRT. In particular, LiF:Mg,Cu,P
(MCP) powder (minimum MCP grain size: 0–45 µm). The observed differences in the PVDR
values up to 20% were attributed to the detector design. The limitations of the reader might
also have played a role [Ptaszkiewicz 2008].
Despite its limitations, the most suitable detector system for MRT available nowadays
seems to be radiochromic films. In particular, Gafchromic R© films [ISP R© 2012]. These films
provide high spatial resolution and enable PVDR values to be assessed. They have been
successfully used to record doses in synchrotron sources and to evaluate PVDR values in
MRT [Crosbie 2008, Bräuer-Krisch 2009, Nariyama 2009, Martínez-Rovira 2012a]. Although
Crosbie et al. found some differences in the measured (films) and calculated (MC) values,
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they were attributed to the simplified models used in the MC calculations [Crosbie 2008].
MC results with an accurate source model showed very good agreement with experimental
data obtained with radiochromic films, as will be presented in section 2.5.
Recently, other detectors such as TL Ge-doped silica fibres [Abdul Rahman 2010], fluo-
rescence nuclear track detectors [Bratz 2011] or high resolution optical calorimetry systems
[Ackerly 2011] are under investigation. Further studies are warranted to completely charac-
terise these detectors and evaluate their use in MRT. Silicon strip detectors have also been
proposed to perform online dosimetry [Cullen 2011].
A review of the systems used or that can be potentially used for MRT can be found
in [Braüer-Krisch 2010a]. Fundamentals on detector systems are beyond the scope of this
work and can be found in the literature [Knoll 2000].
1.5.4 Dosimetry for forthcoming clinical trials in MRT
The success of the preclinical studies opened the way to future clinical trials in MRT at the
ESRF [Renier 2008, Requardt 2010]. In order to minimise the risk, the first phase of the
clinical trials will consist of the treatment of spontaneous tumours in large animals (cats
and dogs) [Bräuer-Krisch 2010b]. The relatively high incidence of some cancers, similar
biological behaviour, large body size, comparable responses to cytotoxic agents, and shorter
overall lifespan are the factors that contribute to the advantages of this pet animal model
[MacEwen 1990].
Within this framework, an important part of this PhD work was devoted to establishing
accurate dosimetry in MRT. In particular, extensive work was performed both from the MC
simulation and experimental dosimetry points of view. An introduction to the MC PENE-
LOPE/PENEASY code used to perform the simulations and the experimental methods em-
ployed in absolute and relative MRT dose measurements will be presented in the following
sections.
1.5.4.1 The MC PENELOPE/PENEASY code
PENELOPE [Baró 1995, Sempau 1997, Salvat 2008], an acronym of PENetration and Energy
LOss of Positrons and Electrons in matter, is a MC simulation package that describes the
coupled transport of photons, electrons and positrons in a wide energy range (from 50 eV to
1 GeV) and in arbitrary materials systems. PENELOPE, which is coded in FORTRAN, is both
free and open source. It was developed at the Universitat de Barcelona and it is distributed
by the Nuclear Energy Agency (NEA) and the Radiation Safety Information Computational
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Center (RSICC) of the Oak Ridge National Laboratory (ORNL). Presently, there are more than
1500 copies of the code distributed around the world.
PENELOPE uses detailed simulation for photon transport and a mixed approach for
charged particle transport. Hard electron and positron interactions are simulated individ-
ually, whereas a condensed simulation is applied for soft interactions. This classification is
based on certain user-defined parameters: the cutoff energy for the production of hard inelas-
tic events (WCC) and hard bremsstrahlung (WCR), the maximum allowed step length (dsmax),
the average angular deflection (C1) and the maximum average energy loss (C2) in a single
multiple-scattering step. All particles are transported until their kinetic energy is below the
absorption energy (EABS), at which the remaining energy is locally absorbed.
PENELOPE is widely used in the medical physics field and, in particular, in dose calcula-
tions for spatially fractionated synchrotron RT techniques (see [Siegbahn 2006, Nettelbeck 2009,
Prezado 2011a, Martínez-Rovira 2012a], among others). The flexibility and simplicity of the
simulation code, along with the accurate physical models implemented in the package, espe-
cially for low-energy radiation transport, have made PENELOPE the best candidate for the
aims of this work.
The most relevant interactions in our energy range (mean energy ∼ 100 keV) are Comp-
ton scattering and the photoelectric effect. Compton scattering cross sections are obtained
from the relativistic impulse approximation (RIA), which accounts for Doppler broadening
and binding effects. Photoelectric cross sections are interpolated from tabulations in the eval-
uated photon data library (EPDL) from the Lawrence Livermore National Laboratory (LLNL)
[Cullen 2011].
The polarisation state of photons is also considered in the scattering events [Salvat 2008].
Polarisation is described by means of the Stokes parameters (P1, P2, P3) [Fano 1954], follow-
ing the convention commonly used in Quantum Mechanics [Salvat 2008]. Thus, in our set-up
(see figure 1.6, right), P3 determines linear polarisation along the horizontal and vertical axis,
P2 represents circular (right and left) polarisation and P1 corresponds to polarisation in the
lines that bisect the transversal plane. Polarisation effects are especially relevant in our case
as synchrotron beams are highly linearly polarised in the electron orbit plane.
As regards electron transport, the dominant energy loss mechanism in our energy range
are inelastic collisions. The description of inelastic scattering of charged particles is per-
formed on the basis of a schematic generalised oscillator strength (GOS) model with mean
excitation energies taken from ICRU Report 37 [ICRU-37 1984]. Elastic collisions of elec-
trons, which are mainly responsible for angular deflections, are simulated by using data
obtained from relativistic partial-wave calculations [Salvat 2005].
PENELOPE users can adapt a steering main program in order to define the radiation
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source, the simulation parameters, the quantities of interest to be scored, variance-reduction
(VR) techniques to be applied and report the final results. The modular general-purpose
main program for PENELOPE named PENEASY [Sempau 2011] has been employed in this
thesis. It was developed at the Institut de Tècniques Energètiques (Universitat Politècnica de
Catalunya) and it is both free and open source.
The PENEASY code permits the dose computation in voxelised geometries as well as its
superposition with objects limited by quadric surfaces. Each voxel is defined by the material
index and the mass density. The code accounts for the density changes between voxels by
scaling the remaining distance up to the following interaction with the inverse of the den-
sity of the voxel being traversed. See the work of Sempau et al. [Sempau 2011] for more
information on this code.
1.5.4.2 Experimental dosimetry methods in MRT
The experimental dosimetry in MRT is divided into two parts. The first is related to the
absolute dosimetry in reference conditions (seamless field), while the second consists of the
dose assessment in non-reference conditions (MRT). Details of both parts are presented here.
Absolute dosimetry in reference conditions (seamless field)
The absolute dosimetry in MRT was performed by following as closely as possible the recom-
mendations compiled in the International Atomic Energy Agency (IAEA) Technical Reports
Series (TRS) 398 [IAEA-TRS-398 2005]. The ‘medium x-ray energies’ recommendations are
associated with x-ray beams with half-value layers (HVL) greater than 2 mm of aluminium.
The MRT beam fits within the medium-energy x-ray range since its aluminium HVL was found
to be 16 mm [Siegbahn 2007].
In this case, the dose measurement in reference conditions (seamless irradiation field,
named broad beam, hereafter) is performed at 2 g/cm2. The reference field size was chosen
to be 2×2 cm2 instead of 10×10 cm2 since it is closer to the field sizes that are going to be
used for MRT treatments.
Cylindrical ionisation chambers (IC) with a cavity volume in the range of 0.1–1.0 cm3
are recommended for reference dosimetry in medium-energy x-ray beams. Although the
most widely used IC for absolute dosimetry is the 0.6 cm3 Farmer R©, our dosemeter of choice
was the Semiflex 31010 IC (active volume of 0.125 cm3) [PTW R© 2012] due to the need
to perform dose measurements for very small fields (down to 1×1 cm2). The IC was cali-
brated in kilovoltage x-rays. During measurement, the reference point of the chamber (on
the chamber axis at the centre of the cavity volume) was placed at the reference depth
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[IAEA-TRS-398 2005].
Water is the recommended medium for measurements of absorbed dose. There should
be a margin of at least 5 g/cm2 beyond all four sides of the largest field size and 10 g/cm2
beyond the maximum depth of measurement. Additionally, the window of the phantom
should be made of plastic with a thickness of 0.2–0.5 cm. Dose measurements for hori-
zontal beams performed with the water tank MP3-P T41029 [PTW R© 2012] (dimensions:
35×45×48 cm3; PMMA entrance window of 0.5 cm) satisfied the recommended criteria
defined in [IAEA-TRS-398 2005]. The water tank was filled with distilled water. The water-
equivalent thickness of the window was calculated as the product of its thickness by the
density of PMMA (ρ=1.19 g/cm3).
These measurements had to be repeated for each experiment and/or refill due to small
misalignments of beamline elements or beam emittance changes that could potentially lead
to differences in the dose of up to 10%. Since the accurate setting of the water tank in
the Biomedical Beamline experimental area is very time consuming, RW3 (Goettingen White
Water) solid-water slab phantoms (30×30×12 cm3) [PTW R© 2012] were used instead in our
measurements. However, this will not be the case for dose assessment before patient treat-
ment in forthcoming MRT clinical trials. The TRS 398 states that solid-water phantoms can be
used for routine measurements provided that the relationship between dosimetry readings in
water and in the solid-water phantom have been previously established [IAEA-TRS-398 2005].
In our case, a 5.7 ± 0.1% higher dose deposition in water with respect to RW3 solid-water
has been measured and computed by MC simulations [Prezado 2011a]. Figure 1.21 shows
both experimental set-ups.
Determination of the absorbed dose to water under reference conditions is expressed as
(see [IAEA-TRS-398 2005])
Dw,Q =MQND,w,Q0 KQ,Q0 , (1.4)
where ND,w,Q0 is the calibration factor in terms of absorbed dose to water for the beam qual-
ity Q0 provided by the calibration laboratory; MQ is the reading of the dosemeter corrected by
influence quantities such as temperature and pressure (KTP = [P0 (273.2 + T )]/[P (273.2 +
T0)], with T0=20 ◦C and P0=101.3 kPa), ionic recombination (Ks=1.000), polarity effect
(Kpol < 0.3%) and electrometer calibration (Kelec=1.000 ± 0.5%) [PTW R© 2012]; KQ,Q0 is
a chamber-specific factor which corrects for differences between the reference beam quality
Q0 and the actual beam quality Q. The calibration laboratory provided us with KQ,Q0 values,
which were obtained from measurements [Ma 1991, PTW R© 2012]. The KQ,Q0 value is 0.953
± 0.031 for the closest beam quality [Prezado 2011a].
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Figure 1.21: Phantoms used in MRT experimental measurements. On the left, a monitored water tank
for horizontal beams (PTW MP3-P T41029 [PTW R© 2012]) full of distilled water is shown. On the right,
a RW3 solid-water slab phantom [PTW R© 2012] is placed on the high-precision goniometer. Inside both
phantoms, the thimble Semiflex IC 31010 [PTW R© 2012] is located at 2 g/cm2.
Standard dosimetry and reference calibration protocols assume exposure of the IC to a
uniform beam. However, as has been mentioned, the vertical dimensions of the beam at the
patient position are defined by the V slit size (50–800 µm). The beam is then scanned in the
vertical direction at constant speed. See figure 1.22. The work of Prezado et al. has proved
that this method is equivalent to measuring the dose deposited with uniform irradiation
[Prezado 2011b].
Figure 1.22: Scheme illustrating the dosimetry configuration. Since the vertical dimensions of the beam
at the patient position are very small, the IC (and the phantom) are moved at constant speed through the
synchrotron beam in order to sweep the whole irradiation field size. Extracted from [Prezado 2011b].
From these measurements, a value of dose rate D˙ was obtained. In particular, for the
maximum electron current and a V slit size of 50 µm, the dose rate was in the order of 60–
70 Gy/(mA.s). The scanning goniometer velocity (v) was set considering the desired dose
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(D), the value of the dose rate, the V slit size (dv) and the beam current (I) as follows
v = D˙ I dv
D
. (1.5)
Dosimetry in non-reference conditions (MRT)
In order to determine the dose deposited with one microbeam (peak dose) from the absolute
dose measured in the broad beam configuration, scatter factors were used [Prezado 2012a].
These factors take into account the field size dependence of dose deposition. Scatter factors
have been measured experimentally by using two alternative detection systems: a large area
chamber (LAC) type (Bragg Peak PTW 34070, with a diameter of 4 cm [PTW R© 2012]), fol-
lowing the method described in the work of Sánchez-Doblado et al. [Sánchez-Doblado 2007],
and HD-810 radiochromic films [ISP R© 2012]. See section 2.6 for more information on this
type of measurements.
Relative dosimetry in MRT was performed with HD-810 radiochromic films in homoge-
neous and heterogeneous slab-phantoms (composed of RW3 solid-water and RW3 solid-water
and bone, respectively). See details of the phantoms and the obtained results in section 2.5.
As has been mentioned, Gafchromic R© HD-810 films [ISP R© 2012] provide the high spatial res-
olution required to measure lateral dose profiles in MRT. Furthermore, the broad dose range
(from 10 to 400 Gy) also enables PVDR values to be assessed. Additionally, the manufacturers
of the HD-810 radiochromic films state that films are energy independent for photons with
energies above 200 keV [ISP R© 2012]; the energy dependence in the low energy range of our
spectrum has been considered sufficiently small to be ignored [Muench 1991, Crosbie 2008].
For the handling and calibration of the films, the recommendations provided by Task
Group 55 of the American Association of Physics in Medicine (AAPM) [Niroomand-Rad 1998]
were taken into account. In particular, films were cut in pieces and the position of each film
on each sheet was carefully numbered. For each dataset measurement, a group of films
was then selected from the same region on the same sheet. In this way, the uncertainties
arising from sheet-to-sheet uniformity (5%) were avoided and those coming from single-
sheet uniformities (3.2%) were minimised.
The spatial resolution of the typical flat bed scanner used in RT is not adapted to perform
dosimetry at the micron scale required in MRT. Instead, a microdensitometer (3CS Micro-
densitometer, J. L. Automation) was employed to read the films. See figure 1.23. This system
has a wide dynamic range (it is sensitive to optical densities (OD) from 0.2 to 6) and a very
high spatial resolution (around 5 µm).
40
1.5. Microbeam radiation therapy (MRT)
Figure 1.23: On the left, the microdensitometer (3CS Microdensitometer, J. L. Automation) used to read
the radiochromic films exposed to MRT irradiations. On the right, a piece of Gafchromic R© HD-810 film
after an MRT irradiation (3×3 cm2 field size).
The output of the microdensitometer is a magnitude named the pen deflection (PD),
which is related somehow to the OD; this magnitude varies at any adjustment of the micro-
densitometer. The dose assessment at one particular point is performed by comparing the
PD value of films irradiated in the broad beam configuration with a well-known dose (Dref)
with the PD value of the film under evaluation. An example of PD profile obtained with the
microdensitometer is shown in figure 1.24. A large representative set of films irradiated with
Dref moving from 0 Gy to 400 Gy (at intervals of 1–2 Gy for low doses, 5 Gy for intermediate
doses and 10–25 Gy for very high doses) was acquired at each experiment. Absolute peak
and valley doses were adjusted to the dynamic range of the HD-810 films and they were
selected to be as near as possible to the expected clinical doses.
The use of these types of systems is extremely time-consuming as the reading speed is very
low (a 1 mm ×1 mm scan at 5 µm step resolution takes more than 1 hour) and the delicate
optical and mechanical parts composing the microdensitometer forced us to frequently adjust
it to avoid any drift in the system [Zimmer 1978, Aydarous 2001]. This meant that we had
to perform short measurements of one profile (for instance 1–2 mm of the whole beam in the
region of interest). For each evaluated point, the measurement was repeated at least twice
on different days/run. In addition, each film was read a minimum of three times to ensure
reproducibility of data.
Further information on the working principle of the microdensitometer can be found
elsewhere [Swing 1998].
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Figure 1.24: Example of pen deflection (PD) profile obtained with the microdensitometer. The dose
assessment is performed by comparing the PD value of the film under study with the PD value of films
irradiated in the broad beam configuration with a well-known dose (Dref).
1.6 Minibeam Radiation Therapy (MBRT)
1.6.1 Introduction
The main drawback of MRT is that its widespread clinical implementation is limited nowa-
days due to the requirement of high dose rates. Only the high photon fluxes present in
synchrotrons enable a fast irradiation process (in a fraction of a second) that prevents arti-
facts caused by cardiosynchronous pulsations [Poncelet 1992]. Thicker beams used in MBRT
overcome these difficulties. Since the MBRT dose profiles are not as vulnerable as those of
MRT to beam smearing from cardiac pulsations, high dose rates are not needed. Hence, it is
conceptually possible to extend this technique by using modified x-ray equipment, creating
an opportunity for its implementation at hospitals [Dilmanian 2006, Babcock 2011].
In addition, the use of higher beam energies is feasible in MBRT (≥200 keV); this results
in lower entrance doses to deposit the same integral dose in the tumour, despite the larger
penumbral doses (penumbras are about 40 µm for a mean energy of 100 keV at 2 cm-depth
in a water phantom) [Prezado 2009c]. Furthermore, the clinical implementation of the inter-
laced method producing an homogeneous dose in the tumour is not possible in MRT due to
the higher technical precision required. These advantages triggered the exploration of MBRT
as a new radiotherapeutic approach.
Since the thicker beams and spacings employed in MBRT in comparison with thin mi-
crobeams may lead to different biological effects than those observed in MRT [Uyama 2011],
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experimental studies are warranted to evaluate the possible different tumour and normal
tissue response between MRT and MBRT.
1.6.2 Previous clinical trials in MBRT
The first hint about the preservation of healthy tissues (rat brain and spinal cord) with
thicker beams (270 µm; entrance dose of 750 Gy) was provided by Dilmanian et al. in 2005
[Dilmanian 2005]. However, the first experiments in MBRT were performed a few years later
by the same group in unidirectional and interlaced geometries [Dilmanian 2006]. Rat spinal
cords were irradiated with four 680-µm-wide minibeams with a spacing of 4 mm. Despite the
fact that some healthy tissue damage was observed, an entrance dose of 400 Gy was tolerated
in three out of four rats, as opposed to what happened in seamless beam irradiations. In addi-
tion, MBRT irradiations (680-µm-wide minibeams spaced by 1360 µm) of rat brains showed
a 4-fold higher tolerance with respect to broad beams [Dilmanian 2006]. This tolerance is
equivalent to that previously found in MRT [Dilmanian 2002]. In interlaced geometries, no
significant damage was observed outside the target area at any time for entrance doses up to
120 Gy [Dilmanian 2006].
This outcome motivated the implementation of this novel technique at the ESRF ID17
Biomedical Beamline [Prezado 2009b]. Some in vitro [Gil 2011] and in vivo [Prezado 2012b]
studies in white-beam MBRT have already been performed. They have showed a gain factor
of three in the mean survival time of 9L gliosarcoma bearing-rats with respect to controls
[Prezado 2012b]. However, additional preclinical studies need to be developed in order to
completely assess the TCP and NTCP curves for this new radiotherapeutic modality. The
use of MBRT with monochromatic x-rays is also being explored at the ESRF [Deman 2011,
Deman 2012].
1.6.3 Previous MC and experimental dosimetric studies in MBRT
The first MC dosimetric study in white-beam MBRT was performed by Dilmanian et al. [Dilmanian 2006].
In this work, a series of MC simulations (EGS4 code) in a water phantom for irradiation of
an array of 680-µm-wide planar minibeams spaced by 1360 µm (field sizes of 1.5×1.5 and
3×3 cm2) was assessed for unidirectional and interlaced irradiation geometries. Posterior
works performed calculations in a realistic voxelised human phantom (MCNPX code); in
particular, dose enhancement due to the presence of contrast agents together with MBRT
(680-µm-wide planar minibeams spaced by 1360 µm; field size of 2×2 cm2) was evaluated
by Gokeri et al. [Gokeri 2010]. Additional MC calculations (PENELOPE code) in 80 keV
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monochromatic MBRT were also performed [Deman 2011]. These MC studies used a simpli-
fied non-divergent irradiation source geometry.
The experimental dose assessment in white-beam [Dilmanian 2008] and monochromatic
[Deman 2011] MBRT was achieved by means of polymer gel dosimetry. MC calculations
showed good correlation with experimental dosimetry despite the large uncertainties (more
than 15%) arising from the gel reading method. Gel dosimetry can be used to check irra-
diation geometries and obtain an estimation of the dose distribution. For instance, these
methods were useful to prove that minibeam interlacing in the brain was possible even in
anthropomorphic head phantoms, since the three-dimensional pattern of the microplanar
arrays was shown not to be distorted by bone [Dilmanian 2008]. However, this method is
not accurate enough for a precise dose assessment, although recently developed PRESAGE R©
polymers read by an optical CT scan seem to achieve a higher spatial resolution [Doran 2010,
Abdul Rahman 2011].
1.6.4 Dosimetry for future preclinical trials in MBRT
In this work, MC calculations in MBRT were also performed with the PENELOPE/PENEASY
code (see section 1.5.4.1).
The experimental dosimetry in reference conditions was performed as has been explained
in section 1.5.4.2. The dose in non-reference conditions (MBRT) was also evaluated by
means of scatter factors. They were assessed by MC simulations and measurements by using
Gafchromic R© HD-810 films [ISP R© 2012]. See section 2.7.
The thicker beams used in MBRT allow radiochromic films to be read with a flat bed
scanner (Epson Perfection V750-M Pro Scanner [EPSON R© 2012]), at 1200 dpi resolution,
instead of the microdensitometer. See figure 1.25. For the reading and analysis of the films,
the methodology described in the work of Devic et al. [Devic 2005] was followed. The trans-
mission scanner readings of the films (I) were obtained by extracting the red channel from
the red-green-blue (RGB) image [Stevens 1996]. The optical density (OD) at each pixel was
then calculated by
OD = −log10
(
I − Iback
I0 − Iback
)
, (1.6)
where I and I0 are the readings for exposed and unexposed film pieces, respectively; and
Iback is the zero-light transmitted intensity value.
The absorbed dose (D) at any point in the film is computed by using the calibration curve
(D versus OD). In order to obtain this curve, films were irradiated in broad beam with well-
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Figure 1.25: On the left, the flat bed scanner (Epson Perfection V750-M Pro Scanner [EPSON R© 2012])
used to read the radiochromic films exposed to MBRT irradiations. On the right, a piece of Gafchromic R©
HD-810 film for an MBRT irradiation (3×3 cm2 field size).
known doses. The dose calibration range went from 10 to 400 Gy (which is the recommended
range of use for HD-810 films [ISP R© 2012]). The central average OD of these films was
evaluated for each dose (equation (1.6)). Figure 1.26 shows an example of calibration curve,
which follows a quadratic polynomial regression, D = c1OD+ c2OD2, where ci (i=1,2) are
the unknown fit parameters. Each film box was calibrated separately.
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Figure 1.26: Example of calibration curve of the Gafchromic R© HD-810 films [ISP R© 2012], which fol-
lows a quadratic polynomial regression D = c1OD + c2OD2, with c1=334.91171 and c2=237.83931,
and a correlation coefficient of R2=0.99998.
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2.1 Global summary
This PhD work deals with different features related to small (micrometre-sized) field dosime-
try involved in spatially fractionated synchrotron radiotherapy techniques: MRT and MBRT.
MC simulations and experimental methods were used with this aim in mind.
The core of this work consisted of the development and benchmarking of a MC-based
computation engine for a treatment planning system (TPS) devoted to MRT within the frame-
work of the preparation of forthcoming MRT clinical trials. Additional achievements were the
definition of safe MRT irradiation protocols, the assessment of scatter factors in MRT and the
further improvement of the MRT therapeutic index by injecting a contrast agent into the
tumour. Finally, a dosimetry protocol for future preclinical studies in MBRT was established.
The work performed in this thesis, which is presented in several papers published in (or
submitted to) peer-reviewed journals, have provided the dosimetric tools for forthcoming
MRT clinical trials in pets and the MBRT preclinical trials in small animals.
2.2 List of contributions
The results of this work are reported in the following six papers:
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I.- I. Martínez-Rovira, J. Sempau, J. M. Fernández-Varea, A. Bravin and Y. Prezado, "Monte
Carlo dosimetry for forthcoming clinical trials in x-ray microbeam radiation therapy",
Phys. Med. Biol. 55, 4375–4388 (2010). Featured article (high-interest article across
IOP). doi:10.1088/0031-9155/55/15/012.
II.- I. Martínez-Rovira and Y. Prezado, "Monte Carlo dose enhancement studies in mi-
crobeam radiation therapy", Med. Phys. 38, 4430–4439 (2011). doi:10.1118/1.3603189.
III.- I. Martínez-Rovira, J. Sempau and Y. Prezado, "Development and commissioning of
a Monte Carlo photon beam model for the forthcoming clinical trials in microbeam
radiation therapy", Med. Phys. 39, 119–131 (2012). doi:10.1118/1.3665768.
IV.- I. Martínez-Rovira, J. Sempau and Y. Prezado, "Monte Carlo-based treatment planning
system calculation engine for microbeam radiation therapy" (manuscript/submitted to
Med. Phys.)
V.- Y. Prezado, I. Martínez-Rovira and M. Sánchez, "Scatter factors assessment in mi-
crobeam radiation therapy", Med. Phys. 39, in press (2012).
VI.- Y. Prezado, I. Martínez-Rovira, S. Thengumpallil and P. Deman, "Dosimetry protocol
for the preclinical trials in white-beam minibeam radiation therapy", Med. Phys. 38,
5012–5020 (2011). doi:10.1118/1.3608908.
For clarity, each paper will be preceded by a brief introduction.
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2.3 Paper I: Monte Carlo dosimetry protocol for forthcoming clin-
ical trials in x-ray MRT
Introduction
When moving from MRT investigations in rodents to clinical application in humans, it is nec-
essary to first perform a risk analysis. In particular, the definition of safe irradiation protocols
is required. The identification of safe dose limits was carried out by evaluating the maximum
peak and valley doses achievable in the tumour to keep the valley dose in the healthy tissue
under well-known tolerances in conventional RT [Dilmanian 2002, Bentzen 2010].
As has been explained in section 1.1.2, the most common RT practice in the last 100 years
is the fractionation of the dose in small doses of radiation (typically in 2 Gy per fraction) for
many days. Since in MRT high doses of radiation are delivered to the tumour in one fraction,
the expected biological effects and tissue tolerances will depart from values in conventional
RT. In order to establish the dose equivalence between the different fractionation schemes,
the concept of normalised total dose (NTD) has been used [Flickinger 1990, Joiner 2009].
The applicability of this radiobiological model in MRT will be discussed and justified in the
paper [Brenner 2008, Kirkpatrick 2009].
Dose distributions in a realistic head phantom were assessed by MC simulations in several
irradiation and phantom configurations, i.e., for various tumour positions, skull thicknesses
and c-t-c distances (PENELOPE/PENEASY code, see section 1.5.4.1). The resulting physical
dose was then translated to biological equivalent dose by using the aforementioned radiobi-
ological models.
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Abstract
The purpose of this work is to define safe irradiation protocols in microbeam
radiation therapy. The intense synchrotron-generated x-ray beam used for the
treatment is collimated and delivered in an array of 50 μm-sized rectangular
fields with a centre-to-centre distance between microplanes of 400 μm. The
absorbed doses received by the tumour and the healthy tissues in a human
head phantom have been assessed by means of Monte Carlo simulations. The
identification of safe dose limits is carried out by evaluating the maximum peak
and valley doses achievable in the tumour while keeping the valley doses in the
healthy tissues under tolerances. As the skull receives a significant fraction of
the dose, the dose limits are referred to this tissue. Dose distributions with high
spatial resolution are presented for various tumour positions, skull thicknesses
and interbeam separations. Considering a unidirectional irradiation (field size
of 2×2 cm2) and a centrally located tumour, the largest peak and valley doses
achievable in the tumour are 55 Gy and 2.6 Gy, respectively. The corresponding
maximum valley doses received by the skin, bone and healthy brain are 4 Gy,
14 Gy and 7 Gy (doses in one fraction), respectively, i.e. within tolerances (5%
probability of complication within 5 years).
(Some figures in this article are in colour only in the electronic version)
1. Introduction
Gliomas are extremely radioresistant tumours. The high absorbed doses needed to ablate
gliomas are limited by the high morbidity of the surrounding healthy tissue, especially
0031-9155/10/154375+14$30.00 © 2010 Institute of Physics and Engineering in Medicine Printed in the UK 4375
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in children (Kagan et al 1976). The average lifespan for these patients is less than
1 year, and generally no patient survives 5 years after treatment (Behin et al 2003). High-
grade gliomas are still of poor prognostic value despite the development of many innovative
therapies. Stereotactic radiosurgery (Phillips et al 1994), intensity-modulated radiation therapy
(Cardinale et al 1998) and boron neutron capture therapy (Barth et al 2005) are some examples.
The use of radiotherapy plus concomitant and adjuvant temozolomide has allowed a significant
prolongation of survival (Stupp et al 2002, 2005, 2009). However, the outcome still remains
unsatisfactory and the management of glioblastomas is mainly palliative.
One possible way to improve the therapeutic index in radiotherapy is to employ new
techniques based on what is known as the dose–volume effect: the smaller the field size,
the higher the tolerance of the healthy tissue (Curtis 1967). Microbeam radiation therapy
(MRT) is a synchrotron radiotherapy technique that relies on this fact. Such an irradiation
can be palliative or curative while causing minimal damage to the contiguous healthy
tissue.
In MRT, the irradiation is carried out by means of an array of parallel x-ray microbeams
(from 25 to 50 μm thick), with a centre-to-centre (c-t-c) distance between microbeams of
200 or 400 μm. The x-ray energy spectrum ranges from about 50 to 500 keV, with a
mean energy around 100 keV (Siegbahn et al 2006). The microbeams are produced by a
multi-slit collimator that spatially fractionates in the horizontal direction the beam coming
from the synchrotron source (Bra¨uer-Krisch et al 2009). Targets are then vertically scanned
through the microfractionated beam to deliver microplanes of x-rays. The synchrotron
origin of the microbeams confers them two crucial features: negligible divergence (allowing
the production of sharply defined beam edges in tissue) and high flux (enabling a fast
irradiation process that prevents motion artifacts of the subject caused by cardiosynchronous
pulsation).
The MRT irradiation scheme results in dose profiles consisting of a pattern of peaks and
valleys, i.e. with high doses in the microbeam paths and low doses in the spaces between them
(Siegbahn et al 2006). The minimum dose in the central region between two microbeams is
named valley dose and the dose in the centre of the microbeam is the peak dose.
The ratio between the peak dose and the valley dose (peak-to-valley dose ratio, PVDR)
depends on the incident x-ray beam energy, the tissue composition, the beam thickness, the
c-t-c distance and the irradiation field size but it does not depend on the peak dose prescription
in the tumour. Despite being an important dosimetric parameter in this type of spatially
fractionated techniques, PVDR is a relative quantity and it is also necessary to have the
information on both peak and valley doses.
During the last two decades, several preclinical studies have shown the sparing effect
of the healthy tissue using MRT on the brain of adult rats (Slatkin et al 1995, Regnard
et al 2008), suckling rats (Laissue et al 1999), duck embryos (Dilmanian et al 2001), piglets
(Laissue et al 2001), chick-embryo chorio-amniotic membranes (Blattmann et al 2005) and
nude mice (Serduc et al 2008). In parallel, it has been proven that MRT can ablate highly
aggressive animal tumour models such as 9L brain gliomas (Laissue et al 1998, Dilmanian
et al 2002, Smilowitz et al 2006), EMT-6 carcinoma (Dilmanian et al 2003) and SCCVII
carcinoma (Miura et al 2006).
Dilmanian et al (2002) stressed the fact that MRT could cure 9L-bearing animals without
killing all tumoral cells. They suggested that MRT effects might involve mechanisms other
than a direct ionizing radiation effect on tumoral cells, like poor regenerative capacity of
tumoral vessels after radiation exposure. Additional mechanisms such as abscopal effects
may also play a role. The analysis of the results for different beam spacings from Dilmanian
et al (2002) and Regnard et al (2008) suggests that a high lesion density induced by the
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microbeams on tumour vasculature could be sufficient to treat brain tumours. Indeed, a
decrease in microbeam spacing may increase the number of vascular lesions per unit volume.
Nevertheless, the biological mechanisms following an MRT irradiation are not yet fully
understood. It has been hypothesized that the sparing effect in the healthy tissue along the
beam paths is due to a rapid biological repair of the microscopic lesions by the minimally
irradiated cells contiguous to the irradiated tissue slices (Slatkin et al 1995, Laissue et al 1998,
Dilmanian et al 2001). Dilmanian et al (2002) have shown that the sparing effect of MRT
seems to depend mostly on the valley dose. The brain-sparing effect (measured by the onset
of the appearance of white matter necrosis) vanishes only when the valley dose approaches
the tissue tolerance to broad beams. As for the PVDRs, the valley doses depend on the x-ray
beam energy spectrum, on the spacing between microbeams, on the irradiation field size but
also on the peak doses. A smaller c-t-c distance results in higher valley doses and in lower
tolerances (Dilmanian et al 2002, Regnard et al 2008).
Following the success of preclinical studies, the Biomedical Beamline ID17 of the
European Synchrotron Radiation Facility (ESRF) is planning to proceed towards clinical
trials (Laissue et al 2007, Renier et al 2008). In this context, Monte Carlo (MC) absorbed
dose calculations in realistic phantoms are needed to define irradiation protocols in MRT.
The first MC dosimetry studies in MRT were done by Slatkin et al (1992). The simulations
were performed for 25 μm thick microbeams spaced 50, 100 or 200 μm, impinging on a
16 cm long cylindrical water phantom with a diameter of 16 cm. Subsequent works considered
similar water phantoms (Stepanek et al 2000, De Felici et al 2005, Siegbahn et al 2006, Spiga
et al 2007). Company and Allen (1998) calculated also the dose distribution in a tissue/lung/
tissue phantom and Orion et al (2000) in a spherical human head phantom with a diameter
equal to 17.2 cm (0.6 cm of skull and 16 cm of brain). Prezado et al (2009b), who investigated
the dose enhancement in MRT by loading the tumour with gadolinium, have also performed
the simulations in a human head phantom inspired by the one described in the work of Harling
et al (1995).
It is important to point out that the use of realistic geometries is essential for a correct dose
assessment. For example, the valley dose in a centrally located tumour in a water phantom is
around 2.8 times higher than that of the head phantom considered in the present study. The
difference has to be mainly ascribed to the presence of the bone.
To the best of our knowledge, the only dosimetric studies carried out in MRT using a
head phantom are those of Orion et al (2000) and Prezado et al (2009b). Orion et al (2000)
used 30 μm thick microbeams, a c-t-c distance between microplanes of 100 and 200 μm and
field sizes of 3×3 and 6×6 cm2. In Prezado et al (2009b), the microbeam width, the c-t-c
distance and the irradiation field size were 50 μm, 200 μm and 2×2 cm2, respectively. The
PVDR value for a lateral irradiation of a centrally located tumour in Prezado et al (2009b) is
in agreement with our results in section 3.4 and in figure 6.
None of the parameters used in previous papers are going to be employed in the
forthcoming clinical trials at the ESRF. The chosen irradiation parameters have been fixed to
a microbeam width of 50 μm and a c-t-c distance of 400 μm in order to reach a compromise
between healthy tissue sparing and tumour eradication.
For the first time, this work presents a systematic study of the dose distribution and the
corresponding conversion of absorbed dose to normalized total dose considering biological
effects in a realistic head phantom with a high spatial resolution. The maximum dose
prescription achievable in the tumour is evaluated in different cases by adopting the criterion of
keeping the valley dose in the healthy tissue as low as possible and below tissue tolerances for
a broad beam (Dilmanian et al 2002). In this way, safe and conservative irradiation protocols
in MRT can be defined.
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2. Materials and methods
2.1. Monte Carlo simulation code: PENELOPE/penEasy
The MC code PENELOPE (Salvat et al 2006, Sempau et al 1997) has been employed.
PENELOPE simulates the coupled transport of photons, electrons and positrons in the energy
interval from 50 eV to 1 GeV, and in arbitrary material systems. PENELOPE has been widely
used in the medical physics field, see for example Sempau et al (2001), Torres et al (2004),
Sempau and Andreo (2006), Ferna´ndez-Varea et al (2007) and Sterpin et al (2008) to name
a few. In this work, penEasy (Sempau and Badal 2008), a structured general-purpose main
program for PENELOPE, has been adopted to do the calculations.
The most relevant photon interaction mechanisms in the energy range of concern in
MRT (mean energy ∼100 keV) are Compton scattering and photoelectric effect. These
interactions are simulated one by one until the photon reaches an energy lower than a user-
defined threshold (the absorption energy). Compton scattering is modelled by means of
the relativistic impulse approximation. This formalism takes into account both Doppler
broadening and binding effects of the atomic electrons. Photoelectric cross sections are
interpolated from the tabulations of the Evaluated Photon Data Library (Cullen et al 1997).
Many-body and aggregation effects are ignored and atoms are considered as independent.
Regarding electron transport, PENELOPE implements a mixed simulation algorithm in
which interactions are classified into hard and soft. They are regarded as hard when the energy
loss or the angular deflection of the transported particle is above certain user-defined cutoffs.
Hard interactions are simulated individually. Soft interactions are simulated by resorting to
multiple-scattering theories. Angular deflections are mainly caused by elastic scattering, while
inelastic collisions are the dominant energy loss mechanism. Elastic scattering cross sections
are calculated from relativistic partial-wave analysis (Salvat et al 2005). Inelastic scattering is
described by means of a schematic generalized oscillator strength model with mean excitation
energy values taken from the ICRU Report 37 (ICRU 1984).
2.2. Simulation geometry and configuration
The considered head phantom is composed of slabs of skin, bone and brain, with thicknesses
equal to 2 mm, 1 cm and 16 cm, respectively. The dimensions of the human brain are taken
from Harling et al (1995).
To obtain the dose distribution for the whole field, we have adopted the following approach.
First, we compute the dose distribution for a single microbeam in the head phantom. Next, for
each spatial location, the dose is evaluated as the sum of the contributions of each individual
microbeam to cover the desired irradiation field. In agreement with previous dosimetry works
(Boudou et al 2005, Prezado et al 2009a, Prezado et al 2009b), a field size of 2×2 cm2 is
assumed in the simulations, which corresponds to the tumour size. In the calculations, the
dose prescription is referred to as the centre of a ‘virtual’ tumour located at a certain depth.
Absorbed doses are tallied in voxels of 2 μm in the lateral direction of the microbeam,
1 mm in the vertical direction of the microbeam and 2 mm in depth. Doses were scored up to
2 cm away from the centre of the microbeam in the lateral direction (see figure 1).
There are different simulation parameters to be considered in PENELOPE. Users are
required to define an absorption energy (EABS) for each particle type (γ , e±) at which histories
are terminated and their remaining energy is locally absorbed. Charged-particle transport also
requires the setting of the following parameters: C1, which determines the average angular
deflection between two consecutive hard elastic events; C2, which defines the maximum
average fractional energy loss in a single multiple-scattering step; WCC, the cutoff energy for
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Figure 1. Scheme of the dimensions and orientation of the head phantom, as well as the voxels
used to tally the dose distribution in the simulations (not to scale).
the production of hard inelastic events; WCR, the cutoff energy for the production of hard
bremsstrahlung; and DSMAX, the maximum allowed step length.
In our simulations, EABS is set to 300 eV for all particles, to ensure that the photon mean
free path and the secondary-electron range are smaller than the minimum bin width used to
tally the dose distributions. C1 and C2 are set to 0.01, which is a very conservative value. WCC
and WCR are set equal to EABS. Finally, the value of DSMAX is chosen to be one tenth of the
different slab thicknesses.
Simulations are discontinued when the average statistical uncertainty is less than 0.5%
(2 standard deviations). This uncertainty is calculated as an average of the uncertainties of the
bins with doses above half of the maximum score.
2.3. Dose equivalence with standard fractionation schemes
Since in MRT the doses are delivered in one fraction, the expected biological effects and
tissue tolerances will depart from the values in conventional radiotherapy, where the doses are
typically delivered in 2 Gy/session (Emami et al 1991, QUANTEC 2010). To establish the
equivalence of the valley dose with the standard fractionation scheme, the normalized total
dose (NTD) has been evaluated from
NTD2.0 = nd
(
1 +
d
α/β
)(
1 +
2 Gy
α/β
)−1
, (1)
where NTD2.0 is the NTD corresponding to the standard fractionation scheme of 2 Gy/fraction,
d is the absorbed dose per fraction and n is the number of sessions. In our case, n = 1 and the
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total dose given in one MRT fraction is D = nd = d. The α/β ratio is a parameter related to
the biological response of the tissue under consideration and depends on its renewal capability.
Equation (1) is derived from the linear-quadratic (LQ) model (Flickinger and Kalend
1990) for the biological response to ionizing radiation, often employed to compare different
fractionation schemes in conventional radiotherapy because it fits the experimental cell survival
curves quite well in most cases. It is widely used to quantify the effects of radiotherapy at low
and medium doses, but it might overestimate the magnitude of cell killing for doses greater
than 10 Gy (Brenner 2008). Several attempts have been made to extend the LQ model to higher
doses per fraction, all of them leading to the inclusion of at least one additional parameter in
the formalism (Lind et al 2003, Guerrero and Li 2004). Unfortunately, the applicability is
limited because most clinical datasets are insufficient to estimate all the parameters (Joiner
and van der Kogel 2009).
There are ongoing discussions in the scientific community on the applicability of the LQ
model at high doses per fraction due to the lack of clinical data (Kirkpatrick et al 2009).
In vivo studies have suggested that the predictions of the LQ model are still acceptable for
the design of clinical trials based on doses per fraction up to 18 Gy (Brenner 2008). In vitro
investigations have shown that the cell survival followed the standard LQ model up to 15 Gy
(Garcia et al 2006). Theoretical works indicate that the LQ model remains valid up to 17 Gy
(Sachs et al 1997). As the valley dose in the present work ranges from 1 to 14 Gy in one
fraction, equation (1) can be used with reasonable confidence.
The values of α/β range from 8 to 15 Gy (Steel 2002) for tumours and early responding
tissues. The skin is a rapidly renewable tissue for which α/β = 8.8 Gy (Turesson and Thames
1989). For late responding tissues such as the brain and the bone, the values of α/β are
smaller: 2 Gy (Steel et al 2002) and 1.8 Gy (Overgaard 1988), respectively. In the latter
cases, the dose fractionation effect and the repair mechanisms between consecutive fractions
are more important than in early responding tissues, where the total absorbed dose plays a
more significant role.
The valley dose is converted into NTD2.0 to assess if it is under the tolerance level
for the well-established conventional radiotherapy limits, following the results by Dilmanian
et al (2002). According to the latest published compilations of values on human patients,
the tolerance doses (with a 5% probability of complication within 5 years from treatment,
irradiation of one-third of the whole organ volume) are 70 Gy for the skin and 50–60 Gy for
the bone (Emami et al 1991). In the case of the brain, a 5% risk of symptomatic radiation
necrosis with the standard fractionation scheme is predicted to occur at 72 Gy (Lawrence
et al 2010). For single fractionation radiosurgery, a clear correlation has been demonstrated
between the target size and the risk of adverse events. For targets smaller than 20 mm in
diameter, the maximum brain tolerance dose is higher than 24 Gy (Shaw et al 2000).
Emami et al (1991) also present the tolerance doses for 50% probability of necrosis within
5 years: >70 Gy for the skin and 65–75 Gy for the brain and the bone. The peak dose relative
to this latter case has been studied as well.
3. Results and discussion
Dose distributions for various positions of a tumour, skull thicknesses and interbeam
separations have been computed. The influence of these variables on the dose distributions
will be presented separately. Dose is reported as absorbed dose to medium.
The valley dose presented in the figures that follow is obtained in the centre of the field
since this is the location of the largest valley dose. A conservative criterion is to consider that
the absorbed dose in this valley must be lower than the tolerances in conventional radiotherapy.
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Figure 2. PVDR as a function of depth in the head phantom considering a unidirectional irradiation
with 50 μm thick microbeams and a c-t-c distance of 400 μm. The three labelled areas correspond
to skin (a), skull (b) and brain (c). Statistical uncertainty bars are at two standard deviations.
For this, we relied on the NTD2.0 to establish the equivalence between the valley dose (given
in one fraction) with the standard fractionation scheme of 2 Gy/fraction.
3.1. Dose distributions for a centrally located tumour
The most conservative tumour location to evaluate the absorbed dose in the healthy tissue is
the centre of the brain. Using a single port irradiation, the optimum ballistics will be given
by a lateral irradiation (ear-to-ear axis). With this configuration, in which the tumour centre
is at a depth of 7.2 cm with respect to the skin entrance (Harling et al 1995), the quantity of
healthy irradiated tissue is minimized.
Figure 2 shows the ratio between the peak dose and the valley dose, i.e. the PVDR, as
a function of depth. The PVDR takes values around 58 in the first 2 mm (skin), but it falls
off rapidly in the bone, reaching a value of 18 in the interface with the brain. This drastic
reduction in bone with respect to skin is due to the increase of the fluence of photons that
are Compton scattered into the valley region. These photons have a larger probability per
unit mass of undergoing a photoelectric absorption in bone since its average atomic number is
higher. This results in a higher local dose deposition. In the brain, the PVDR remains almost
constant (PVDR  25).
Figures 3 and 4 display the valley dose distribution, the peak dose distribution and the
NTD2.0 for different dose prescriptions in the centre of the tumour ranging from 40 to 65 Gy
in one fraction. The maximum valley doses are 2–5 Gy in the skin, 9–17 Gy in the bone and
4–8 Gy in the brain. The maximum values of NTD2.0 are 2–6 Gy in the skin, 30–80 Gy in the
bone and 6–18 Gy in the brain. Owing to the high effective atomic number of the bone, the
skull receives a substantial dose and it will be the limiting organ to establish the maximum
peak dose in the tumour.
The tolerance for the bone lies between 50 and 65 Gy for a 5 % probability of complications
within 5 years (Emami et al 1991). Therefore, from figure 4, the maximum tumour peak dose
prescription achievable is 55 Gy and the corresponding valley dose in the tumour is 2.6 Gy
(see figure 3 left). Considering this and the information displayed in figure 3, the maximum
peak and valley doses for all the tissues can be established. The maximum skin entrance dose
is 200 Gy and the maximum peak doses in the skull and the brain are 315 and 150 Gy. The
corresponding valley doses in the skin, skull and brain are 4, 14 and 7 Gy, respectively. In
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Figure 3. Valley dose (left) and peak dose (right) distributions for skin (a), skull (b) and brain
(c) for the indicated peak dose prescriptions in the tumour, situated at a depth of 7.2 cm. The
c-t-c distance between the 50 μm thick microbeams is 400 μm. Each curve is proportional to the
tumour dose prescription.
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Figure 4. NTD2.0 valley dose distribution for the different tissues: skin (a), skull (b) and brain (c)
for the indicated peak dose prescriptions in the tumour, situated at a depth of 7.2 cm. The c-t-c
distance between the 50 μm thick microbeams is 400 μm.
summary, if the peak dose prescription in the tumour is smaller than 55 Gy, the valley dose in
the healthy tissue will be kept under tolerances. If peak doses of 62 Gy were delivered to a
centrally located tumour, the 50 % probability of bone necrosis within 5 years in bone would
be reached (see figure 4).
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Figure 5. Absorbed dose (left) and NTD2.0 (right) valley dose distributions for skull thicknesses
ranging from 8 to 12 mm. The prescribed peak dose in the centre of the tumour, situated at a depth
of 7.2 cm, is 55 Gy in one fraction. The c-t-c distance between the 50 μm thick microbeams is
400 μm.
Table 1. Maximum peak dose prescription and valley dose in the tumour in one fraction keeping the
healthy tissue under tolerances (5% complication probability within 5 years) for different tumour
positions.
Depth of Maximum peak Corresponding
tumour (cm) dose (Gy) valley dose (Gy)
1.5 145 5.9
2.5 125 5.2
3.5 105 4.5
4.5 90 4.1
5.5 75 3.5
6.5 65 2.9
7.2 55 2.6
3.2. Dose distributions as a function of tumour position
The valley doses and the corresponding NTD2.0 values have been calculated for a number of
tumour positions with respect to the head surface. Table 1 lists, for several tumour locations,
the maximum peak dose that can be prescribed in the tumour to keep the corresponding valley
doses below healthy tissue tolerances. As can be seen, a deeper-seated tumour implies a lower
maximum peak dose prescription to fulfil the requested condition.
3.3. Dose distributions as a function of bone thickness
The above calculations have been done for a skull thickness of 10 mm. However, there might
be some slight variation among individuals. Figure 5 shows the valley and NTD2.0 dose
distributions for several skull thicknesses close to the value used in this work (8, 9, 11 and
12 mm). Doses were obtained for a tumour dose prescription of 55 Gy in one fraction. There
are appreciable differences in the bone but there is no variation of the deposited dose as a
function of depth (beyond 2 cm). It is important to point out that the difference in NTD2.0
between considering 8 mm or 12 mm of skull is about 15 Gy. As a consequence, one should
prescribe doses that are several Gy below the tissue tolerances to account for these variations.
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Figure 6. PVDR as a function of depth for two separations between microbeams. The dashed and
solid curves correspond to c-t-c separations of 400 and 200 μm, respectively.
0
5
10
15
20
25
30
0 1 2 3 4 5 6 7 8 9 10
D
va
ll
ey
(G
y
)
depth (cm)
a
b
c
c-t-c = 200 µm
c-t-c = 400 µm
Figure 7. Valley dose distribution as a function of depth for two separations between the
microbeams. The dashed and solid curves correspond to c-t-c separations of 400 and 200 μm,
respectively. The prescribed peak dose in the centre of the tumour, situated at a depth of 7.2 cm,
is 55 Gy in one fraction.
3.4. Dose distributions as a function of the separation between microbeams
Figure 6 compares the PVDR values for two c-t-c distances between microbeams, namely 200
and 400 μm. The PVDR for a c-t-c distance of 200 μm is lower because of the higher valley
dose. Figure 7 presents the valley dose distribution corresponding to a peak dose prescription
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of 55 Gy in the centre of the tumour. With a 200 μm c-t-c distance, it is possible to deliver a
maximum dose of only 27 Gy in the tumour, maintaining the healthy tissue under tolerances,
i.e. half than that for a c-t-c separation of 400 μm. The valley dose in a centrally located
tumour is now 3.3 Gy. Therefore, to scale up the doses with respect to the ones in conventional
radiosurgery, a c-t-c distance of 400 μm is recommended.
4. Conclusions
MC simulations in a human head phantom have been performed to define safe irradiation
protocols for the forthcoming clinical trials in MRT. The aim of these trials is the quest
for a radical treatment of gliomas, which are the most aggressive and radioresistant brain
tumours. The results of this work show that it is possible to deliver a relatively large dose to
the tumour and, at the same time, keep the valley dose in the healthy tissue under tolerances.
In order to establish the equivalence of the valley dose (one fraction) with the standard
fractionation scheme, the NTD2.0 has been used. The maximum peak dose that can be
prescribed to the tumour while sparing the surrounding normal tissue has been evaluated for
various tumour positions. The skull is the organ with the largest absorbed doses. For the
most conservative tumour location, i.e. in the centre of the brain, the maximum peak and
valley doses accomplishable in the tumour are 55 Gy and 2.6 Gy, respectively, in one fraction
and with a unidirectional irradiation. In this way, the valley dose in the healthy tissue will
remain under tolerances (5% probability of complication within 5 years). A level of 50%
probability of bone necrosis would be reached if the tumour were irradiated with a peak dose
of 62 Gy. Although there is no data on the doses required to ablate glioma tumours in humans
using MRT, existing data from conventional radiotherapy indicate that an aggressive treatment
would enhance the patient lifespan.
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Introduction
The remarkable therapeutic index in MRT can be further improved by the combination with
enhanced absorption induced by contrast agents, as has been explained in section 1.5.1.3.
The aim of this work was to assess MRT dose enhancement due to the presence of these
high-Z elements.
To this end, an exhaustive MC dosimetric study using different head phantoms (hu-
man and rat), MRT irradiation configurations (MRT spectrum and monochromatic beam of
175 keV; c-t-c distances of 200 and 400 µm), several contrast agents clinically used or at the
development stage (I, Gd, Ho, Er, Yb, Lu, Hf, Au and Tl) and feasible concentrations (5 and
10 mg/mL) was performed. The MRT irradiation modalities correspond to the clinical trials
(MRT spectrum and c-t-c distance of 400 µm) and preclinical trials (MRT spectrum and c-t-c
distance of 200 µm) settings. The monochromatic beam of 175 keV corresponds to the en-
ergy that provides the optimum balance between dose deposition in the tumour and sparing
of healthy tissue [Prezado 2009a].
The optimum dose enhancer was assessed by the maximisation of the ratio between the
PVDR values in healthy tissue with respect to the PVDR in the tumour and by the minimisation
of bone and brain valley doses.
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Purpose: A radical radiation therapy treatment for gliomas requires extremely high absorbed doses
resulting in subsequent deleterious side effects in healthy tissue. Microbeam radiation therapy
(MRT) is an innovative technique based on the fact that normal tissue can withstand high radiation
doses in small volumes without any significant damage. The synchrotron-generated x-ray beam is
collimated and delivered to an array of narrow micrometer-sized planar rectangular fields. Several
preclinical experiments performed at the Brookhaven National Laboratory (BNL) and at the Euro-
pean Synchrotron Radiation Facility (ESRF) confirmed that MRT yields a higher therapeutic index
than nonsegmented beams of the same characteristics. This index can be greatly improved by
loading the tumor with high atomic number (Z) contrast agents. The aim of this work is to find the
high-Z element that provides optimum dose enhancement.
Methods: Monte Carlo simulations (PENELOPE/penEasy) were performed to assess the peak and
valley doses as well as their ratio (PVDR) in healthy tissue and in the tumor, loaded with different
contrast agents. The optimization criteria used were maximization of the ratio between the PVDR
values in healthy tissue respect to the PVDR in the tumor and minimization of bone and brain val-
ley doses.
Results: Dose enhancement factors, PVDR, and valley doses were calculated for different high-Z
elements. A significant decrease of PVDR values in the tumor, accompanied by a gain in the valley
doses, was found in the presence of high-Z elements. This enables the deposited dose in the healthy
tissue to be reduced. The optimum high-Z element depends on the irradiation configuration. As a gen-
eral trend, the best outcome is provided by the highest Z contrast agents considered, i.e., gold and
thallium. However, lanthanides (especially Lu) and hafnium also offer a satisfactory performance.
Conclusions: The remarkable therapeutic index in microbeam radiation therapy can be further
improved by loading the tumor with a high-Z element. This study reports quantitative data on
several dosimetric magnitudes in order to find the optimum contrast agent. Although the final
choice of the element will also depend on possible cytotoxicity, three elements were found to be
worthy of mention: gold, thallium, and lutetium. VC 2011 American Association of Physicists in
Medicine. [DOI: 10.1118/1.3603189]
Key words: microbeam radiation therapy, synchrotron radiation, Monte Carlo simulations, dose
enhancement
I. INTRODUCTION
A fundamental challenge in radiation-based cancer therapies
is the optimization of cell killing within the tumor, while pre-
serving surrounding healthy tissue. There are some particu-
larly radio-resistant tumors, such as gliomas, for which
radical radiation therapy treatment does not exist. The control
of such tumors requires high doses, whereas the surrounding
healthy tissue shows high morbidity.1 The use of concomitant
and adjuvant temozolomide and radiation therapy has
enabled significant prolongation of survival.2 However, the
outcome still remains unsatisfactory in most cases.
In the quest for possible ways of improving the therapeu-
tic index in radiation therapy (ratio of the normal tissue
tolerance dose to the required dose for tumor control), a new
technique that explores the limits of dose-volume effects3,4
is under development at Biomedical Beamline ID17 of the
European Synchrotron Radiation Facility (ESRF). This inno-
vative method is called microbeam radiation therapy (MRT).
MRT irradiation is carried out by using an array of parallel,
extremely intense x-ray microbeams 25–75 lm-thick with a
center-to-center (c-t-c) distance of 200–400 lm.
The MRT irradiation scheme results in dose profiles con-
sisting of a pattern of peaks and valleys, i.e., with high doses
in the microbeam paths and low doses in the spaces in
between.5 The dose in the central region between two
microbeams is named the valley dose, while the dose at the
center of the microbeam is called the peak dose. The ratio
between the peak and the valley doses (peak-to-valley dose ra-
tio, PVDR) is also an important magnitude in spatially
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fractionated techniques. The PVDR depends on the incident x-
ray beam energy, tissue composition, beam thickness, the c-t-c
distance, and the irradiation field.6–9 In order to spare healthy
tissue, the PVDR should be high, with a valley dose as low as
possible and always below the tolerance level for seamless
irradiation. However, low tumor PVDR values show high
lesion density, which suppress possible repair mechanisms.9,10
MRT has proved to offer remarkable healthy tissue
sparing.11–15 Moreover, MRT protocols have been shown to
be able to ablate highly aggressive animal tumor mod-
els.10,15–21 MRT, therefore, yields a higher therapeutic index
than nonsegmented beams of a similar energy spectrum.10,20
The outcome of MRT can be further improved by combining
MRT irradiation with dose enhancers such as high-Z-labeled
compounds. These can be selectively accumulated within
the tumor prior to any irradiation protocol. This idea was
first proposed by Dilmanian et al.22 and applied experimen-
tally by Re´gnard et al.23 The probability of undergoing a
photoelectric interaction increases significantly for the
energy range of the MRT spectrum and in the presence of
high-Z contrast agents. Localized tumor dose enhancement
is thus achieved.
Among the high-Z elements, Gd (Z¼ 71) compounds are
both widely and routinely used for medical imaging as non-
specific magnetic resonance imaging contrast agents. Pilot
in vivo experiments performed at ESRF showed an impor-
tant increase in survival time when the tumor was loaded
with gadolinium compounds [resulting from the union of
Gd with diethylene triamine pentaacetic acid (DTPA)].23
Gd concentrations of 5 mg/ml have been reported.24 Due to
the continuous improvement of contrast agent delivery
methods and their chemistry, higher achievable concentra-
tions are expected in the near future. Other lanthanides that
have the same chemical properties as Gd can also be
encountered in a biocompatible formulation by the similar
complexion with DTPA. Thus, holmium (Z¼ 67), erbium
(Z¼ 68), ytterbium (Z¼ 70), and lutetium (Z¼ 71) have
also been evaluated as MRT dose enhancers in this study.
Some of them (Ho, Er, and Lu) have already been used and
commercialized for medical applications.25,26
Gold (Z¼ 79) and iodine (Z¼ 53) were also successfully
used as dose enhancers in preclinical trials with kilovoltage
x-rays27,30 and numerous gold nanoparticle-based applica-
tions for solid tumor therapy are under investigation.31,32 Au
concentrations higher than 5 mg/ml have been reported in
preclinical trials without any toxicity effect.27,28 Tumor io-
dine concentrations up to 4–5 mg/ml are routinely obtained
by intravenous administration for brain tumor imaging.33,34
In order to maximize iodine concentration, other methods of
contrast delivery may provide tumor iodine concentrations
of 10–20 mg/ml.35
Due to its high atomic number (Z¼ 81), thallium is also a
good candidate for dose enhancement in MRT. This element
has already been employed for experimental treatment of
glioma-bearing rats.36,37
Some new nanoparticles based on hafnium (Z¼ 72) have
recently been developed38 such as inert crystalline nanopar-
ticles of hafnium oxide with a simple coating formulated in
water for injection. The crystalline structure of the nanopar-
ticles prevents metabolization by living organisms, so its use
as a dose enhancer is promising.
Previous Monte Carlo (MC) dosimetric studies have con-
firmed the remarkable dose enhancement when the tumor is
loaded with high-Z elements in several radiation therapy
treatments (see Refs. 35,39–42), including MRT.43,44 This
work reports the first exhaustive dosimetric study using dif-
ferent head phantoms (human and rat), MRT irradiation con-
figurations, several contrast agents (I, Gd, Ho, Er, Yb, Lu,
Hf, Au, and Tl), and concentrations (5 and 10 mg/ml). As
has been pointed out above, a concentration of 5 mg/ml
within the tumor is feasible for most of the studied elements.
A higher concentration of 10 mg/ml is either currently
achievable or expected to be in the near future. This would
offer a higher gain in dose deposition. The final aim was to
evaluate the optimum high-Z element which will be used as
a dose enhancer as a function of the MRT configuration.
Maximization of the PVDR quotient values in healthy tissue
with respect to the PVDR in the tumor and minimization of
the valley doses in healthy tissue were used as the criteria.
II. MATERIALS AND METHODS
II.A. Radiation source
The ESRF is a third-generation synchrotron with a 6-GeV
electron storage ring. The photon beam used in MRT is
generated by a wiggler that has 21 poles, a period of 15 cm,
and a maximum magnetic field of 1.6 T. The generated pho-
ton beam crosses different filters in order to eliminate low
energies and other beam modifiers such as diaphragms, slits,
etc. The patient position is located 42 m from the source.
The final x-ray spectrum, hereafter named MRT spectrum,
ranges from 50 to 600 keV, with a peak energy at 80 keV.5
The microbeams are generated by a multislit collimator45
which spatially fractionates the beam in the horizontal direc-
tion. As the natural vertical aperture of the synchrotron beam
is extremely small, targets are vertically scanned through the
microfractionated beam to deliver microplanes of x-rays.
Synchrotron microbeams possess two important features:
negligible divergence and high flux. These properties allow
the production of sharply defined beam edges and delivery
of the dose in a fraction of a heart beat, which minimizes
cardiosynchronous motion effects in the brain.46
II.B. Monte Carlo simulation code:
PENELOPE\penEasy
The 2008 version of the MC code PENELOPE (Refs. 47
and 48) and penEasy,49 a general-purpose main program for
PENELOPE, were employed. PENELOPE allows the
coupled transport of electrons, photons, and positrons to be
simulated in a very wide energy range and in arbitrary mate-
rials. It has been frequently used in the medical physics field
(see, for example, Refs. 50–52).
The predominant photon interactions for the energy range
and materials used in this study are the photoelectric effect
and Compton scattering. Figure 1 shows the attenuation
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coefficients l/q for these interactions in terms of incoming
photon energy. The photoelectric cross sections are interpo-
lated from tabulations in the evaluated photon data library
from the Lawrence Livermore National Laboratory.53 The
photoelectric effect is especially important in bone or in a tu-
mor loaded with a high-Z element. The Compton cross sec-
tions are obtained by using the relativistic impulse
approximation, which takes into account both Doppler broad-
ening and binding effects of atomic electrons. Many-body
and aggregation effects are ignored.
II.C. Phantom description and simulation details
Two geometries were considered in the simulations: a
human head phantom and a rat head phantom. The human
head phantom is composed of slabs of skin (0.2 cm), skull
(0.8 cm), and brain (12 cm), with a tumor located at the cen-
ter of the brain. The thicknesses correspond to a lateral irra-
diation in order to minimize the length of irradiated healthy
tissue.54 The tumor, loaded with different contrast agents,
was modeled by a 2-cm-diameter cylinder of 2 cm height. The
size of the tumor was inspired by others that were published in
previous dosimetry works55,56 rather than from clinical data,
which is highly dependent on type of tumor, location, etc.
The rat head phantom consists of slabs of skin (700 lm),
bone (500 lm), and brain (2.6 cm). These thicknesses were
extracted from MRI images.43 A cylindrical tumor of 4 mm in
height and 4 mm in diameter was placed 6.7 mm from the
head surface to mimic the tumor model used in the
experiments.23
The tumor was loaded with different elements in both
phantoms: iodine (Z¼ 53), gadolinium (Z¼ 64), holmium
(Z¼ 67), erbium (Z¼ 68), ytterbium (Z¼ 70), lutetium
(Z¼ 71), hafnium (Z¼ 72), gold (Z¼ 79), and thallium
(Z¼ 81). A concentration of 5 mg/ml in the tumor was
assessed for each element. In the human case, additional
simulations with 10 mg/ml were performed. Several MRT
configurations were evaluated for each geometry.
• MRT irradiation parameters that will be used in the forth-
coming clinical trials, i.e., 50-lm-wide microbeams with a
c-t-c of 400 lm and the MRT energy spectrum (hereafter
referred to as MRTctc400).
• 175 keV monochromatic 50-lm-wide microbeams with a
c-t-c of 400 lm (denoted as 175 keVctc400). This energy
provides the optimum balance between dose deposition in
the tumor and sparing of healthy tissue.43
• Common preclinical trial irradiation conditions: 50-lm-
wide microbeams, 200 lm c-t-c distance, and MRT energy
spectrum (hereafter, called MRTctc200).
• 175 keV monochromatic 50-lm-wide microbeams with a
c-t-c distance of 200 lm (175 keVctc200).
The dose computation was divided into two parts. First,
the absorbed dose distribution for a single microbeam in the
phantom was simulated. A simplified model in which beam
divergence is not included was used. The single dose distri-
bution was then shifted and added to the total dose distribu-
tion at each depth in order to cover the irradiation field size:
2 2 cm2 for the human phantom and 1 1 cm2 for the rat
phantom. Although these simplifications are common prac-
tice for many authors of theoretical MRT studies,5,7,8 it
should be pointed out that these unsophisticated models have
some limitations detailed in the work of Nettelbeck et al.57
For the human head phantom, doses were scored in
voxels of 2 lm along the microbeam width and 2 mm in the
vertical direction of the microbeam and in depth. These
dimensions were reduced by half for the rat head phantom,
as a higher spatial resolution was required.
The simulation parameters were the following. The
absorption energies, EABS, were set to 1 keV for electrons
and 0.1 keV for photons. The average angular deflection
FIG. 1. Photoelectric (left) and Compton (right) attenuation coefficients for bone and the brain after being loaded with different contrast agents.47
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between two consecutive events, C1, and the maximum
average fractional energy loss in a single multiple-scattering
step, C2, were fixed at 0.1. The cut-off energies for the pro-
duction of hard inelastic, WCC, and hard bremsstrahlung
events, WCR, were set equal to electron and photon EABS
(Refs. 47 and 58). The simulations were discontinued when
the average statistical uncertainty was less than 0.5% (two
standard deviations, 2r).
III. RESULTS AND DISCUSSION
In this section, dose enhancement factors (DEFs), PVDR
values and valley doses (Dvalley) in the tumor and healthy tis-
sue are reported for several configurations, contrast agents,
and concentrations in the two phantoms. The results for the
different irradiation configurations in the human head phan-
tom will be first discussed. Calculations for the rat phantom
geometry will then be presented.
III.A. Dose enhancement studies on a human head
phantom irradiated with an array of 50-lm-wide
microbeams with a spacing of 400 lm
III.A.1. Dose enhancement factors (DEFs)
DEFs quantify the overall dose enhancement in the tu-
mor. They are defined as the ratio of the absorbed dose in
the tumor loaded with a contrast agent to the absorbed dose
in the absence of any element. Table I shows the DEF values
for two concentrations (5 and 10 mg/ml) of the several high-
Z elements as a function of beam energy.
The photoelectric effect plays a major role for dose
enhancement in the tumor in the presence of high-Z ele-
ments. Higher DEF values were obtained when using the
MRT spectrum in comparison with the 175 keV monochro-
matic beam. This is due to the fact that the photoelectric
effect cross section decreases with energy. Photoelectric
absorption also increases drastically with the atomic number
of the medium. For Hf, Au, and Tl, however, the DEF dimin-
ished when the MRT spectrum was used since its peak is
located at the K-edge of these elements. DEF also increased
with element concentration. The average ratio between
energy deposited in the tumor loaded with a concentration of
10 mg/ml with respect to 5 mg/ml was 1.22 for the MRT
spectrum and 1.10 for a 175 keV beam. Hence, the effect of
the element concentration was enhanced when the MRT
spectrum was used.
DEF values provide a general idea of the global dose
deposition gain when the tumor is loaded with a high-Z
element. However, this magnitude does not offer a complete
picture in the case of spatially fractionated techniques such as
MRT. For this reason, other dosimetric magnitudes were
evaluated.
III.A.2. PVDR assessment
As stated in Sec. I, the lower the tumor PVDR (PVDRtumor),
the higher the achievable tumor control probability. How-
ever, PVDR in healthy tissue (PVDRHT) should remain high
with the lowest possible valley dose, always below the toler-
ance level for seamless irradiation.10
Figure 2 (top) presents the PVDR values versus depth for a
nonloaded tumor, called unloaded tumor. Both MRTctc400 and
175 keVctc400 configurations were assessed. In the first case,
PVDR took values around 59 in the first 2 mm (skin) and
then fell off rapidly in the bone down to a value of 19 at the
interface with the brain. PVDR remained almost constant
throughout the brain (20–25). For the 175 keV monochro-
matic beam, PVDR in the skin was approximately 80, while it
decreased to 30 when it entered the brain, where it remained
constant (25–30). Healthy tissue PVDR values were higher
for the 175 keV monochromatic beam than for the MRT spec-
trum due to its higher penetration power, thus offering better
tissue sparing. This is important as the aim was to study how
much this sparing can be enhanced by using high-Z elements.
Figure 2 also shows the tumor PVDR values versus depth
for a tumor loaded with different high-Z elements. Two con-
figurations, MRTctc400 (center) and 175 keVctc400 (bottom),
were assessed. The presence of high-Z contrast agents
increased both the photoelectric and Compton cross sections
in the peaks and in the valleys. The peak dose average gain
in the tumor (10 mg/ml) was 1.5 and 1.1 for MRTctc400 and
175 keVctc400, respectively. The increase in valley doses for
these configurations was 2.0 and 1.6. The higher gain in val-
ley doses rather than in the peaks was responsible for the
overall reduction of PVDR values in the tumor.
Table II shows quantitative PVDRtumor values as a function
of microbeam energy and element concentration. The lowest
PVDR values were obtained in the case of the MRT spectrum.
No remarkable differences were encountered among the dif-
ferent elements, despite the fact that they were more pro-
nounced when the 175 keV monochromatic beam was used.
The degree to which PVDRtumor decreased with respect to the
unloaded tumor was similar for both energies and depended
on the concentration. The average reduction of PVDRtumor
was about 16% and 26% for 5 and 10 mg/ml. Therefore,
we can state that the higher the concentration, the lower
PVDRtumor, which produced higher normal tissue sparing.
As explained in Sec. I, the optimum contrast media would
be that which provides maximization of the quotient between
PVDR in healthy tissue and PVDR in the tumor. In addition,
the values of valley doses in normal tissues with respect to
TABLE I. DEF values for different contrast media as a function of
microbeam energy and element concentration in the human head phantom.
Statistical uncertainty corresponds to 2r.
MRT spectrum Monochromatic 175 keV
Z Element 5 mg/ml 10 mg/ml 5 mg/ml 10 mg/ml
53 I 1.242(1) 1.478(1) 1.063(1) 1.125(1)
64 Gd 1.298(1) 1.585(1) 1.095(1) 1.189(1)
67 Ho 1.305(1) 1.599(1) 1.104(1) 1.208(1)
68 Er 1.306(1) 1.603(1) 1.108(1) 1.215(1)
70 Yb 1.307(1) 1.603(1) 1.113(1) 1.226(1)
71 Lu 1.308(1) 1.606(1) 1.117(1) 1.232(1)
72 Hf 1.306(1) 1.602(1) 1.119(1) 1.237(1)
79 Au 1.304(1) 1.597(1) 1.138(1) 1.274(1)
81 Tl 1.301(1) 1.592(1) 1.142(1) 1.281(1)
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those in the tumor must be minimized. Table III lists the
maximum PVDR in the bone (PVDRmax bone) and the aver-
age PVDR in the brain (PVDRaverage brain), both with respect
to PVDRtumor. When the PVDRHT/PVDRtumor is higher, a
major healthy tissue sparing is expected. Maximum sparing
of the bone (highest PVDRmax bone/PVDRtumor ratios) was
obtained with an incoming beam energy of 175 keV, since
photoelectric absorption in the bone is reduced at high ener-
gies. However, both energies provided similar gain in brain
tissue sparing (PVDRaverage brain/PVDRtumor were close). The
elements that provide the minimum PVDRtumor and the max-
imum PVDRHT/PVDRtumor values were I and Tl for the
MRT spectrum and Au and Tl for the 175 keV monochro-
matic beam.
III.A.3. Valley dose quantification
Despite the fact that PVDR is an important parameter, it
is a relative quantity. Evaluation of valley doses in healthy
tissue (Dvalley, HT) is also required as they are the most im-
portant magnitude in order to examine tissue sparing. Figure
3 shows the ratio of valley doses in healthy tissue with
respect to the valley dose in the tumor for MRTctc400 (top)
and 175 keVctc400 (bottom). Dose enhancement is observed
in the tumor due to the increase of the photoelectric cross
sections. The use of high-Z elements has led to a reduction
in healthy tissue valley doses in delivering a given dose to
the tumor (normalized to the tumor in Fig. 3). Bone is the tis-
sue that receives the highest doses, so it will be the limiting
organ.9,59
Table IV gives the quotients between the maximum val-
ley dose in the bone (Dvalley, max bone) and the average valley
dose in the brain from 2 to 5 cm depth (Dvalley, average brain),
both with respect to the valley dose in the tumor
(Dvalley, tumor). As explained above, these quotients quantify
the effective reduction in healthy tissue valley doses in the
presence of high-Z elements. A total of 175 keVctc400
favored bone sparing while MRTctc400 contributed slightly
more to brain preservation.
The elements that provide the best outcome were lutetium
and thallium, despite the rest of lanthanide elements and haf-
nium offered also a satisfactory performance. The valley
doses in bone and in the brain were 3.34 and 1.105 times the
valley dose in the tumor for Lutetium (Lu) at a concentration
of 5 mg/ml. For 175 keVctc400, the best results were provided
by gold and thallium. Differences in performance between
elements were more pronounced in this configuration. The
TABLE II. PVDRtumor for different contrast media as a function of
microbeam energy and element concentration in the human head phantom
(c-t-c: 400 lm, field size: 2-by-2 cm2). Statistical uncertainty corresponds
to 2r.
MRT spectrum 175 keV
Z Element 5 mg/ml 10 mg/ml 5 mg/ml 10 mg/ml
Unloaded 21.1(1) 26.9(2)
53 I 17.5(1) 15.33(8) 23.6(1) 20.9(1)
64 Gd 17.7(1) 15.70(8) 22.9(1) 20.4(1)
67 Ho 17.7(1) 15.77(8) 22.8(1) 20.1(1)
68 Er 17.8(1) 15.87(8) 22.6(1) 20.0(1)
70 Yb 17.9(1) 15.88(8) 22.7(1) 19.9(1)
71 Lu 17.6(1) 15.84(8) 22.7(1) 19.7(1)
72 Hf 17.8(1) 15.82(8) 22.7(1) 19.6(1)
79 Au 17.7(1) 15.75(8) 22.3(1) 19.25(8)
81 Tl 17.6(1) 15.48(8) 22.2(1) 19.4(1)
FIG. 2. PVDR values versus depth for a nonloaded (top) and loaded tumor
in the human head phantom. The MRTctc400 (center) and 175 keVctc400 (bot-
tom) irradiation configurations were assessed (c-t-c: 400 lm, field size:
2-by-2 cm2). Each line corresponds to a different high-Z element (10 mg/ml).
Statistical uncertainty bars are at 2r.
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maximum benefit in the Dvalley, HT/Dvalley, tumor for a loaded
tumor compared to the same ratio for a nonloaded tumor was
obtained at a concentration of 10 mg/ml; the average gain in
the presence of high-Z elements was about 48% for
MRTctc400 and 32% for 175 keVctc400 compared with the ab-
sence of a contrast agent.
III.A.4. Discussion
Table V gives the elements that provide the best results
for each dosimetric parameter (bold letters indicate the opti-
mum case among the irradiation configurations). The differ-
ences in performance among the high-Z elements were more
pronounced for 175 keVctc400 than for MRTctc400 and
increased with concentration. Two elements stand out in the
175 keVctc400 configuration: thallium and gold. The best out-
come for MRTctc400 was achieved by employing thallium,
together with lanthanide elements (especially, lutetium). Io-
dine provided a significant reduction of PVDRtumor that was
not accompanied by an increase in the valley dose, which
lost effectiveness in terms of tumor control. In the present
study, only dosimetric considerations have been taken into
account. Nevertheless, the possible cytotoxicity of the differ-
ent contrast agents should also be considered.
III.B. Dose enhancement studies on a human head
phantom irradiated with an array of 50-lm-wide
microbeams with a spacing of 200 lm
Analogous calculations were performed for a c-t-c dis-
tance of 200 lm. Table VI presents PVDR values in the cen-
ter of the tumor. I, Au, and Tl are the elements that provide
the highest decrease in PVDRtumor for MRTctc200. The lan-
thanides and hafnium are the elements that give the best out-
come in the case of 175 keVctc200, in contrast to 175
keVctc400. This is explained in Fig. 4, where the lateral dose
profiles for one microbeam at the central tumor position are
plotted. The K-edge energies of lanthanides are lower than
those of Au/Tl. Therefore, the products of the photoelectric
interactions in the presence of lanthanides have a higher ki-
netic energy at 100 lm. Consequently, the dose deposition
in the valleys (and the decrease of PVDRtumor) is more effec-
tive for lanthanides than it is for Au/Tl in this irradiation
configuration (c-t-c of 200 lm).
TABLE III. PVDRmax bone/PVDRtumor (left) and PVDRaverage brain/PVDRtumor (right) as a function of microbeam energy and element concentration in the human
head phantom (c-t-c: 400 lm, field size: 2-by-2 cm2). Statistical uncertainty corresponds to 2r.
Bone Brain
MRT spectrum 175 keV MRT spectrum 175 keV
Z Element 5 mg/ml 10 mg/ml 5 mg/ml 10 mg/ml 5 mg/ml 10 mg/ml 5 mg/ml 10 mg/ml
Unloaded 1.33(1) 1.63(1) 1.110(1) 1.114(1)
53 I 1.60(1) 1.82(1) 1.86(1) 2.10(1) 1.335(2) 1.519(2) 1.268(2) 1.427(2)
64 Gd 1.59(1) 1.78(1) 1.92(1) 2.16(1) 1.322(2) 1.484(2) 1.302(2) 1.466(2)
67 Ho 1.58(1) 1.78(1) 1.92(1) 2.19(2) 1.318(2) 1.480(2) 1.310(2) 1.486(2)
68 Er 1.58(1) 1.77(1) 1.94(1) 2.18(2) 1.312(2) 1.471(2) 1.320(2) 1.490(2)
70 Yb 1.57(1) 1.77(1) 1.94(1) 2.12(2) 1.306(2) 1.470(2) 1.317(2) 1.498(2)
71 Lu 1.59(1) 1.77(1) 1.94(1) 2.22(2) 1.324(2) 1.470(2) 1.322(2) 1.515(2)
72 Hf 1.58(1) 1.77(1) 1.93(1) 2.24(2) 1.314(2) 1.474(2) 1.313(2) 1.525(2)
79 Au 1.59(1) 1.77(1) 1.97(1) 2.27(1) 1.318(2) 1.481(2) 1.339(2) 1.553(2)
81 Tl 1.60(1) 1.80(1) 1.99(1) 2.27(2) 1.328(2) 1.507(2) 1.347(2) 1.541(2)
FIG. 3. Valley dose with respect to Dvalley, tumor versus depth in the human
head phantom. The MRTctc400 (top) and 175 keVctc400 (bottom) irradiation
configurations were assessed (c-t-c: 400 lm, field size: 2-by-2 cm2). Each
line corresponds to a tumor loaded with a different high-Z element (10 mg/ml).
The three labeled areas correspond to skin (a), skull (b), and the brain (c).
Statistical uncertainty bars are at 2r.
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Table VII presents Dvalley, max bone/Dvalley, tumor and Dvalley,
average brain/Dvalley, tumor. The 175 keVctc200 irradiation config-
uration favors bone sparing. The two energies provided a
similar gain in brain dose reduction. Values of Dvalley,
average brain/Dvalley, tumor less than one were observed for a
contrast agent concentration of 10 mg/ml. This indicated the
average valley dose deposited in the brain was lower than
the one in the tumor. Dvalley, HT/Dvalley, tumor values were sig-
nificantly smaller than the ones presented for an unloaded tu-
mor. Thus, the use of high-Z elements led to a reduction in
healthy tissue valley doses in delivering a given dose to the
tumor. Au and Tl were the optimum choice for MRTctc200
while lutetium stand out in the 175 keVctc200 configuration.
Therefore, choice of the optimum element depends not only
on the energy of the incoming beam but also on the c-t-c dis-
tance between microbeams.
III.C. Dose enhancement studies on a rat head
phantom irradiated with an array of 50-lm-wide
microbeams with a spacing of 200 and 400 lm
Analogous calculations were performed on a rat head
phantom with the most relevant contrast media: lutetium,
gold, and thallium with a concentration of 5 mg/ml. The
average DEF values were around 1.31 for the MRT spectrum
and 1.12 for the 175 keV monochromatic beam.
Table VIII shows PVDRtumor, PVDRmax bone/PVDRtumor,
and PVDRaverage brain/PVDRtumor (average from 3 to 4 mm)
for all irradiation configurations. The best outcome was pro-
vided by Au and Tl in all configurations except for 175
keVctc200, where Lu was once again the element with mini-
mum PVDRtumor. The healthy tissue valley doses with
respect to Dvalley, tumor followed the same trend as the human
TABLE IV. Dvalley, max bone/Dvalley, tumor (left) and Dvalley, average brain/Dvalley, tumor (right) as a function of microbeam energy and element concentration in the
human head phantom (c-t-c: 400 lm, field size: 2-by-2 cm2). Statistical uncertainty corresponds to 2r.
Bone Brain
MRT spectrum 175 keV MRT spectrum 175 keV
Z Element 5 mg/ml 10 mg/ml 5 mg/ml 10 mg/ml 5 mg/ml 10 mg/ml 5 mg/ml 10 mg/ml
Unloaded 4.94(3) 2.37(2) 1.632(2) 1.505(2)
53 I 3.50(2) 2.71(2) 2.04(1) 1.77(1) 1.157(1) 0.893(1) 1.296(2) 1.130(1)
64 Gd 3.37(2) 2.55(1) 1.92(1) 1.67(1) 1.118(1) 0.849(1) 1.244(2) 1.070(1)
67 Ho 3.38(2) 2.54(2) 1.93(1) 1.64(1) 1.114(1) 0.845(1) 1.232(2) 1.047(1)
68 Er 3.40(2) 2.57(2) 1.89(1) 1.62(1) 1.121(1) 0.847(1) 1.219(1) 1.041(1)
70 Yb 3.39(2) 2.57(2) 1.89(1) 1.61(1) 1.124(1) 0.848(1) 1.218(1) 1.028(1)
71 Lu 3.34(2) 2.55(2) 1.90(1) 1.58(1) 1.109(1) 0.847(1) 1.211(1) 1.012(1)
72 Hf 3.37(2) 2.56(2) 1.90(1) 1.57(1) 1.117(1) 0.847(1) 1.218(2) 1.004(1)
79 Au 3.40(2) 2.58(1) 1.85(1) 1.506(8) 1.123(1) 0.853(1) 1.177(1) 0.959(1)
81 Tl 3.38(2) 2.55(2) 1.80(1) 1.514(9) 1.120(1) 0.843(1) 1.162(1) 0.963(1)
TABLE V. Overview of the elements providing the best outcome for each dosimetric parameter in the human head phantom (c-t-c: 400 lm, field size: 2-by-2
cm2). Bold letters indicate the best case among the different irradiation configurations. The asterisk signals the optimum element(s) despite the fact that statisti-
cal differences are not significant (the values agree within the error bars).
MRT spectrum 175 keV
Parameter Table 5 mg/ml 10 mg/ml 5 mg/ml 10 mg/ml
Maximum DEF I Lu Lu Tl Tl
Minimum PVDRtumor II I/Lu/Tl* I/Tl Au/Tl Au/Tl
Maximum PVDRmax bone/PVDRtumor III I/Tl* I/Tl Au/Tl Au/Tl
Maximum PVDRaverage brain/PVDRtumor IV I/Tl I/Tl Au/Tl Au/Tl
Minimum Dvalley, max bone/Dvalley, tumor V Lu* Ho* Au/Tl Au/Tl*
Minimum Dvalley, average brain/Dvalley, tumor VI Lu Tl* Au/Tl Au/Tl
TABLE VI. PVDRtumor for different contrast media as a function of
microbeam energy and element concentration in the human head phantom
(c-t-c: 200 lm, field size: 2-by-2 cm2). Statistical uncertainty corresponds
to 2r.
MRT spectrum 175 keV
Z Element 5 mg/ml 10 mg/ml 5 mg/ml 10 mg/ml
Unloaded 10.04(4) 13.81(6)
53 I 8.27(3) 7.32(3) 10.97(4) 9.36(3)
64 Gd 8.33(3) 7.44(3) 10.30(4) 8.34(3)
67 Ho 8.34(3) 7.42(3) 10.18(4) 8.23(3)
68 Er 8.37(3) 7.44(3) 10.17(4) 8.16(3)
70 Yb 8.38(3) 7.48(3) 10.14(4) 8.20(3)
71 Lu 8.35(3) 7.45(3) 10.07(4) 8.21(3)
72 Hf 8.36(3) 7.45(3) 10.16(4) 8.24(3)
79 Au 8.24(3) 7.31(3) 10.56(4) 8.71(2)
81 Tl 8.23(3) 7.30(3) 10.66(4) 8.91(3)
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FIG. 4. Lateral dose profile of a single microbeam at the central tumor position (human head phantom) when the irradiation is performed using the MRT spec-
trum (left) and the 175 keV monochromatic beam (right). The different lines correspond to the different high-Z elements studied (10 mg/ml).
TABLE VII. Dvalley, max bone/Dvalley, tumor (left) and Dvalley, average brain/Dvalley, tumor (right) as a function of microbeam energy and element concentration in the
human head phantom (c-t-c: 200 lm, field size: 2-by-2 cm2). Statistical uncertainty corresponds to 2r.
Bone Brain
MRT spectrum 175 keV MRT spectrum 175 keV
Z Element 5 mg/ml 10 mg/ml 5 mg/ml 10 mg/ml 5 mg/ml 10 mg/ml 5 mg/ml 10 mg/ml
Unloaded 4.91(2) 3.11(1) 1.651(1) 1.526(1)
53 I 3.42(1) 2.64(1) 2.42(1) 2.009(8) 1.151(1) 0.888(1) 1.182(1) 0.983(1)
64 Gd 3.30(1) 2.489(9) 2.231(9) 1.739(7) 1.110(1) 0.840(1) 1.092(1) 0.851(1)
67 Ho 3.38(2) 2.474(9) 2.192(9) 1.704(7) 1.104(1) 0.833(1) 1.075(1) 0.833(1)
68 Er 3.30(1) 2.471(9) 2.193(9) 1.685(6) 1.109(1) 0.832(1) 1.071(1) 0.824(1)
70 Yb 3.31(1) 2.48(1) 2.174(9) 1.682(7) 1.108(1) 0.835(1) 1.064(1) 0.821(1)
71 Lu 3.29(1) 2.472(9) 2.164(9) 1.678(6) 1.105(1) 0.832(1) 1.054(1) 0.818(1)
72 Hf 3.30(1) 2.484(9) 2.175(9) 1.679(6) 1.107(1) 0.834(1) 1.062(1) 0.820(1)
79 Au 3.27(1) 2.460(8) 2.226(9) 1.721(5) 1.099(1) 0.827(1) 1.089(1) 0.841(1)
81 Tl 3.28(1) 2.475(9) 2.228(9) 1.755(7) 1.104(1) 0.829(1) 1.090(1) 0.858(1)
TABLE VIII. PVDR dosimetric study in the tumor and healthy tissue for dif-
ferent contrast media as a function of microbeam energy and the c-t-c dis-
tance in the rat head phantom (field size: 1-by-1 cm2). Statistical uncertainty
corresponds to 2r.
MRT spectrum 175 keV
Z Element 400 lm 200 lm 400 lm 200 lm
PVDRtumor
Unloaded 64.7(7) 25.0(2) 78.1(8) 37.7(3)
71 Lu 58.0(6) 21.6(1) 65.1(6) 22.2(1)
79 Au 57.3(6) 20.9(1) 62.8(6) 24.4(1)
81 Tl 56.7(6) 20.7(1) 62.7(6) 25.4(2)
PVDRmax bone/PVDRtumor
Unloaded 1.40(2) 1.37(1) 1.85(3) 1.18(1)
71 Lu 1.56(2) 1.56(1) 2.22(4) 2.01(2)
79 Au 1.58(2) 1.61(2) 2.27(4) 1.82(2)
81 Tl 1.58(2) 1.62(2) 2.29(4) 1.75(2)
PVDRaverage brain/PVDRtumor
Unloaded 1.117(8) 1.105(5) 1.140(8) 1.140(6)
71 Lu 1.200(9) 1.231(5) 1.33(1) 1.743(7)
79 Au 1.215(9) 1.255(6) 1.359(9) 1.608(7)
81 Tl 1.222(9) 1.266(6) 1.356(9) 1.553(7)
TABLE IX. Dvalley, max bone/Dvalley, tumor and Dvalley, average brain/Dvalley, tumor
for different contrast media as a function of microbeam energy and the c-t-c
distance in the rat head phantom (field size: 1-by-1 cm2). Statistical uncer-
tainty corresponds to 2r.
MRT spectrum 175 keV
Z Element 400 lm 200 lm 400 lm 200 lm
Dvalley, max bone/Dvalley, tumor
Unloaded 1.12(2) 1.18(1) 0.85(1) 1.17(1)
71 Lu 0.80(1) 0.808(7) 0.68(1) 0.653(6)
79 Au 0.80(1) 0.795(7) 0.65(1) 0.707(7)
81 Tl 0.79(1) 0.793(7) 0.65(1) 0.733(7)
Dvalley, average brain/Dvalley, tumor
Unloaded 0.934(7) 0.943(5) 0.910(7) 0.908(5)
71 Lu 0.720(6) 0.700(4) 0.68(1) 0.584(3)
79 Au 0.719(6) 0.695(4) 0.731(6) 0.621(3)
81 Tl 0.718(6) 0.691(3) 0.729(6) 0.639(3)
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head phantom, despite the fact that the brain receives
equivalent doses to the skull for the rat head phantom (see
Table IX).
Our Monte Carlo predicted dosimetry data from the rat
head phantom were equivalent to data from the human head
phantom. This equivalence may prove useful when moving
from preclinical rodent studies to clinical trials in humans.
IV. CONCLUSIONS
MRT is a synchrotron radiation therapy technique with
the potential to cure brain tumors. Many preclinical studies
have proved that MRT is able to ablate highly aggressive
tumors while sparing healthy tissue. A further improvement
in its remarkable therapeutic index can be achieved by load-
ing the tumor with a high-Z element in order to enhance the
deposited dose. In this study, Monte Carlo calculations have
been performed to assess the optimum high-Z element in dif-
ferent irradiation configurations. Maximization of the quo-
tient between PVDR in healthy tissue and PVDR in the
tumor and minimization of the valley doses in bone and the
brain were used as criteria. The optimum element depends
on the irradiation configuration used. The best outcome is
provided by the highest Z contrast agents studied, i.e., gold
and thallium. However, results obtained with lanthanide ele-
ments (in particular lutetium) or hafnium are extremely satis-
factory in some configurations. Analogous data were
obtained for a rat head phantom. This may be useful to trans-
fer preclinical studies to future clinical trials in patients. In
the present work, only dosimetric considerations were taken
into account, but the final choice on the element and its con-
centration would also depend on the degree of cytotoxicity.
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2.5. Paper III and IV: MC-based TPS calculation engine devoted to MRT
2.5 Paper III and IV: Monte Carlo-based treatment planning sys-
tem calculation engine for MRT
Introduction
Accurate dose calculations in a ‘virtual’ model of the patient (typically extracted from com-
puter tomography (CT) data) are required to treat patients in RT. This is done by what is
called a treatment planning system (TPS).
The distinct features of MRT (beam generation, machine geometry, energy range, microm-
etre-sized fields, etc.) with respect to conventional linacs (see figure 1.2 and section 1.3) have
required the development of a dedicated TPS. In particular, a MC-based dose calculation
engine was developed and benchmarked experimentally in this thesis. It will constitute an
essential tool for future MRT clinical trials.
International Reports [ICRU-24 1976, ICRU-42 1987, AAPM-85 2004] reflected that an
accuracy of around ±2–5% is needed in the delivery of absorbed dose to the target volume
if the eradication of the primary tumour is sought. Due to the slope of the TCP and NTCP
curves, a dose error of 5% might lead to a TCP change of 10–20% and to even larger NTCP
changes [AAPM-85 2004]. Since MC results yield the highest possible dose calculation ac-
curacy [Reynaert 2007], this was the method of choice for the MRT TPS calculation engine
(PENELOPE/PENEASY code, see section 1.5.4.1). A scheme of this work, which was divided
into two papers (III and IV), is presented in figure 2.1.
Figure 2.1: Scheme of the MC-based TPS calculation engine for MRT.
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Chapter 2. Results
Whereas statistical uncertainties due to the limited number of histories can be reduced
by increasing the simulation time, inaccuracies coming from approximations used in cross
section libraries or in beam modelling are not always easily predictable. The first source
of uncertainties is typically considered negligible [Fraass 2003]. In order to reduce the un-
certainties arising from the beam model, the first objective consisted of the development of
precise and realistic modelling of the radiation source (paper III), in contrast to the simplified
models used in previous MC studies (see section 1.5.2). In particular, the ID17 x-ray source
was modelled by the synchrotron ray-tracing code SHADOW (see section 1.3.3.1). The MC
simulation code PENELOPE/PENEASY was employed to transport the photon beam from the
source to the patient position through the beamline. The phase-space state variables of the
particles reaching the patient position were saved in a phase-space file (PSF). The informa-
tion contained in this PSF was used as an input to generate a photon beam model.
Computed dose distributions from photons sampled according to probability distributions
derived from the beam model were experimentally verified by using HD-810 radiochromic
films [ISP R© 2012] analysed with a microdensitometer (see section 1.5.4.2). The bench-
marking process (both in homogeneous and heterogeneous media) was essential in order
to assess both the performance of the photon source model and the TPS calculation engine
[IAEA-TRS-430 2004].
The second part (paper IV) reports the use of the photon model to perform dose calcula-
tions in a voxelised model of the patient. To this end, the decoupling of the CT image voxel
grid (size in the order of mm3) to the dose bin grid, which has micrometre-sized dimensions
in the direction transversal to the microbeams, was required. Since the calculation of such
small voxels demands high computation times, work on optimising the simulation efficiency
was also carried out by using variance-reduction (VR) techniques and parallelisation of the
simulations, among other methods.
Both publications are presented in this section.
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Purpose: A new radiotherapy technique, named microbeam radiation therapy (MRT), is under de-
velopment at the ID17 Biomedical Beamline of the European Synchrotron Radiation Facility
(ESRF). This innovative method is based on the fact that normal tissue can withstand high radiation
doses in small volumes without any significant damage. The promising results obtained in the pre-
clinical studies have paved the way to forthcoming clinical trials, which are currently in prepara-
tion. Highly accurate dose calculations at the treatment planning stage are required in this context.
The aims of this study are the development and experimental benchmarking of a photon beam
source model, which will be the core of the future MRT treatment planning system (TPS).
Methods: The ID17 x-ray source was modeled by the synchrotron ray tracing code SHADOW. The
Monte Carlo (MC) simulation code PENELOPE/PENEASY was employed to transport the photon beam
from the source to the patient position through all the beamline components. The phase-space state
variables of the particles reaching the patient position were used as an input to generate a photon
beam model. Computed dose distributions in a homogeneous media were experimentally verified
by using Gafchromic
VR
films in a solid–water phantom. Benchmarking was split into two phases.
First, the lateral dose profiles and the percentage depth-dose (PDD) curves in the broad beam con-
figuration were considered. The acceptability criteria for radiotherapy dose computations recom-
mended by international protocols such as the Technical Reports Series 430 (TRS 430) of the
International Atomic Energy Agency (IAEA) were used. Second, the analogous dosimetric magni-
tudes in MRT irradiations, i.e., PDD of the central microbeam and the corresponding peak-to-valley
dose ratios (PVDR) were evaluated and compared with MC calculations.
Results: A full characterization of the ID17 Biomedical Beamline (ESRF) synchrotron x-ray source
and the development of an accurate photon beam model were achieved in this work. Calculated and
experimental dose distributions agreed to within the recommended acceptability criteria described in
international codes of practice (TRS 430) for broad beam irradiations. The overall deviation in low
gradient areas amounted to 2%–3%. The maximum distance-to-agreement in high gradient regions
was lower than 0.7 mm. MC calculations also reproduced MRT experimental results within uncertainty
bars. These results validate the photon beammodel for its use in MRT radiation therapy calculations.
Conclusions: The first MC synchrotron photon beam model for MRT irradiations that reproduces
experimental dose distributions in homogeneous media has been developed. This beam model
will constitute an essential component of the TPS calculation engine for patient dose computa-
tion in forthcoming MRT clinical trials. VC 2012 American Association of Physicists in Medicine.
[DOI: 10.1118/1.3665768]
Key words: synchrotron radiation, microbeam radiation therapy, Monte Carlo simulations, clinical
trials
I. INTRODUCTION
Microbeam radiation therapy (MRT) is a new radiation ther-
apy method that uses synchrotron radiation. This innovative
technique is under development at the National Synchrotron
Light Source (NSLS) in Upton, USA, and at the European
Synchrotron Radiation Facility (ESRF) in Grenoble, France.
The ultimate goal is the treatment of inoperable brain tumors
with especial emphasis on gliomas. MRT irradiation is per-
formed by means of an array of intense parallel x-ray
microbeams (25–50 lm wide) with a 200–400 lm center-to-
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center (c-t-c) distance. The microbeams are produced by a
multislit collimator (MSLC), which fractionates the beam in
the horizontal direction.1 The resulting dose profiles consist
of a pattern of peaks and valleys, i.e., with high doses in the
microbeam paths and low doses in the spaces between
them.2 The minimum dose in the central region between two
microbeams is named the valley dose and the dose at the
center of the microbeam is the peak dose.
MRT has several interesting properties which seem to
challenge many of the current paradigms in conventional
radiation therapy. Healthy tissue exhibits an exceptional
resistance to very high doses (100 Gy) in one fraction.3–10
In addition, malignant tissue mass appears to respond to
MRT by significant growth delay and, in some cases, com-
plete tumor ablation.11–15 despite the small fraction of tumor
mass irradiated with the high-dose microbeams.
The biological mechanisms following MRT irradiation
are not yet fully understood. The preferential effect on
malignant tissue has been mainly attributed to selective
effects of microbeams on immature tumor vessels versus a
lack of microbeam effects on the differentiated normal vas-
culature,12 although other factors might be operative.10 In
addition, it has been hypothesized that the sparing effect in
healthy tissue along the beam paths is due to rapid biological
repair of the microscopic lesions by the minimally irradiated
cells contiguous to the irradiated tissue slices.4,12 Dilmanian
et al.12 showed that the sparing effect of MRT seems to
depend mostly on the valley dose. The brain-sparing effect
(measured by the onset of the appearance of white matter ne-
crosis) vanishes only when the valley dose approaches the
tissue tolerance to broad beams. Animal experiments carried
out indicate that both valley doses and the peak-to-valley
dose ratio (PVDR) are relevant parameters as regards radio-
biological response.
Following the success of preclinical studies, the Biomedi-
cal Beamline ID17 of the ESRF is proceeding toward clini-
cal trials on pets,16,17 which, if successful, may lead to
clinical administration of MRT to humans. Such an imple-
mentation demands a precise MRT dose computation.
There is strong evidence that an accuracy of 62%–5% in
dose delivery is required to effectively treat certain types of
cancers and to reduce complications, as reflected in the 24
and 42 reports of the International Commission on Radiation
Units and Measurements (ICRU).18,19 In order to minimize
discrepancies between the calculated dose distributions at the
treatment planning stage and those delivered to the patient,
precise dose computation methods are required. Monte Carlo
(MC) simulations are considered to be the most accurate
approach20–22 for particle transport, and thus, it will be the
method used in this study. Whereas statistical uncertainties
can be reduced by increasing the number of simulated histor-
ies, systematic inaccuracies coming from approximations
used in physical models, geometrical descriptions, etc. are
not always easily predictable. Hence, precise and realistic
modeling of the radiation source is a fundamental require-
ment in MC radiation therapy calculations.
Simplification of the real irradiation source geometry is a
common practice adopted by authors of theoretical MRT
studies. Thus, identical, parallel, perfectly rectangular
microbeams are usually considered.2,23–29 The dose distribu-
tion of a single microbeam is simulated and a superposition
algorithm is used in order to generate the dose profile of the
complete array. These simplifications fail to account for the
source size and shape, the beam divergence along the dis-
tance from the synchrotron source to the patient position or
any geometrical and scattering effect arising from the radia-
tion transport through the beamline. Nettelbeck et al.30
showed, by using simple models, that these approximations
can lead to inaccuracies in the valley doses, penumbral
regions of dose profiles and in the PVDR. If beam diver-
gence is included, there is an increase of 26% in the penum-
bra region and 10% in the valley doses.30 Modeling of a
synchrotron-distributed source rather than a point source
resulted in almost a 30% larger penumbral dose.30 In addi-
tion, the effect of linear polarization of the synchrotron
beam was partially accounted for in the work of De Felici et
al.25 and it appeared to be non negligible. This could explain
part of the discrepancies between measured and calculated
valley doses presented in previous MRT studies.28,31 In both
cases, 25 lm-wide microbeams spaced by 200 lm were
considered. A MOSFET detector was used in the work of
Siegbahn et al.28 MC simulations estimated PVDR values up
to 50% higher than experimental data; the main source of
discrepancies between measured and simulated doses was
attributed to the energy dependence response of the MOS-
FET detector. The work of Crosbie et al.31 presented film
dosimetry compared with different MC values previously
published. Differences up to 50% were also reported.
Due to the aforementioned reasons and within the frame-
work of the forthcoming clinical trials preparation, the
development of both an accurate and reliable synchrotron
beam model is essential. Therefore, full characterization of
the ID17 Biomedical Beamline (ESRF) photon source beam,
its modeling and benchmarking with experimental data has
been addressed in this work. The beam model will constitute
an essential component of the calculation engine of the future
MRT treatment planning system (TPS). A complete set of
both MC and experimental dosimetric data for the MRT
clinical trial irradiation conditions (50 lm-wide microbeams
spaced by 400 lm) is reported for the first time.
II. MATERIALS AND METHODS
II.A. ESRF ID17 Biomedical Beamline source
The ESRF is a third-generation synchrotron with a 6.04
GeV electron storage ring. The x-ray source differs from med-
ical linear accelerators in photon generation, type and dimen-
sions of beam modifiers, intensity, energies, etc. In third-
generation synchrotron sources, extremely bright synchrotron
radiation is produced when the trajectories of the accelerated
(relativistic) electrons are deflected at the so-called insertion
devices (ID), which consist of arrays of magnets. Synchrotron
radiation (SR) is emitted in a narrow cone with a typical natu-
ral opening angle of about 1/c (rad). The Lorenz factor (c) can
be expressed as c¼ 1þE/(mc2), where E is the kinetic energy
of the electron, m is the rest mass of the electron and c is the
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speed of light in vacuum. The vertical and horizontal diver-
gences of the SR beam are 2c1 and 2Kc1 (rad), respec-
tively.32 The deflection parameter K describes the electron
motion in an ID and can be expressed as
K ¼ 0:934 B½Tku½cm; (1)
where B is the magnetic field (in T), which depends on the
wiggler gap (see below), and ku is the magnetic field period
(in cm).32
The ID type at the ID17 Biomedical Beamline is a wig-
gler. In this kind of ID, the horizontal divergence is much
larger than the natural opening angle of SR (K is large) and
the radiation emitted at each pole adds incoherently. Table I
reports the parameters of the ESRF storage ring electron
beam and of the ID17 wiggler. These characteristics deter-
mine the properties of the generated SR beam, which traver-
ses different types of beam modifiers, such as slits, filters,
etc. (see Fig. 1). The main features of the ID17 beam modi-
fiers are reported in Table II.
Targets are placed on a three-axis Kappa-type high-
precision goniometer (Huber, Germany),17 located 40.5 m
downstream from the wiggler center. The maximum achiev-
able horizontal and vertical dimensions of the beam at the
patient position are 4.1 and 0.25 cm, respectively. In order to
fill the desired vertical irradiation field size, targets are verti-
cally scanned at constant speed (in the range between 10 and
100 mm/s). The chosen speed depends on the desired dose,
beam current, and vertical slit size. This scanning method is
equivalent to a broad beam irradiation.34
The irradiation modality depends on the presence or ab-
sence of the multislit collimator.1 If the MSLC is not in the
beam path, the irradiation corresponds to a seamless field
irradiation, hereafter named broad beam. If the MSLC is in
the beam path, an MRT irradiation is carried out. The syn-
chrotron high-dose rate (13 440 Gy/s for the maximum elec-
tron current) provides a fast irradiation and minimizes
cardiosynchronous motion effects in the brain.35 This, along
with the low beam divergence, allows the production of
sharply defined beam edges. The MRT irradiation parame-
ters used in this study correspond to those fixed in the forth-
coming MRT clinical trials, i.e., 50 lm-wide microbeams
with a c-t-c of 400 lm.
II.B. Simulation codes: SHADOW and PENELOPE
Two simulation codes were used: SHADOW and PENELOPE/
PENEASY. The synchrotron ray tracing code SHADOW was
employed to generate particles emerging from the ID17
wiggler.36–39 SHADOW considers wigglers as a series of pseu-
dobending magnets. The code uses MC methods to sample
photon emission along a realistic electron trajectory inside
the wiggler, which includes the electron beam emittance.
The ESRF and ID17 wiggler parameters (Table I) were
required as an input for the simulations. The phase-space
state variables of the photons exiting the ID17 wiggler, i.e.,
energy, spatial position, direction of flight, and polarization
state were obtained as the output.
The transport of photons from the wiggler to the patient
position was performed with the MC code PENELOPE v.
2008,40,41 which allows the simulation of the coupled trans-
port of electrons, photons, and positrons in a wide energy
range and in arbitrary material systems. The two codes were
directly linked by inserting a new source model into the
general-purpose main program for PENELOPE named PENEASY.42
This methodology can be easily extended to any other syn-
chrotron source by changing the electron beam and wiggler
parameters and the geometry of the beamline modifiers.
The final photon beam spectrum at the patient position
exhibits a continuous distribution with a range from 27 keV
TABLE I. ESRF storage ring electron beam parameters and ID17 wiggler
characteristics (Ref. 33).
ESRF electron beam parameters
Electron energy 6.04 GeV
Maximum current 0.2 A
Horizontal emittance 3.9 nm
Vertical emittance 0.039 nm
RMS horizontal source sizea 57 lm
RMS vertical source sizea 10.3 lm
ID17 wiggler parameters
Magnetic field period ku 15 cm
Number of periods 11
Gap (for the MRT irradiation conditions) 2.48 cm
Maximum magnetic field B (gap¼ 2.48 cm) 1.592 T
Deflection parameter K¼ 0.934B[T]ku (cm) 22.30
aRoot mean square (RMS) source size at the ID17 wiggler position
FIG. 1. Scheme of the ID17 beamline elements from the wiggler to the patient position (not to scale).
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to 600 keV and a mean energy of about 100 keV. The most
relevant photon interaction mechanisms in this energy range
are the photoelectric effect and Compton scattering. Photo-
electric cross sections included in the PENELOPE code are inter-
polated from tabulations of the Evaluated Photon Data
Library from the Lawrence Livermore National Laboratory.43
The Compton cross section is obtained by having recourse to
the relativistic impulse approximation, which takes into
account both Doppler broadening and binding of the atomic
electrons, but does not include many-body and aggregation
effects. The scattering of polarized photons is also considered
in the simulations.40 Polarization effects will be especially
relevant in our case as synchrotron beams are highly linearly
polarized in the electron orbit plane. We shall describe the
polarization state of electromagnetic radiation by means of
the Stokes parameters (P1, P2, P3),
44 following the conven-
tion commonly used in Quantum Mechanics.40 Thus, P3
determines linear polarization along the x and z axis, P2 rep-
resents circular (right and left) polarization and P1 corre-
sponds to polarization in the lines that bisect the x-z plane.
MC simulations with the PENELOPE/PENEASY code were
split into different stages. First, the transport of photons up
to the vertical slit placed just before the MSLC (at 38.8 m
from the wiggler center) was performed. Electron transport
was not considered in this part of the simulations as second-
ary electrons generated from photon interactions in the vari-
ous beamline elements will not reach the patient position
(the range in air for a 100 keV electron is 14 cm). At the ver-
tical slit position, a phase-space file (PSF) containing the
state variables of the photons was generated for each consid-
ered horizontal field size (1, 2, and 3 cm).
The code was compiled with the Intel Fortran compiler v.
10.0 and run on a 2.9 GHz Intel Xeon Processor X5670. The
simulation time needed to obtain 107 photons in the PSF was
approximately 7 days. The fraction of photons passing
through the diaphragm was 8.8%, while the fraction of par-
ticles crossing the primary slits (2 0.1 cm2 field size) was
1.4%. After traversing all the beam modifiers, only 0.04% of
the primary photons generated in the wiggler reached the
patient position (for a 500 lm vertical slit size). Further-
more, reading particles from the PSF involved some addi-
tional processing time. Therefore, a photon source model
was developed based on the phase-space distribution of the
particles exiting the beamline. This model will be presented
in Secs. II E and III A.
Particles sampled from our model were transported up to
a water phantom to compute absorbed dose distributions.
Dimensions and characteristics of the simulated water phan-
tom are given in Sec II C. Two irradiation modalities were
studied: broad beam and MRT. In the latter case, the trans-
port of particles going through the MSLC was performed.
The MSLC was carefully modeled following real propor-
tions and chemical composition.1 For each case, three field
sizes were considered: 1 1, 2 2, and 3 3 cm2. For the
broad beam, doses were scored in 0.04 cm voxels in the hori-
zontal and vertical direction of the beam and 0.1 cm in
depth. The dose bin size along the horizontal direction was
reduced to 5 lm for MRT irradiations.
The simulation parameters for the broad beam calcula-
tions were the following. The absorption energies, EABS,
were set to 5 keV for photons and 50 keV for electrons. For
charged particles, the average angular deflection in a
multiple-scattering step, C1, and the maximum average frac-
tional energy loss along that step, C2, were fixed to 0.1; the
cutoff energies for the production of hard inelastic, WCC,
and hard bremsstrahlung events, WCR, were set equal to
electron and photon EABS, respectively.40,45 The absorption
energies in the MRT simulations were reduced to 1 keV for
photons and to 10 keV for electrons to account for the
reduced beam size in the x direction.
Simulations were discontinued when the average relative
statistical uncertainty was less than 1% for the broad beam
and less than 2.5% for the MRT simulations (2 standard
deviations, 2r). This uncertainty was calculated as a root
mean square average of the uncertainties of the bins with
doses above half of the maximum score.
II.C. Relative dosimetry: experimental dose
distributions
Percentage depth-dose (PDD) and lateral dose profile
curves were measured for several field sizes (1 1, 2 2,
and 3 3 cm2) and for the two irradiation configurations,
i.e., broad beam and MRT.
The lateral dose profiles measurements (for broad beam)
performed with a thimble ionization chamber [PTW 31010,
TABLE II. Description of the ID17 beamline elements.
Beamline element Distance to wiggler Main characteristics
Diaphragm 21.6 m Avoidance of heat load, maximum field size definition (HV: 2.4 0.15 cm2)
Be window Several Separation between vacuum sections (thickness: 300–500 lm)
Kr gas filter 27.6 m Beam attenuation
Primary slits 29.3 m Delimitation of the field size at patient position (aperture variable)
C, Al, and Cu filters 30.2 m Elimination of low-energy photons
Ionization chamber 34.1 m Monitoring of the beam (Al foil of 500 lm-thick at the entrance/exit)
Al Foil 37.1 m Separation between vacuum section and air (thickness: 500 lm)
Vertical slit 38.8 m Delimitation of the vertical field size (50, 100, or 500 lm) before scanning
Multislit collimatora 39.3 m Generation of an array of 50 lm-wide microbeams spaced by 400 lm
aOnly in MRT irradiation modality.
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0.125 cm3 (Ref. 46)] in a water tank for horizontal beams
[PTW MP3-P T41029 (Ref. 46)] revealed insufficient spatial
resolution for this detector system in steep dose gradient
regions for the studied field sizes. In addition, the thickness of
the water tank entrance window (0.5 cm of PMMA) and the
external diameter of the ionization chamber prevented meas-
urements of the PDD curves in depths shallower than 1 cm.
In contrast, Gafchromic
VR
HD-810 films47 provide the
high spatial resolution required to measure lateral dose
profiles, including the submillimetre field sizes used in
MRT. The broad dose range (from 10 to 400 Gy) also ena-
bles PVDR values to be assessed. Gafchromic HD-810 films
have already been used successfully to record doses in
synchrotron sources48 and to evaluate PVDR values in
MRT.31 The handling and accurate positioning of this type
of radiochromic films in water is very delicate. Thus, the
films were placed at different depths (from 0.3 to 10.0 cm)
in a RW3 (Goettingen White Water) solid–water slab phan-
tom of dimensions 30 12 30 cm3.46 This phantom
allowed the evaluation of PDD curves starting from the sur-
face. Lateral dose profiles were measured up to 4 cm from
the center of the field. Each measurement was performed at
least twice in order to reduce experimental uncertainties.
For the handling and calibration of the films, the recom-
mendations provided by Task Group 55 of the American
Association of Physics in Medicine (AAPM) (Ref. 49) were
taken into account. The dose calibration range used went
from 10 to 400 Gy (that is the recommended range of use of
HD-810 films.47 The dose in broad beam was measured with
a thimble ionization chamber [PTW 31010, 0.125 cm3 (Ref.
46)] calibrated in kilovoltage x-rays. The calibration curve
followed a quadratic polynomial regression D¼ c1OD
þ c2OD 2, where D is the dose, OD is the optical density and
ci (i¼ 1,2) are the unknown fit parameters. Each film box
used was calibrated separately. One example of this fitting
was c1¼ 334.91 and c2¼ 237.84, with a correlation coeffi-
cient of R2¼ 0.99998.
The films receiving broad beam irradiation were analyzed
with a flat bed scanner [Epson Perfection V750-M Pro Scan-
ner (Ref. 50)] following the widely used methodology
described in the work of Devic et al.51 However, the spatial
resolution of this scanner limited its use to performing do-
simetry at the micron scale required in MRT. Instead, a
microdensitometer (3CS Microdensitometer, J. L. Automa-
tion) was employed to read the films. This system has a wide
dynamic range (it is sensitive to optical densities OD from
0.2 to 6) and a very high spatial resolution (around 5 lm).
The dose assessment was performed by comparing the OD
of films irradiated in the broad beam configuration with a
well-known dose with the OD of the film under evaluation.
The use of this type of system is very time-consuming as the
reading speed is very low and the delicate optical and me-
chanical parts composing the microdensitometer forced us to
frequently adjust it to avoid any drift in the system.52,53 Fur-
ther details on the working principle of the microdensitome-
ter can be found elsewhere.54
For each evaluated point, the measurement was repeated
at least two times in different days/run. Moreover, the films
were read out a minimum of three times to ensure the repro-
ducibility of the data. Therefore, the measurement uncertainty
is taken into account nonuniformities in the films, small dif-
ferences in beamline alignment in different days, etc.
II.D. Experimental validation of the Monte Carlo
simulations
Benchmarking of the MC calculation engine (and espe-
cially the beam model) is an essential step toward the final
development of a TPS for clinical trials in MRT. Since MRT
is a complex technique, this process was divided into two
steps. First, a comparison of the calculations and experimen-
tal data for broad beam irradiation was performed. Fine tun-
ing of the modeling was then verified for MRT irradiations
in a second stage.
The TPS acceptability criteria described in the TRS 430
(Ref. 55) were followed for the broad beam configuration. In
particular, the method to quantify differences between MC
and experimental data proposed by Venselaar et al.56 was
employed. Relative deviations (d) were evaluated as
d ¼ DMC;p  Dexp;p
Dexp;p
; (2)
where DMC,p and Dexp,p are the normalized calculated and
experimental dose values at a certain point p, respectively.
In addition, an overall confidence limit D was defined as
D ¼ jdj þ 1:5sd; (3)
where d is the mean deviation between calculations and
measurements for a number of data points p (depending on
the region, see next paragraph) and sd is the standard devia-
tion of the difference. The factor 1.5 represents a confidence
interval of 87%.56
Venselaar et al.56 proposed that the recommended accept-
ability criteria varied as a function of the region of the dose
distributions since dose algorithms provide better accuracy
in some zones than in others. The different regions and toler-
ances for homogeneous and simple irradiation geometries
are listed.
• Deviations of the points beyond the maximum dose Dmax
in PDD curves are quantified by d1 (or D1) and should take
values lower than 2%.
• Deviations of points in the build-up region of PDD curves
(from the phantom surface to the depth of the 90% Dmax
isodose) are described by d2 (or D2). In the case of lateral
dose profiles, d2 (or D2) represents the points in the penum-
bra region (from 80 to 20% of the dose at the central axis
Dcax). The maximum recommended deviation between MC
and experimental data are 10% or 2 mm, in terms of dis-
tance-to-agreement. These values are preferably expressed
in millimetres.
• The deviation of the points in the beam (excluding the
three central beam axis points) in the lateral dose profiles
is quantified by d3 (or D3). The acceptability criteria rec-
ommend values lower than 3%.
• d4 (or D4) indicates the differences between calculations
and measurements for points off the geometrical beam
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axis in the lateral dose profiles (less than 20% Dcax). Due
to the inherently low accuracy of dose calculations in this
region, deviations are expressed as a percentage of the cen-
tral axis dose. The maximum recommended value in this
case is 3%.
Fine tuning of the MC calculations for the MRT configu-
ration was also verified experimentally by confirming that
the respective uncertainty intervals overlap. The central peak
and valley doses and the corresponding PVDR values were
assessed for each field size at different depths. These are the
most relevant dosimetric parameters in this kind of spatially
fractionated techniques,12 and thus, they represent a good
estimate of MRT dose calculation performance.
II.E. Photon source characterization
Complete photon source characterization including the
phase-space variables, i.e., the energy, spatial position,
divergence and polarization state, of the beam at different
positions in the beamline is reported in this section. This
information was used to generate a photon source model,
which will be presented in Sec. III A.
Figure 2 (upper part) shows the top view of the photons
generated in the wiggler (left) and the beam cross section at
the exit (right). The phase-space representing all possible
values of position and divergence at the wiggler exit in the
horizontal (x, u) and vertical (z, w) coordinates is plotted at
the bottom of the same figure. The full width at half maxi-
mum (FWHM) of the distribution of photons along the x and
the z coordinates is 0.280 and 0.018 cm, respectively. The
phase-space distribution of wiggler radiation as a superposi-
tion of contributions from different poles is clearly visible in
the (x, u) diagram, where each ellipse corresponds to one
pole. In the high-brightness central region, the contribution
from different poles intersects.
Photons exiting the wiggler are emitted in a continuum of
energies from the infrared to the x-ray region. The highest
energies are concentrated on the central part of the beam,
while the low-energy content is higher in the outer beam
region. The integrated spectrum over the full beam at differ-
ent beamline positions is plotted in Fig. 3. The maximum
photon energy is around 600 keV. Low-energy photons are
absorbed by the Kr, C, Al, and Cu filters. At the patient posi-
tion, the spectrum ranged from 27 to 600 keV with a peak
FIG. 2. Top view of the particles generated in the wiggler (top left) and beam cross section at the wiggler exit (top right). Phase-space diagrams in the horizon-
tal (bottom left) and vertical (bottom right) coordinates at the end of the wiggler. Each point represents a photon (each plot contains 14 000 photons).
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energy at 75 keV. The mean energy was 99 keV. The final
fraction of photons with energies higher than 300 keV was
very small (0.1%).
Another relevant property of synchrotron light is its polar-
ization. Figure 4 shows the P3 values in terms of the vertical
divergence (w) at the patient position. Negative values corre-
spond to a linear polarization in the horizontal plane accord-
ing to our reference system. Therefore, the beam is highly
linearly polarized in the horizontal direction as 95% of the
photons have P3 values between 0.98 and 1. The lowest
P3 values were encountered in the outer part of the beam.
One can quantify the degree of linear polarization (DOPL)
in terms of the Stokes parameters (defined in Sec. II B) as
DOPL ¼ ðP21 þ P23Þ1=2: (4)
DOPL ranges from zero (nonlinearly polarized light) to one
(completely linearly polarized light). Since the skew polariza-
tion in a wiggler is zero (P1¼ 0), DOPL¼ jP3j. Table III lists
DOPL values at different positions in the beamline. The cal-
culated DOPL value at the wiggler exit is low (0.660) as all
the photons emerging from the wiggler are considered. How-
ever, the beam modifiers progressively cut the external part
of the beam and consequently, the polarization reaches a
value of 0.992 after the primary slits (0.1 cm vertical field
size). At the patient position, DOPL is 0.994, which indicates
that the beam is highly linearly polarized along the x axis.
DOPL values did not change with the horizontal field size.
Spatial beam features are modified as photons cross the
different elements in the beamline. The final horizontal and
vertical divergences are approximately 0.5 mrad and 0.02
mrad, respectively, for the standard MRT irradiation condi-
tions. These values are significantly lower than in a conven-
tional linear accelerator (around 35 mrad).
Figure 5 shows the dependence of the phase-space distri-
butions just before the patient position, both in the horizontal
and vertical direction. The probability density functions p(x)
and p(z) (1/cm per history) are also presented in the insets,
which show a homogeneous photon distribution along x
and z.
The knowledge of the phase-space variables of the pho-
tons at the patient position contained in the PSF and
described above allowed us to generate a photon source
model (see Sec III A).
III. RESULTS AND DISCUSSION
In this section, the ID17 photon source modeling is
described. Comparisons between MC computations and
experimental dose distributions in homogeneous media, both
for seamless and MRT irradiations, are also presented.
III.A. ID17 photon source modeling
In this section, a description of the photon beam model
(“virtual source”) is presented. The model was developed
based on the source characterization results reported in
Sec. II E.
In our model, the photon energy was sampled from the
MC calculated spectrum at the patient position (see Fig. 3),
which ranged from 27 to 600 keV with a mean energy of
99 keV. The high degree of polarization showed in Sec. II E
indicated that the beam is extremely linearly polarized along
the x axis when reaches the patient position. Therefore, a P3
value of 1 has been considered in the calculations.
The probability distribution of the x coordinate was
approximated as a uniform distribution with a width equal
to the field size (from 1 to 1 cm in the example showed in
FIG. 3. Integrated spectrum obtained by MC simulation at different beam-
line locations: at the wiggler exit, after the first diaphragm, after the primary
slits (2 0.1 cm2 field size at the patient position), before the Cu filter,
before the vertical slit position and at the patient position (500 lm vertical
slit size). The final energy spectrum ranges from 27 to 600 keV with a mean
energy at 99 keV. The fraction of photons with energies higher than 300
keV is very small (0.1%).
FIG. 4. P3 values as a function of the vertical divergence (w) at the patient
position for 500 lm vertical slit size. Each point corresponds to a photon.
TABLE III. DOPL at different positions in the beamline.
Position DOPL
Wiggler 0.660
After the first diaphragm 0.952
After the primary slits
(vertical field size: 0.1 cm at the patient position)
0.992
Patient position (500 lm vertical slit size) 0.994
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the inset of Fig. 5). The joined distribution for position
and divergence, i.e., x and u, was approximated by a straight
line obtained by the linear regression u¼ ax, where a¼
0.000256(4) is the regression coefficient (see Fig. 5). An
analogous approach was taken for the z coordinate and its
associated divergence value (w), leading to a linear regres-
sion w¼ bz with b¼ 0.0002603(1).
In the case of MRT irradiations, particles were trans-
ported through the MLSC. The vertical scanning of the beam
at the patient position was modeled by computing the verti-
cal position as zþ dfield (n 0.5), where dfield is the vertical
irradiation field size and n is a random number uniformly
distributed in the interval (0,1).
Photons sampled from our source model have been used
to compute absorbed dose distributions in homogeneous
media. The commissioning of this model with experimental
data will be detailed in next section.
III.B. Experimental validation of the MC simulations
Photon beam model validation and MC calculation per-
formance assessment were done by comparing the simulated
dose distributions (PDD and lateral dose profiles at the
patient position) with experimental data for different field
sizes. As it has been explained in previous sections, the pro-
cess was divided into two parts (seamless and MRT). First,
the broad beam configuration was assessed. For this irradia-
tion modality, the TPS acceptability criteria described in
Sec. II D were followed.
III.B.1. Broad beam irradiation
Figure 6 (left) compares the theoretical and experimental
PDD curves for seamless 1 1, 2 2, and 3 3 cm2 field
sizes. Dose values are normalized with respect to the central
dose at a depth of 2 cm for a 2 2 cm2 field size. An
FIG. 5. Phase-space diagrams in the horizontal (left) and vertical (right) coordinates at the vertical slit position, just before the patient position (500 lm vertical
slit size, 2 cm horizontal field size). Each point represents a photon. Probability density functions p(x) and p(z) (1/cm per history) are also shown in the insets.
FIG. 6. Comparison of calculated (MC) and measured (Film) PDD values for 1 1, 2 2, and 3 3 cm2 field sizes (right). Dose values are normalized with
respect to the central dose at a depth of 2 cm for a 2 2 cm2 field size. Statistical uncertainty bars are at two standard deviations. Individual deviations (d)
between experimental and MC PDD data for the reference field size (2 2 cm2) are also presented on the left.
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example of the point-to-point deviations (d) for the reference
field size (2 2 cm2) at a depth of 2 cm is also presented in
Fig. 6 (right). The trend of the point-to-point deviations is
similar for the 1 1 and 3 3 cm2 field sizes. In general, d
values are contained within 62%. Although a few data
points show high deviations, the overall deviation (D)
between calculated and measured relative dose values is
2%–3%. Table IV shows the quantitative analysis of the
deviation parameters D1 and D2 (%) in the PDD curves for
the different field sizes. MC calculations fulfill acceptability
criteria in the build-up region since differences with experi-
mental data, which are quantified by D2, are much lower
than 10%. D1 values, which account for the deviations of
central beam axis points, slightly exceed the recommended
2%. This is probably linked to the difficulties in the measure-
ment of the PDD curves with Gafchromic
VR
films due to
remaining air gaps between the slabs of the solid–water
phantom.57 This would also explain the oscillations in the
point-to-point deviations observed in Fig. 6 (right).
Figure 7 shows the comparison between calculated and
measured lateral dose profiles at a depth of 2 cm along the
horizontal (H) and vertical (V) directions for the three stud-
ied field sizes. An example of the point-to-point deviations is
also presented for a 2 2 cm2 field size at a depth of 2 cm in
Fig. 8. d values are within 63% in the horizontal direction
and within 61% in the vertical one, respectively. The maxi-
mum d deviations are observed in the vicinity of the penum-
bra region. The tendency of the individual deviations is
similar for the other two field sizes.
The quantitative analysis of the overall deviations was
performed by evaluating the parameters D2 (penumbra), D3
(points in the beam), and D4 (tails) of the lateral dose pro-
files. The average D2 value was around 0.2 mm, with a maxi-
mum at 0.7 mm for the highest field sizes and depths. These
values are much lower than the maximum recommended
deviation (2 mm). The highest D3 values were encountered
for a 3 3 cm2 field size but they never exceeded the recom-
mended limit (3%). D4 values increased as a function of
depth, although they also remained within tolerances. Figure
9 shows the D3 (left) and D4 (right) for all the studied cases.
Deviations in the vertical profile are generally lower than
in the horizontal case. As electrons are mostly moving in the
x-y plane, any deviation from the ideal wiggler case
produces changes in the trajectory followed by the electron
beam and, consequently, in the final photon phase-space
diagram (x,u). The focusing power of the wiggler along the z
direction will also be affected by wiggler imperfections.
However, the beam is scanned along the vertical direction at
the patient position and the possible effect on beam model-
ing is reduced.
Other possible reasons for the deviations between experi-
mental data and MC simulations can be found in the uncer-
tainties of the beam modifiers characteristics (dimensions,
shape or composition), in the reflection of the beam in very
polished slits (not considered in the simulations), in possible
small and uncontrolled misalignments in the beamline, etc.
This is, of course, added to the inherent uncertainty of the
experimental method and of the MC calculations.
However, calculated and experimental dose distributions
agreed to within the recommended acceptability criteria
described in international codes of practice. Thus, despite
some deviations between MC simulations and measured
data, the overall agreement is satisfactory.
TABLE IV. PDD overall deviation (D1 and D2) values for 1 1, 2 2, and
3 3 cm2 field sizes. Computed data were compared with the experimental
PDD obtained from HD-810 Gafchromic films placed in a solid–water
phantom.
Field size (cm2) D1 (%) D2 (%)
1 1 2.9 2.4
2 2 2.0 2.9
3 3 3.0 1.8
FIG. 7. Comparison of calculated (MC) and measured (Film) lateral dose profiles (at a depth of 2 cm) in the lateral (left) and vertical (right) direction, for
1 1, 2 2, and 3 3 cm2 field sizes. Dose values are normalized with respect to the central dose at a depth of 2 cm for a 2 2 cm2 field size. Statistical
uncertainty bars are at two standard deviations.
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III.B.2. MRT irradiation
The second phase of the benchmarking of photon beam
model consisted in the comparison of MC calculations and
experimental data in the MRT configuration.
Table V shows simulated (MC) and measured (Film)
PDD curves of the central microbeam for different array
sizes (1 1, 2 2, and 3 3 cm2). Normalized peak dose
values follow the same trend for the three field sizes (PDD
values are normalized with respect to the dose at a depth of
2 cm). The maximum peak dose values are encountered
near the surface (0.3 cm) and a decrease of PDD values is
observed in depth.
PVDR values as a function of depth and field size are pre-
sented in Table VI. The highest PVDR values are located
near the phantom surface. Then, the PVDR decreases up to a
depth of 5 cm due to an increase of the fluence of photons
that are Compton-scattered into the valley region. The fact
that PVDR values remain almost constant in depth (beyond
5 cm) indicates that both the peaks and the valleys decrease
at more or less the same rate. Moreover, a reduction of
PVDR values is observed when the field size (number of
beams) increases, in agreement with other authors.58,59 For
instance, PVDR in depth (beyond 5 cm) take values in the
order of 15 for a field size of 1 1 cm2, while in the case of
3 3 cm2, the PVDR reaches values of approximately 45.
MC simulations reproduced the experimental data within
the uncertainty bars, both for the peak and PVDR values.
Possible deviations between experimental data and MC sim-
ulations have already been detailed in Sec III B 1. Further-
more, the experimental method for the dose assessment in
MRT included the use of a microdensitometer. The problem-
atic of using this kind of systems has already been briefly
discussed in Sec. II C. Despite the inherent experimental
uncertainties, the good agreement between MC calculations
and experimental data in both broad beam and MRT irradia-
tion configurations confirms the validity of our photon beam
model.
FIG. 8. Point-to-point deviations (d) between experimental and MC lateral
dose profiles (at a depth of 2 cm) in the horizontal (H) and vertical (V) direc-
tion for a 2 2 cm2 field size.
FIG. 9. D3 (left) and D4 (right) confidence limits versus depth for different field sizes (1 1, 2 2 and 3 3 cm2) in the vertical (V) and horizontal (H) direc-
tions. The solid line corresponds to the maximum recommended tolerance value of 3%.
TABLE V. Calculated (MC) and measured (Film) central microbeam PDD
(%) at different depths. MRT irradiation parameters: 50 lm-wide microbe-
ams spaced by 400 lm; three field sizes: 1 1, 2 2, and 3 3 cm2. The
normalization point is at a depth of 2 cm. Statistical uncertainty corresponds
to two standard deviations.
Central microbeam PDD (%)
1 1 cm2 2 2 cm2 3 3 cm2
Depth (cm) MC Film MC Film MC Film
0.3 1326 1 1316 9 1336 3 1366 9 1326 3 1356 9
0.5 1286 1 1316 9 1276 3 1306 9 1286 3 1356 9
1.0 1186 1 1196 8 1176 3 1266 8 1176 3 1156 8
2.0 1006 1 1006 7 1006 2 1006 7 1006 3 1006 7
4.0 71.16 0.8 716 6 726 2 706 6 726 2 726 6
6.0 50.96 0.7 516 5 516 1 496 5 526 2 526 5
8.0 36.36 0.5 346 5 376 1 396 5 376 1 386 5
10.0 26.06 0.4 286 3 26.56 0.9 256 3 276 1 276 3
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III.C. Examples of dose distributions in an
homogeneous phantom
Figure 10 shows the MC dose distribution at a depth of 2
cm for an irradiation with an array of microbeams (solid
line) covering an area of 1 1 cm2. The dose profile consists
in peaks and valleys, with a PVDR value of approximately
50. The small divergence of synchrotron beams and the
energy range used in MRT resulted in sharp penumbras (less
than 10 lm). In the same figure, the dashed line represents
the simulated dose distribution obtained for an irradiation
with a Gamma Knife
VR
(GKF).60 The main differences
between both profiles are the spatial fractionation and the
extreme conformality of the dose deposition in MRT in com-
parison with the homogeneous GFK dose distribution and its
much larger penumbras.
As explained in the introduction, MRT is capable of
delaying the tumor growth and, in some cases, of producing
complete tumor ablation, despite the small fraction of tumor
mass irradiated with the high-dose microbeams. Therefore,
the spatial dose fractionation along with the high conformal-
ity (low penumbras) provide a remarkable healthy tissue
sparing while tumoricidal doses are achieved. In GKF, the
total doses in the target are reduced in comparison with
MRT due to normal tissue radiosensitivity. In addition, the
low penumbras in MRT represent a great advantage for the
treatment of tumors close to an organ at risk and for avoiding
serious secondary effects in healthy tissue.
In order to further increase the dose deposited in the tu-
mor with MRT and keep the same dose in the healthy tissue,
other methods can be explored. For instance, the dose
enhancement with the injection of a high atomic number ele-
ment prior the MRT irradiation61 or the use of more complex
MRT configurations such as crossfiring62 or interlacing.63
IV. CONCLUSION
In the quest for a radical treatment of gliomas, clinical
trials in MRT are under preparation at the ID17 Biomedical
Beamline (ESRF). An accurate treatment planning system
for dose computations in the patients was required for this
purpose. Therefore, a full characterization of the synchrotron
x-ray source at the ID17 (ESRF) and the development of an
accurate photon beam model was carried out. The use of this
beam model saves computation time. The methodology
developed in this work can be easily extended to other syn-
chrotron sources by changing the storage ring characteristics,
ID parameters and geometry of the beamline modifiers.
The satisfactory agreement between calculated and meas-
ured dose distributions validates the photon beam model for
its use in MRT radiation therapy calculations. This is the first
published work where MRT theoretical dose maps faithfully
reproduce the experimental data. The beam model developed
in this study will constitute an essential component of the
TPS calculation engine for patient dose computation in
forthcoming MRT clinical trials at the ESRF. Future work
along this line of research includes calculations in voxelized
images and optimization of the computation time.
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Monte Carlo-based treatment planning system calculation engine
for microbeam radiation therapy
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Purpose: Microbeam Radiation Therapy (MRT) is an innovative synchrotron radiotherapy tech-
nique that explores the limits of the dose-volume effect. Preclinical studies have shown that MRT
irradiation (arrays of 25–75-µm-wide microbeams spaced by 200–400 µm) is able to eradicate highly
aggressive animal tumor models. Furthermore, healthy tissue is preserved. These promising results
have provided the basis for the forthcoming clinical trials at the ID17 Biomedical Beamline of the
European Synchrotron Radiation Facility (ESRF). The first step includes irradiation of pets (cats
and dogs) as a milestone before treatment of human patients. Within this context, accurate dose
calculations are required. The distinct features of both beam generation and irradiation geometry
in MRT with respect to conventional techniques requires the development of a specific MRT Treat-
ment Planning System (TPS). In particular, a Monte Carlo-based calculation engine for the MRT
TPS has been developed in this work. Experimental verification in heterogeneous phantoms and
optimization of the computation time have also been achieved.
Methods: The PENELOPE/penEasy MC code was used to compute dose distributions from a
realistic beam source model. Experimental verification was carried out by means of radiochromic
films placed within heterogeneous slab-phantoms. Once validation was completed, dose computa-
tions on a virtual model of a patient, reconstructed from Computed Tomography (CT) images, were
performed. To this end, decoupling of the CT image voxel grid (a few mm3 volume) to the dose
bin grid, which has micrometer dimensions in the transversal direction of the microbeams, was per-
formed. Optimization of the simulation parameters, the use of variance-reduction (VR) techniques
and other methods, such as the parallelization of the simulations, were applied in order to speed up
dose computation.
Results: A good agreement between MC simulations and experimental results was achieved, even
at the interfaces between two different media. Optimization of the simulation parameters and the
use of VR techniques saved a significant amount of computation time (a factor of 8). Finally,
parallelization of the simulations even further improved the calculation times, which reached one
day for a typical irradiation case envisaged in the forthcoming clinical trials in MRT. An example
of MRT treatment to a dog’s head is presented, showing the performance of the calculation engine.
Conclusions: The development of the first MC-based calculation engine for the future TPS devoted
to MRT has been accomplished. This will constitute an essential tool for the future clinical trials on
pets at the ESRF. The MC engine is able to calculate dose distributions in micrometer-sized bins in
complex voxelized CT structures in a reasonable amount of time. Minimization of the computation
time by using several approaches has led to timings that are adequate for pet radiotherapy at
synchrotron facilities. The next step will consist of its integration into a user-friendly graphical
front-end.
Keywords: Microbeam Radiation Therapy, Monte Carlo simulations, Treatment Planning System, clinical
trials
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2I. INTRODUCTION
Microbeam Radiation Therapy (MRT) is a
synchrotron-based technique that is potentially able
to widen the therapeutic window for some radiore-
sistant tumors such as gliomas. Irradiation is car-
ried out by means of an array of parallel x-ray 25–
75-µm-wide microbeams with a center-to-center dis-
tance (c-t-c) of 200–400 µm and a mean energy of
approximately 100 keV [1, 2]. The MRT irradiation
scheme results in dose profiles consisting of peaks
and valleys with high doses along the microbeam
path and low doses between them. The central dose
between two microbeams is named the valley dose,
while the dose at the center of the microbeam is
the peak dose. The ratio between the peak and the
valley doses is called the peak-to-valley dose ratio
(PVDR) and plays an important role in biological
response [3].
Distinct features of MRT are the spatial frac-
tionation of the dose and the use of submillimeter
field sizes, which explore the limits of the dose-
volume effect [4, 5]. This combination shifts the
dose-response curve of healthy tissue towards very
high doses, while growth delay or complete ablation
of highly aggressive animal tumors is achieved. See
[3, 6–11], among others. This has paved the way
for the forthcoming MRT clinical trials at the ID17
Biomedical Beamline of the European Synchrotron
Radiation Facility (ESRF) [12, 13]. For the sake of
safety, the fist phases of the clinical trials will con-
sist of the treatment of spontaneous tumors in pets,
e.g., cats and dogs [13].
The trials require MRT dose computations and,
therefore, an adequate MRT Treatment Planning
System (TPS). However, none of the commercially
available TPSs is suitable in our case due to the
distinct features of the MRT irradiation geometry,
beam source and energy spectrum in comparison
with conventional radiotherapy. Therefore, the de-
velopment of an MRT TPS was needed. The cal-
culation engine developed in this work is based on
Monte Carlo (MC) simulations, which are consid-
ered to be the most accurate approach for particle
transport and dose computation.
The main challenge was to calculate the ab-
sorbed dose at a micrometric scale in voxelized
structures in a reasonable amount of time. In our
previous work [1], complete photon source charac-
terization was achieved. This characterization in-
cluded the phase-space variables, i.e., the energy,
spatial position, direction of flight and polarization
state, of the beam at different positions in the beam-
line. This information was used to generate a pho-
ton source model, which was experimentally vali-
dated in homogenous media. The use of this source
model instead of phase-space files (PSF) enables the
reduction of a significant amount of computation
time.
In the present work, the performance of our
model in heterogeneous structures is assessed. In
addition, the MC code was adapted for dose calcu-
lation in micrometric bins in computed tomography
(CT) images. A further reduction of computation
time was achieved by optimizing the simulation pa-
rameters, by using variance-reduction (VR) tech-
niques and parallelizing the simulations.
To our knowledge, only the work of Gokeri et
al. [14] has dealt with dose calculation in voxelized
structures in micrometer-sized bins. However, their
work is on dose calculations in the presence of con-
trast agents rather than development of a calcula-
tion engine for MRT. Furthermore, the beam width
(680 µm) and c-t-c distance (680 µm) correspond
to Minibeam Radiation Therapy (MBRT), where
thicker beams are used. Additionally, they used a
simplified irradiation source geometry and no exper-
imental benchmarking was performed [14]. There-
fore, this is the first work where both a realistic
source model and voxelized patient geometry are
considered in MRT.
II. MATERIALS AND METHODS
A. ID17 Biomedical Beamline (ESRF)
The ESRF is one of the largest and brightest syn-
chrotrons in the world. In third-generation sources,
such as the ESRF, insertion devices (ID) are in-
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3terposed in the relativistic electron beam path to
deliver extremely brilliant x-rays. At the ID17
Biomedical Beamline, the ID used is a wiggler. The
emitted radiation consists of a continuum of ener-
gies ranging from the infrared to the x-ray region.
Other relevant characteristics of the beam are its
high degree of linear polarization in the electron or-
bit plane and its low divergence [1]. These syn-
chrotron beam features allow minimization of car-
diosynchronous motion effects in the brain [15] and
help to define sharp beam edges.
Photons are transported approximately along
40.5 m until they reach the patient position. Sev-
eral beam modifiers tune the beam along its path
[1]. For instance, some filters eliminate low energies
of the spectrum, while diaphragms and slits shape
the beam to the desired field size. The final energy
spectrum ranges from 27 to 600 keV, with a mean
energy of 99 keV [1, 2]. The last element is a mul-
tislit collimator (MSLC) [16], which allows the gen-
eration of microbeams from a seamless beam. The
MRT irradiation beam used in this study consisted
of 50-µm-wide microbeams with a c-t-c of 400 µm
(clinical settings).
Phantoms or animals are placed on a high-
precision goniometer [12]. Maximum horizontal and
vertical irradiation dimensions at this position are
4.1 and 0.25 cm, respectively. Wider vertical field
sizes are achieved by scanning the targets at con-
stant speed [17]. More details on the different
beam modifiers and physical beam properties can
be found in our previous work [1].
B. PENELOPE/penEasy code description
PENELOPE [18–20] is a MC code widely used
in the medical physics field and, in particular, in
dose calculations for synchrotron radiotherapy tech-
niques [1, 2, 21–24]. This code enables the simula-
tion of the coupled transport of photons, electrons
and positrons in a very wide energy range and in
arbitrary material systems.
The relevant photon interactions in MRT (mean
energy ∼ 100 keV) are Compton scattering and the
photoelectric effect. Compton scattering cross sec-
tions are obtained from the relativistic impulse ap-
proximation, which accounts for Doppler broaden-
ing and binding effects. The polarisation state of
photons is considered in the scattering events [18].
Photoelectric cross sections are interpolated from
tabulations in the Evaluated Photon Data Library
from the Lawrence Livermore National Laboratory
(LLNL) [25].
As regards electron transport, PENELOPE
uses a mixed approach in which hard interactions
are simulated individually whereas condensed sim-
ulation techniques are applied for soft interactions.
The dominant energy loss mechanism for electrons
in our energy range is inelastic collisions. The de-
scription of inelastic scattering of charged particles
is performed on the basis of a schematic generalized
oscillator strength (GOS) model, with mean excita-
tion values taken from ICRU Report 37 [26]. Differ-
ential cross sections of elastic collisions of electrons,
which are responsible for most angular deflections,
are obtained from relativistic partial-wave calcula-
tions [27].
The simulation parameters in PENELOPE
were set as follows. The absorption energies (EABS),
at which the transport is discontinued, were set so
as to ensure that the photon mean free path and
the range of secondary electrons at EABS were both
smaller than the minimum bin used to tally the dose
distributions, that is, 10 keV for electrons and 1 keV
for photons. In Section III B 1, optimization of these
parameters is studied. Charged-particle transport
involves the following parameters: the maximum
average angular deflection in a multiple-scattering
step (C1) and the maximum average fractional en-
ergy loss along that step (C2) were fixed to 0.1; the
cut-off energies for the production of hard inelastic
events (WCC) and hard bremsstrahlung (WCR) were
set equal to EABS for electrons and photons, respec-
tively [18, 28].
The general-purpose main program for PENE-
LOPE, named penEasy [29], was employed in this
work. The code includes different source models,
tallies and the possibility of applying several VR
techniques. penEasy allows dose computation in
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4voxelized structures, as well as their superposition
with objects limited by quadric surfaces.
C. ID17 photon beam source model
A detailed simulation of photon beam transport
from the wiggler source to the patient position has
been described in Mart´ınez-Rovira et al. [1]. The
synchrotron ray tracing code Shadow [30] was used
to generate particles from the ID17 wiggler, while
the PENELOPE code [18] was employed to trans-
port the particles through the beamline. Both codes
were directly linked by inserting a new source model
into the penEasy program [1, 29].
As a result, a PSF with the phase-space state
of the particles before the patient position was gen-
erated. This information was used to construct a
‘virtual’ photon beam source model. MC simula-
tions reproduced (within uncertainty bars) the ex-
perimental peak doses and PVDR values in a wa-
ter phantom for different field sizes (1×1, 2×2 and
3×3 cm2). This source model was adopted as the
input source in this work.
D. MC calculations in heterogeneous media
Particles sampled from the photon beam model de-
scribed above [1] were transported up to the patient
position in order to compute absorbed dose distri-
butions in heterogeneous media. In particular, two
different inhomogeneous phantoms, both composed
of slabs of cortical bone (Gammex® 450 [31]) and
RW3 (Goettingen White Water [32]), were consid-
ered:
• A 1-cm slab of bone followed by 10 slabs
(10 cm) of RW3 solid-water phantom. This
geometry corresponds to the human head
phantom [22] and it will hereafter be called
phantom ‘A’.
• The same geometry but with the bone shifted
by one centimeter, i.e., 1 cm of RW3 solid-
water, 1 cm of bone and 9 cm of RW3 solid-
water. This phantom will be referred to as
‘B’.
To accurately account for the dose deposited at
the interfaces between different materials, geometric
details of the detector system were also included in
the simulations [33, 34].
Phantoms were irradiated in the MRT config-
uration (50-µm-wide microbeams with a c-t-c dis-
tance of 400 µm) and three field sizes were evalu-
ated: 1×1, 2×2 and 3×3 cm2. Doses were scored
in 5-µm-wide bins along the transversal direction of
the microbeams, 2 mm in the vertical direction and
1 mm in depth (bin volume of 10−5 cm3). The av-
erage relative statistical uncertainty was computed
as the root mean square of the uncertainties of the
bins with doses above half the maximum score. Sim-
ulations were terminated when this uncertainty was
less than 2% (two standard deviations, 2σ).
E. Experimental validation of MC calculations
in heterogeneous media
Absolute central peak doses and PVDR values were
evaluated experimentally for several field sizes (1×1,
2×2, 3×3 cm2) in function of depth. The detector
system used was Gafchromic® HD-810 films [33],
which were placed between slabs at several depths
in the two phantoms described in Section IID. Both
the high spatial resolution and the broad dose range
of these films make them the best candidate for
MRT dose assessment. They were previously used
for such delicate measurements in previous studies
[1, 35].
Guidelines for handling the films provided by
Task Group 55 of the American Association of
Physics in Medicine (AAPM) [36] were followed. As
regards calibration, the considered range went from
10 to 400 Gy. The broad beam dose was measured
with a thimble ionization chamber (PTW 31010
with an active volume of 0.125 cm3 [32]) calibrated
by kilovolt x-rays. Each film box was calibrated
individually.
A microdensitometer (3CS Microdensitometer,
J. L. Automation) was used to read the films [37]
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5due to the higher resolution compared with typical
flat bed scanners used for seamless irradiation in ra-
diotherapy. The use of this kind of system is very
time-consuming and delicate. Therefore, each mea-
surement had to be repeated a minimum of three
times. To our knowledge, no other system could
provide more accurate measurements in the field
of MRT. Further details can be found elsewhere
[1, 38, 39].
F. The calculation engine of the treatment
planning system for MRT
After validating our photon source model in het-
erogenous media, the next step consisted of opti-
mization of computation time.
1. Optimization of computation time
The statistical uncertainty in MC dose calculations
can be reduced by increasing the number of histories
and, therefore, the computation time. However, to
be able to treat patients, the time devoted to TPS
calculations must be reasonably short. In order to
reduce this time without compromising accuracy,
several methods were examined.
The first approach was the optimization of the
simulation parameters. The influence of the ab-
sorption energies of photons (EABS(γ)) and elec-
trons (EABS(e−)) on several dosimetric magnitudes
was evaluated. In particular, EABS(e−) values from
10 keV to 50 keV and EABS(γ) values from 1 keV to
50 keV (in steps of 5 keV) were assessed. Since the
transport of particles in the human or animal body
will be mainly performed in tissues with properties
equivalent to water, dose distributions were initially
assessed in a water phantom. Simulations were dis-
continued when the average relative statistical un-
certainty was less than 1% (2σ).
The second optimization method consisted of
employing a VR technique [18, 40], known as inter-
action forcing, for all photon interactions [18]. This
VR method consists of increasing the probability of
occurrence of the process of interest artificially by
using a forcing factor (FORCING). This technique is
implemented in the PENELOPE/penEasy code
[29]. Several FORCING values were evaluated, from
1 to 150.
Simulations were run on the ESRF cluster [42]
and were parallelized by using independent random
sequences [41]. To further increase efficiency, the
valley doses were computed as an average of the
dose in several dose bins. This last approach was
possible since valley regions are ‘flat’ in the cen-
tral region (100 µm) between microbeams (c-t-c is
400 µm). Quantitative details on simulation times
will be presented in Section III B.
2. Calculations in voxelized structures with
PENELOPE/penEasy
To treat patients, the dose computation in voxelized
structures is required. Typically, the patient model
is extracted from CT images. Attenuation informa-
tion in CTs is expressed in Hounsfield Units (HU).
However, most MC codes do not deal with HUs, but
with the mass density and material index of each
CT voxel. The conversion from HUs to density and
material is performed in two steps. Firstly, the mass
density is obtained from a calibration curve (mass
density versus HU), provided by the hospital where
the CT has been obtained. Secondly, the material
index of each voxel is obtained by using a classi-
fication approach, that is, by defining a mapping
between HU intervals and the material index.
Due to MRT dosimetric requirements, peak and
valley doses need to be measured on a micrometer-
size scale. However, the penEasy code associates
the dose voxel size (hereafter named ‘bin’) to the
CT voxel size (hereafter named ‘voxel’) [29]. Note
that the lateral voxel size is typically of the order
of one or several millimeters, in other words, its di-
mension is much larger than the necessary dose bin
size. Thus, decoupling of the two grids was per-
formed. To this end, the corresponding tally for
dose distribution in voxelized structures was mod-
ified to compute the dose in micrometer-sized bins
along the transversal direction of the microbeams.
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requirements and the bin size was set to the voxel
size. Additionally, a program in Matlab® was
developed to orientate the CT image along the di-
rection of the microbeams for a given irradiation
angle. This program also performs the correspond-
ing format transformation between CT image files
(typically in DICOM, Digital Imaging and Com-
munication in Medicine, format) and the penEasy
voxelized image format.
An example of a dose calculation in a dog’s head
will be presented in Section III C. The CT image
was classified into three materials: soft tissue, bone
and air. Soft tissue was identified as water with a
varying mass density. This method has been used
by other authors for dose calculation in clinical cases
[43]. The reliability of the assimilation of soft tissue
to water was assessed by evaluating the variation of
peak and valley doses in function of depth for differ-
ent materials (brain, fat, muscle, skin). Root-mean-
relative-square differences for selected cases are less
than 1%. The dog’s skull composition was taken
to be the same as the human skull composition in
ICRU 46 [44] as there is no comprehensive refer-
ence values for pet tissues and only some data can
be found in the literature [45]. The same approach
was also followed by other authors in pet dose cal-
culations [46].
III. RESULTS AND DISCUSSION
In this section, MC calculations will first be vali-
dated with experimental data in heterogeneous me-
dia. The results on the optimization of the calcula-
tion time will be then presented. Finally, the feasi-
bility of the developed MC dose calculation engine
will be shown by means of an example of an MRT
treatment scenario on a dog’s head.
A. Experimental validation of MC simulations
in heterogeneous media
MC simulations were validated by comparing sim-
ulated central peak and PVDR dose distributions
with experimental data. Our study focuses on these
two magnitudes since they are the most relevant in
these types of spatially fractionated techniques [3].
Table I shows simulated (MC) and experimen-
tal (film) central peak values in function of depth
in the phantom ‘A’ (see Section IID). Values are
normalized to the peak dose at a depth of 2 cm.
In general, MC simulations faithfully reproduce the
experimental data (within uncertainty bars), even
at the interface with bone (depth of 1 cm).
Simulated (MC) and measured (film) PVDR val-
ues in function of depth in phantom ‘A’ are pre-
sented in Table II. Good agreement is also obtained.
Maximum deviations are generally observed at the
interface between the two materials. This is due to
both the complexity of the measurements and the
high gradient of the PVDR values in this region.
PVDR values decrease in bone due to the fact that
the Compton-scattered photons reaching the valley
region have a larger probability of suffering photo-
electric absorption. This is a consequence of the
higher average atomic number of the bone with re-
spect to RW3 solid-water. A decrease of PVDR is
also observed when the field size is increased. Both
trends have also been observed in previous works
[22, 23]. PVDR values beyond bone heterogeneity
(beyond a depth of 2 cm) are similar to those found
in a homogenous phantom [1].
In order to further test the MC calculations, the
central peak doses and PVDR values were evaluated
in phantom ‘B’ (see Section IID). In this geome-
try, the dosimetric magnitudes could also be eval-
uated at the entrance of the bone. Since PVDR
at depth showed no significant differences between
PVDR values computed in the homogeneous phan-
tom [1], the dose assessment in phantom ‘B’ only in-
cluded values at the interfaces (see Table III). Peak
dose values are expressed as a percentage of the dose
at a depth of 3 cm (not at 2 cm) due to the presence
of the interface at the reference depth. Good agree-
ment between MC calculations and experimental
data once again confirmed the performance of MC
dose calculations.
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7TABLE I: Calculated (MC) and measured (film) percentage depth dose along the central peak (%) in the phantom
‘A’. MRT irradiation parameters: 50-µm-wide microbeams spaced by 400 µm; field sizes: 1×1, 2×2 and 3×3 cm2.
The normalization point is at a depth of 2 cm. Statistical uncertainties correspond to 2σ.
depth (cm)
percentage depth dose along the central peak (%)
1×1 cm2 2×2 cm2 3×3 cm2
MC film MC film MC film
1.0 182 ± 2 177 ± 14 183 ± 3 178 ± 14 180 ± 3 177 ± 14
2.0 100.0 ± 0.4 100 ± 7 100.0 ± 0.8 100 ± 7 100 ± 1 100 ± 7
4.0 71.3 ± 0.3 74 ± 6 71.2 ± 0.7 67 ± 6 74 ± 1 70 ± 6
6.0 51.2 ± 0.3 53 ± 5 51.7 ± 0.5 54 ± 5 52.4 ± 0.8 54 ± 5
8.0 36.7 ± 0.2 37 ± 4 37.1 ± 0.4 37 ± 4 37.9 ± 0.7 35 ± 4
TABLE II: Calculated (MC) versus measured (film) central PVDR at different depths in the phantom ‘A’. MRT
irradiation parameters: 50-µm-wide microbeams spaced by 400 µm; field sizes: 1×1, 2×2 and 3×3 cm2. Statistical
uncertainties correspond to 2σ.
depth (cm)
PVDR
1×1 cm2 2×2 cm2 3×3 cm2
MC film MC film MC film
1.0 31 ± 2 27 ± 5 22 ± 2 18 ± 4 20 ± 2 17 ± 3
2.0 45.5 ± 0.4 43 ± 6 25.0 ± 0.3 24 ± 3 18.0 ± 0.3 18 ± 3
4.0 44.4 ± 0.4 42 ± 6 23.2 ± 0.3 20 ± 3 16.8 ± 0.3 14 ± 2
6.0 43.4 ± 0.5 44 ± 6 22.6 ± 0.4 21 ± 3 15.5 ± 0.4 14 ± 2
8.0 42.6 ± 0.6 43 ± 6 22.2 ± 0.5 22 ± 3 15.2 ± 0.4 15 ± 2
TABLE III: Calculated (MC) and measured (film) percentage depth dose along the central peak (%) and PVDR values
at different depths in the phantom ‘B’. MRT irradiation parameters: 50-µm-wide microbeams spaced by 400 µm; field
sizes: 1×1, 2×2 and 3×3 cm2. The normalization point is at a depth of 3 cm. Statistical uncertainties correspond
to 2σ.
depth (cm)
percentage depth dose along the central peak (%)
1×1 cm2 2×2 cm2 3×3 cm2
MC film MC film MC film
1.0 212 ± 2 216 ± 17 212 ± 3 207 ± 17 212 ± 4 208 ± 17
2.0 183 ± 2 181 ± 14 182 ± 3 183 ± 14 178 ± 4 181 ± 14
depth (cm)
PVDR
1×1 cm2 2×2 cm2 3×3 cm2
MC film MC film MC film
1.0 35 ± 3 36 ± 7 24 ± 2 24 ± 5 19 ± 2 19 ± 4
2.0 32 ± 3 27 ± 5 21 ± 2 16 ± 3 13 ± 2 13 ± 2
B. Optimization of the calculation time
In this section, efficiency is expressed in terms of the
time needed to reach a statistical uncertainty of 2%
(2σ) for the dose in the central valley at 2-cm depth.
Simulations were run on a 2.93 GHz Intel Xeon Pro-
cessor X5670. PENELOPE/penEasy was com-
piled with the Intel Fortran compiler (option -O3).
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81. Optimization of the absorption energies
Firstly, the influence of the different absorption en-
ergies for photons and electrons, i.e., EABS(γ) and
EABS(e−), on the relevant MRT dosimetric magni-
tudes was studied. The evaluation was performed
on an homogeneous water phantom for a 2×2 cm2
field size. A similar study had previously been car-
ried out by De Felici et al. for 50 keV monochro-
matic microbeams [47].
In previous MRT studies [1, 2, 21–23, 47],
EABS(e−) was fixed following the criterion that the
secondary electron range had to be smaller than the
half bin dimensions used to tally the dose distri-
butions. For example, for a 5 µm bin size along
the x direction, the corresponding EABS(e−) was
10 keV since the range of a 10 keV electron in wa-
ter is approximately 2.5 µm. However, this is an
extremely conservative value and it can be opti-
mized in order to gain in simulation efficiency. With
this aim in mind, the variation of peak and valley
depth dose curves in function of absorption energy,
from 10 keV to 50 keV, in steps of 5 keV, was as-
sessed. The dose distribution curves obtained with
an EABS(e−)=10 keV were considered as the refer-
ence values.
Average differences in the depth-dose curves
along the central peak are not significant (less than
1%) for EABS(e−) values up to 20 keV. This energy
corresponds to an electron range in water of about
14 µm. Higher EABS(e−) values lead to an over-
estimation of peak doses since electrons produced
from photoelectric interactions in the peak region
are directly absorbed at the interaction point.
Average differences in the depth-dose curves
along the central valley are not statistically signifi-
cant since the main dose contribution to this region
arises from Compton-scattered photons in the peak
region. Some differences are observed in the shoul-
ders and penumbra region of the lateral dose profiles
(see left part of Figure 1), where the electron con-
tribution is still important. The highest EABS(e−)
results in sharper beam edges and a shorter penum-
bra region. For an EABS(e−)=20 keV, the shape of
the profile is not significantly altered.
In a similar way, EABS(γ) was fixed to ensure
that the photon mean free path was smaller than
half a bin. Typical EABS(γ) values found in the lit-
erature are 1 keV or less [1, 2, 21–23]. The mean
free path for a 1 keV photon in water is 2.5 µm.
This value is also very conservative since photons
are mainly directed in the forward direction, where
bin size is 1–2 mm. The influence on the central
peak and valley doses in function of EABS(γ) values
ranging from 1 keV to 50 keV, in steps of 5 keV,
was assessed. The respective mean free path for
these energies are 2.5 µm (EABS(γ)=1 keV) and
4.4 cm (EABS(γ)=50 keV). Dose distribution curves
obtained with an EABS(γ)=1 keV were considered
as the reference values.
Differences in the depth dose curves along the
central valley and peak increase with EABS(γ). De-
viations start to be significant (higher than 1%) at
around 30 keV. This energy approximately corre-
sponds to the energy where the Compton cross sec-
tion starts to be of the same order as the photo-
electric cross section in water. Photons with ener-
gies lower than 30–40 keV mainly interact by the
photoelectric effect and their energy is absorbed in
the nearby area. However, higher energy photons
interact both by the Compton and the photoelec-
tric effect. The valley dose depends on the balance
between the number of Compton-scattered photons
and the probability of absorption of these photons
once they reach the valley region. For low ener-
gies (50 keV), the second factor is more important,
while the first factor is dominant at higher energies
(100 keV).
Figure 1 (right) presents the MRT lateral dose
profiles at 2 cm in a water phantom for several
EABS(γ). Despite the fact that absolute peak and
valley doses depend on EABS(γ), the shape of the
profile is maintained since it is mainly determined
by secondary electron transport.
The same analysis was performed for the peak
and valley doses at the edge of the array, where pho-
tons have a higher divergence, and the same conclu-
sions were reached.
Table IV presents the effective reduction in
computation time when EABSs are increased up
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FIG. 1: Lateral dose profile of the central microbeam at a depth of 2 cm in a water phantom for an MRT irradiation
(50-µm-wide microbeams spaced by 400 µm; 2×2 cm2 field size) considering different EABS(e−), from 10 keV to
50 keV (left), and several EABS(γ), from 1 keV to 100 keV (right). Statistical uncertainty bars are at 2σ.
to a maximum that guarantees the accuracy as
analyzed above, i.e., EABS(e−)= 20 keV and
EABS(γ)=30 keV. A reduction of approximately 50%
in calculation time is observed when EABS(e−) is in-
creased from 10 keV (reference) to 20 keV. An ad-
ditional reduction of 5% is achieved when EABS(γ)
changes from 1 to 30 keV. The latter reduction in
computation time is less effective because a 30 keV
photon will mainly interact by the photoelectric ef-
fect and it will therefore be absorbed in any case.
Consequently, the two situations (EABS(γ)=1 or
30 keV for an EABS(e−)= 20 keV) are similar in
terms of computation time.
2. Variance reduction techniques: interaction forcing
In order to further minimize the computation time,
VR techniques were explored [18, 40]. In particu-
lar, interaction forcing was applied to photon trans-
port. Different values of the forcing factor FORC-
ING, by which the mean free path of interactions
will be reduced, were studied. Following the results
of the last section, EABS(γ) was set to 30 keV and
EABS(e−) to 20 keV. The gain in simulation time
for the several FORCING values in a water phantom
is reported in Table V. The optimum FORCING value
is 75, which corresponds to a mean free path of ap-
proximately 1 mm for the mean energy of the spec-
trum (100 keV). Therefore, each photon interacts
once in each bin, which has 1 mm size in depth. At
this point, computation time has been reduced by
a factor of 8 with respect to the case where no VR
techniques and no optimization of the simulation
parameters were applied.
3. Other methods
The improvement in the calculation time is propor-
tional to the number of cores used when paralleliz-
ing the simulations. Additionally, the valley dose
was calculated by averaging the valley dose of sev-
eral dose bins. However, the dose assessment in vox-
elized and more complex geometries (or for deeper
tumors) required some additional time. In order to
perform a good estimation of the computation time,
a real irradiation geometry case would have to be
evaluated.
C. Calculations in voxelized structures: MRT
irradiation of a dog’s head
An example of a possible treatment plan in the
forthcoming clinical trials in pets is presented in
this section. Coronal, axial and sagittal views of the
dog’s head are plotted in Figure 2 (left). Dose dis-
tributions arising from an anterior-posterior (AP)
MRT irradiation (field size of 2×2 cm2) of a dog’s
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TABLE IV: Simulation times for different EABS values. Efficiency is expressed in terms of the number of days to
reach a statistical uncertainty of 2% (2σ) in the central valley dose in a water phantom at a depth of 2 cm. Values are
normalized with respect to the simulation time for the most conservative EABS (EABS(γ)= 1 keV, EABS(e−)= 10 keV),
which corresponds to 132 days on a 2.93 GHz Intel Xeon Processor X5670. Compiler: Intel Fortran (option -O3).
FORCING=75.
EABS(γ) (keV) EABS(e−) (keV) Normalized simulation time
1 10 ≡ 1.00
1 20 0.50
30 20 0.45
TABLE V: Simulation times for different FORC-
ING values: from 0 to 150 (EABS(γ)=30 keV,
EABS(e−)=20 keV). Efficiency is expressed in terms of
the number days to reach a statistical uncertainty of 2%
(2σ) in the central valley dose in a water phantom at
a depth of 2 cm. Values are normalized with respect to
the simulation time for FORCING=0, which corresponds
to 515 days on a 2.93 GHz Intel Xeon Processor X5670.
Compiler: Intel Fortran (option -O3).
FORCING Normalized simulation time
1 ≡ 1.0
10 0.19
25 0.16
50 0.13
75 0.12
100 0.12
150 0.14
head were assessed in all the irradiated volume.
Dose is reported as absorbed dose to medium.
Figure 2 (right) represents the dose map in the
dog’s head obtained when the bin size is equal to
the voxel size (0.074×0.074×0.125 cm3). Typical
dose distribution maps, such as isodoses, used in
radiotherapy are not useful in these kinds of spa-
tially fractionated techniques since dose homogene-
ity in the target is not sought. Thus, quantitative
data related to the peak doses, valley doses, and
the corresponding PVDR is needed for the correct
assessment of the treatment. To this end, the dose
was computed on the micron scale in a region of
interest (ROI) of 2.2×13.5×2.2 cm3. Voxels were
divided into 75 parts along the transversal direc-
tion of the microbeams, which gives a dose bin size
of approximately 10 µm. Along the other two di-
rections, the bin size corresponded to the voxel size
(bin volume of approximately 0.9×10−5 cm3).
Figure 3 represents the central peak (left) and
valley (right) values in function of depth. Dose in
the air cavities is not represented due to the large
inherent statistical uncertainties and because it is
not clinically relevant. The enhancement both in
the peak and valley dose deposition and the cor-
responding reduction in the PVDR at 3, 6 and
10.5 cm-depth from the phantom surface is due to
the presence of bone. PVDR in function of depth
is presented in Figure 4. PVDR takes values of ap-
proximately 25 in soft tissue (water), in agreement
with the results presented in Section IIIA and in
other papers [1, 22, 23].
The lateral dose profile in a ‘virtual’ tumor lo-
cated at a depth of 4–5 cm is represented in Figure 5
(left). The profile in the healthy bone located at a
depth of 10–11 cm is also shown in Figure 5 (right).
In both cases, one can clearly see the variations in
the peak dose due to the distinct path traversed by
the different microbeams.
Relative uncertainties in the central peak and
valley doses at the tumor position are in the order
of 1.2% and 1.9% (2σ), respectively. These values
comply with the accuracy of ±2–5% in dose delivery
that is required to effectively treat certain types of
cancers and to reduce complications, as reflected in
the 24 and 42 reports of the International Commis-
sion on Radiation Units and Measurements (ICRU)
[48, 49].
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FIG. 2: On the left, a coronal, axial and sagittal view of the irradiated dog’s head. The arrow represents the beam
direction (AP) and the line indicates the central part of the beam in depth. The square in the coronal view corresponds
to the whole irradiation field size (2×2 cm2). On the left, a dose map at a depth of 8 cm from the dog’s head surface.
MRT parameters: AP irradiation, 50-µm-wide microbeams spaced by 400 µm; field size: 2×2 cm2.
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FIG. 3: Depth dose curves along the central peak (left) and valley (right) in a dog’s head. MRT parameters: AP
irradiation, 50-µm-wide microbeams spaced by 400 µm; field size: 2×2 cm2. The central part of the beam in depth
is indicated by the solid lines in Figure 2 (left). Doses are normalized with respect to the central peak dose at the
entrance. Statistical uncertainty bars are at two standard deviations.
The final calculation time was less than one day
(0.94 days) by using 60 cores (2.93 GHz Intel Xeon
Processor X5670. Compiler: Intel Fortran, option
-O3). Thus, this example confirms the feasibility
of the TPS calculation engine developed for future
clinical trials in MRT. The combination of the effi-
ciency optimization methods described was enough
to reduce the computation time to reasonable times
for synchrotron radiation therapy on pets, i.e., one
day. It is important to note that the flexibility in the
timings for clinical trials in synchrotrons is higher
than in a pure clinical environment.
IV. CONCLUSIONS
The first MC-based calculation engine for the future
treatment planning system in MRT has been devel-
oped. This will be an essential tool for future MRT
clinical trials in pets. It was a non-trivial task due
to the specific characteristics of an MRT irradiation.
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FIG. 4: Central PVDR values in function of depth in a
dog’s head. MRT parameters: AP irradiation, 50-µm-
wide microbeams spaced by 400 µm; field size: 2×2 cm2.
The central part of the beam in depth is indicated by the
solid lines in Figure 2 (left). Statistical uncertainty bars
are at two standard deviations.
In our previous work, a photon source model was
developed and verified in homogeneous phantoms.
Thus, the first step of the present study included the
validation of the dose calculations in heterogeneous
phantoms. MC calculations reproduced the exper-
imental peak doses and PVDR values within un-
certainty bars. The following step consisted of the
adaptation of the PENELOPE/penEasy code for
the MRT dose calculation in micrometer-sized bins
in voxelized structures. Finally, evaluation of the
computation time and its minimization by means of
optimization of the simulation parameters, the use
of VR techniques and the parallelization of the sim-
ulations were assessed. Overall, the dose calculation
time is adequate for pet radiotherapy in synchrotron
facilities. An example of treatment planning sce-
nario for AP irradiation of a dog’s head has been
presented, showing the performance of the devel-
oped MRT calculation engine. Future perspectives
include integration of the developed MRT TPS cal-
culation engine into a user-friendly graphical front-
end.
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microbeams spaced by 400 µm; field size: 2×2 cm2. Doses are normalized with respect to the central peak dose at
the entrance. Statistical uncertainty bars are at two standard deviations.
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Introduction
As has been explained in section 1.5.4.2, the absolute dosimetry in MRT is divided into two
steps. Firstly, the dose in reference conditions (seamless field) is measured. The conversion of
the dose deposited with that broad beam is then translated to peak dose by means of scatter
factors. The objective of this part of the thesis consisted of evaluating scatter factors for the
MRT clinical trial settings (50-µm-wide microbeams spaced by 400 µm).
Due to the complexity of the study, the scatter factors were computed by two MC codes:
PENELOPE/PENEASY (see section 1.5.4.1) and GEANT4 [GEANT4 2005]); and experimen-
tally by using several detector systems: HD-810 radiochromic films [ISP R© 2012] and a LAC
chamber of 4 cm diameter [PTW R© 2012].
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Purpose: The success of the preclinical studies in Microbeam Radiation Therapy (MRT) paved the
way to the clinical trials under preparation at the Biomedical Beamline of the European Synchrotron
Radiation Facility. Within this framework, an accurate determination of the deposited dose is
crucial. With that aim, the scatter factors, which translate the absolute dose measured in reference
conditions (2×2 cm2 field size at 2 cm-depth in water) to peak doses, were assessed.
Methods: Monte Carlo (MC) simulations were performed with two different widely used codes,
PENELOPE and Geant4, for the sake of safety. The scatter factors were obtained as the ratio
of the doses that are deposited by a microbeam and by a field of reference size, at the reference
depth. The calculated values were compared with experimental data obtained by radiochromic (ISP
HD-810) films and a PTW 34070 Large Area Chamber.
Results: The scatter factors for different microbeam field sizes assessed by the two MC codes
were in agreement and reproduced the experimental data within uncertainty bars. Those correction
factors were shown to be non-negligible for the future MRT clinical settings: an average 30% lower
dose was deposited by a 50 µm microbeam with respect to the reference conditions.
Conclusions: For the first time the scatter factors in MRT were systematically studied. They
constitute an essential key to deposit accurate doses in the forthcoming clinical trials in MRT. The
good agreement between the different calculations and experimental data confirms the reliability of
this challenging micrometric dose estimation.
Keywords: Synchrotron radiation, Microbeam Radiation Therapy, small-field dosimetry, scatter factors,
clinical trials
I. INTRODUCTION
A major restriction to achieve a curative radiother-
apy (RT) treatment for some radioresistant tumors,
like gliomas, is the high morbidity of the surround-
ing healthy tissue. This is also the case for tumors
located close to an organ at risk, such as the spinal
cord. In order to overcome this limitation, small
radiation fields are increasingly used in the delivery
of advanced RT techniques. This is the case of in-
tensity modulated radiotherapy (IMRT) and stereo-
tactic radiosurgery (SRS). The purpose is to try to
take advantage of the so-called dose-volume effect:
the smaller the field size is, the higher the toler-
ances of the healthy tissues are [1, 2]. In Microbeam
Radiation Therapy (MRT), a new RT approach un-
der development at the Biomedical Beamline of the
European Synchrotron Radiation Facility (ESRF),
the limits of the dose-volume effect are explored.
The irradiation is performed with arrays of parallel
beams whose widths range from 25 to 100 µm and
their center-to-center (c-t-c) distances from 200 to
400 µm (spatial fractionation of the dose). The en-
ergy spectrum has a mean energy of 99 keV [3, 4].
The dose profiles consist of a pattern of peaks and
valleys, i.e., with high doses in the beam paths and
111
2low doses in the spaces between them [5]. The min-
imum dose in the central region between two beams
is named valley dose whereas the dose in the centre
of each beam is the peak dose.
The preclinical studies performed until now
showed that the combination of submillimetric field
sizes and a spatial fractionation of the dose leads to
an exceptional normal tissue resistance to very high
doses (≥100 Gy) in one fraction [6–16] combined
with ablation of highly aggressive tumor models,
like 9L rat glioma [17–23]. The promising results
obtained in those biological investigations paved the
way to the clinical trials under preparation at the
ESRF [24]. In this context, a precise knowledge of
the dose deposited by the microbeams (peak doses)
was essential.
The use of subcentimeter field sizes presents
some challenges in order the dosimetry to be ac-
curately characterized [25]. In particular, the elec-
tronic equilibrium that exists on the central axis of
larger fields breaks down for narrow fluence profiles.
Absorbed dose cannot be easily calculated and/or
measured unless a state of electronic equilibrium ex-
ists, which only occurs at some distance into the
medium (tissue) and for large fields [25, 26]. As
the irradiation field size decreases, electronic equi-
librium is lost, which translates into a remarkable
fall off in ionization produced in the volume. For
the energy spectrum used in MRT, the majority of
the secondary electrons have ranges in water longer
than 40 µm. Therefore, the electronic equilibrium
condition is not satisfied for the MRT sizes used
(≤100 µm). Additionally, small-field dose measure-
ments are more susceptible to geometric imprecision
and to dose-averaging effects of larger detectors [27].
If accurate characterization of small-field dosimetry
in SRS and IMRT requires measurements that are
time consuming and error prone, the dose assess-
ment of the micrometer-sized fields used in MRT
represents a great challenge.
This work reports the first systematic assess-
ment of the scatter factors for the MRT clinical tri-
als settings: 50 µm-wide microbeams with a c-t-c
distance of 400 µm. Due to the fact that the de-
termination of the scatter factors is very sensitive,
it was performed both by Monte Carlo (MC) simu-
lations and by experimental measurements, for the
sake of safety.
II. MATERIALS AND METHODS
A. Radiation source and microbeam
generation
At ID17 Biomedical Beamline, the x-rays source is
situated 40.5 meters from the patient positioning
system. It consists of two wigglers with 15 cm and
12.5 cm period, respectively, and a maximum mag-
netic field of 1.6 T. However, only the first wiggler
is used in MRT irradiations. The x-ray energy spec-
trum after filtering ranges from about 27 to 600 keV,
with a mean energy of around 99 keV [3, 4].
The microbeams are produced when a multi-
slit collimator spatially fractionates the beam com-
ing from the synchrotron source [28]. Targets are
then vertically scanned through the microfraction-
ated beam to deliver microplanes of x-rays.
The animals or samples are placed in a 3-axis
Kappa-type high-precision goniometer (Huber, Ger-
many) [24]. At that position, the maximum field
dimensions achievable are 2.5 mm in height and
41 mm in width, approximately. Since the beam
height is very thin, the animals or phantoms are
scanned vertically through the beam. It has been
demonstrated that the integration of the dose rate
while scanning the ionization chamber with a con-
stant and well-known speed is equivalent to measure
the dose deposited with an uniform irradiation [40].
A more detailed technical description of the
beamline layout can be found elsewhere [24].
B. MC simulations
In this work, two different MC codes were used,
namely, PENELOPE 2008 [29, 30] and Geant4
[31] were employed. Both codes were previously
used for dose distribution assessment in MRT [3,
32, 33, 35, 36]. The coupled transport of photons
and electrons and its interactions in a wide energy
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3range are considered.
In PENELOPE a careful implementation of ac-
curate low energy electron cross sections, which
are of particular importance in this work, was
performed. The simulation algorithm is based
on a scattering model that combines numerical
databases with analytical cross sections for the dif-
ferent interaction mechanisms and it is applicable
to energies (kinetic energies in the case of electrons
and positrons) from a few hundred eV to 1 GeV. It
uses a mixed simulation scheme in which hard inter-
actions are simulated collision by collision and small
angular deflections and energy losses are treated in
a grouped manner.
Since the working energy range is a few hundreds
of keV, the most relevant interactions are photo-
electric effect and Compton scattering. The pho-
toelectric cross sections used in PENELOPE are
obtained by numerical interpolation in a table ex-
tracted from the Lawrence Livermore National Lab-
oratory (LLNL) Evaluated Photon Data Library
(EPDL) [37]. PENELOPE considers bounding
effects and Doppler broadening when simulating
Compton interactions.
In Geant4, the simulations are made follow-
ing an analytical approach that reproduces a set of
processes, originally implemented in PENELOPE.
An exception is the multiple scattering process,
for which Geant4 adopts an innovative advanced
model. The results are reliable for energies ranging
from a few hundred eV to 1 GeV [31]. The ana-
lytical model of the Compton scattering offers two
additional features with respect to the correspond-
ing parametrized model: Doppler broadening and
the atomic relaxation resulting from the vacancy
generated by the primary scattering.
While PENELOPE uses a pure class II algo-
rithm, Geant4 employs a combination of class II
(bremsstrahlung) and class I (elastic, inelastic col-
lisions) schemes. The comparison of results from
both codes reinforces the confidence in our results.
1. Simulation geometry and irradiation configuration
A homogeneous RW3 (Goettingen White Water)
solid-water phantom (30×30×12 cm3) [39] and a
water tank PTW MP3-P 41029 (35×35×38 cm3)
[39]) were considered in the simulations. Several
irradiation geometries were investigated:
• seamless beams of 1×1, 2×2 and 3×3 cm2;
• a 50 µm-wide and 2 cm-high microbeam;
• arrays of 50 µm-wide microbeams with a c-t-
c distance of 400 µm covering different areas:
1×1, 2×2 and 3×3 cm2.
These field sizes are foreseen to be the most fre-
quently used in the forthcoming clinical trials with
pets.
The simulation parameters were chosen as fol-
lows. In PENELOPE, the absorption energy was
set to 1 keV. In PENELOPE, the cutoff energies
for the production of hard inelastic events, WCC,
and for the production of hard bremsstrahlung,
WCR, were set equal to the absorption energy
(1 keV). The average angular deflection between
two consecutive hard elastic events, C1, and the
maximum average fractional energy loss in a single
multiple-scattering step, C2, were selected to be 0.1.
In Geant4, low energy electromagnetic processes
were used with associated data G4EMLOW6.9.
The default cut value for the production of sec-
ondary particles was set to 10 nm.
Doses were scored in voxels of 5 µm along the
lateral direction of the microbeams, 2 mm in the
vertical direction of the microbeam and 1 mm in
depth in PENELOPE. The voxel size in Geant4
calculations was 4 µm × 4 µm × 4 mm for the
microbeams case and 4×4×4 mm for broad beam
irradiation. Both sizes guaranteed that no volume
averaging effects were encountered.
C. Scatter factors assessment
In the forthcoming clinical trials, the absolute
dosimetry will be performed following the recom-
mendations compiled in the International Agency
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4of Atomic Energy (IAEA) TRS 398 Code of Prac-
tice [38]. The first step in this dosimetry method-
ology is to measure the dose in reference conditions
(seamless irradiation field).
In agreement with the TRS 398 for medium x-
ray energies, the dose measurement in reference con-
ditions is performed with a thimble ionization cham-
ber [39]. The cavity volume of the ionization cham-
ber (reference point of the chamber) was placed at
2 g cm−2 (reference depth). The reference field size
was chosen to be 2×2 cm2. Since the average elec-
tron range in water is in the order of 100 µm for our
energy spectrum, the lateral electronic equilibrium
is guaranteed for that field size.
As reported in section II.A, the maximum field
dimensions achievable are 2.5 mm in height and
41 mm in width. Since the beam height is very
thin, the animals or phantoms are scanned verti-
cally through the beam. The dose delivered is equiv-
alent to the dose deposited with an uniform irradi-
ation [40].
To determine the dose deposited with one mi-
crobeam (peak dose) from the absolute dose mea-
sured in the broad beam configuration the scatter
factors were used. They take into account the dif-
ferent contribution from the scattered radiation as
a function of the field size. Due to the low energies
used and the fact that the closest collimators are
around 2 m away from the patient, the collimator
scatter factor is negligible [40] and only the scatter
radiation originated in the phantom has a contribu-
tion. Therefore, the phantom scatter factor Sp can
be assumed to be equal to the total scatter factor.
Sp for one microbeam was determined as the ra-
tio of the dose deposited in the central point of the
irradiated field at 2 cm-depth in water by the mi-
crobeam and the reference field. It can be expressed
mathematically as:
Sp, microbeam =
Dpeak, 2 cm
Dreference
(1)
where Sp, microbeam is the phantom scatter factor
for one microbeam, Dpeak, 2 cm refers to the dose
deposited by one microbeam (peak dose) at 2 cm
depth in water, Dreference is the absolute dose de-
posited by a 2×2 cm2 field size at the same depth.
Both Dpeak, 2 cm and Dreference were assessed by
MC simulations (see details in section II.B.1.) and
by measurements. The experimental evaluation was
performed by using two alternative types of detec-
tors [34]:
• Gafchromic films HD 810 [41], which provide
a very high spatial resolution and a wide dose
range (from 10 to 400 Gy). A microdensito-
meter was employed to read the films follow-
ing the methodology described in the work of
Mart´ınez-Rovira et al. [4]. The microdensit-
ometer gives as output a magnitude named
‘pen deflection’ (PD). The dose assessment
was performed by comparing the PD of the
different films with the PD of films irradi-
ated with a well-known dose. To assure re-
producibility, each irradiation was performed
at least twice and each film was analyzed sev-
eral times, as described elsewhere [4].
• A large Bragg Peak chamber (PTW 34070),
also called LAC (large area chamber), with a
diameter of 4 cm, following the method de-
scribed in the work of Sa´nchez-Doblado et al.
[42]. The collected charge by the LAC cor-
responds to both primary and scatter radia-
tions.
To assess the peak dose at 2 cm-depth corre-
sponding to an array of microbeams, the equation
(1) is multiplied by a factor farray, which takes
into account the contribution of the tails of the mi-
crobeams to the central peak. To determine the
peak and valley doses at any depth the percentage
depth-dose curves, and PVDR ratios are used [5].
III. RESULTS AND DISCUSSION
In this section, the scatter factors determined both
by simulations (MC) and experimentally will be
presented.
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5A. Scatter factors for different broad beam
configurations
The experimental evaluation of Sp for broad field
sizes (≥ 1 cm2) was performed by using a thimble
ionization chamber (IC) and gafchromic films (GF).
Since this is a direct and accurate measurement, the
excellent match (see table I) between MC and ex-
periment data provided a first test of the calcula-
tions performance. A 9% lower dose is deposited
with a 1×1 cm2 with respect to the reference filed
size, whereas an average 10% higher dose deposition
is reached with a 3×3 cm2 field size. Those values
are consistent with the output factor estimation re-
ported in the work of Prezado et al. [40] for same
range of energies in Stereotactic Synchrotron Ra-
diation Therapy (SSRT). Additionally, they reflect
the fact that as the field size increases, the scatter
factors take higher values since the contribution of
the scattered radiation to the absorbed dose also
augments.
B. Scatter factor of a 50 µm-wide and
2 cm-high microbeam
Table II shows the comparison among the
Sp, microbeam values assessed by MC simulations, by
GF and by the Bragg-Peak chamber (LAC) method.
There is a good agreement between the results of
the two different MC codes and between the calcu-
lations and the experimental data, which permits to
validate the simulations. The differences observed
between the two MC values are probably due to the
different algorithms used by the two codes. The ex-
perimental uncertainty bars correspond to the stan-
dard deviation of the measurements. From the re-
sults in table II, it can be concluded that the con-
tribution of the scatter radiation to the dose depo-
sition in the central part of the radiation field is
significantly less important for a microbeam than
for the reference field size. The partial loss of elec-
tronic equilibrium due to the fact that some sec-
ondary electrons have a shorter range than the field
size greatly contributes the drastic decrease (30%)
of the dose deposited by one microbeam.
Table III presents the calculated (PENELOPE
and Geant4) and experimental (GF) farray values
for some microbeam arrays to be used in the fu-
ture clinical trials. The contribution of microbeams
tails leads to a 3%, 5% and 8% dose increase to the
central beam of 1×1, 2×2 and 3×3 cm2 arrays, re-
spectively. The dedicated MRT treatment planning
system (TPS) under preparation [4] will be able to
calculate the farray for any combination of arrays
using the Sp value for one microbeam (50 µm-wide
and 2 cm-high) as an input.
IV. CONCLUSIONS
The enhanced tissue dose tolerance to reduced field
sizes is in the origin of increased use of smaller
and smaller field sizes as, for example, in radio-
surgery. An extreme case of this is a new approach
called MRT, a synchrotron radiotherapy technique,
in which micrometer-sized (50 µm) and spatially
fractionated irradiation field sizes are employed. If
small field dosimetry is widely known to be highly
demanding and error prone, dose assessment in
MRT represents a challenge. Within the framework
of clinical trials preparation, a methodology to de-
termine dose deposited by the very small fields used
in MRT was developed. Since the reference dosime-
try will be performed in seamless irradiation with
an IC, the assessment of the scatter factors was es-
sential. Due to the complexity of experimental mea-
surements, two different methods were used and the
results compared to two independent MC calcula-
tions. The good agreement among all the obtained
values confirmed the reliability of this method.
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6TABLE I: Scatter factors for several seamless field sizes. MC values shows an excellent agreement with the two sets
of experimental data. The uncertainties correspond to one standard deviation.
Field size (cm2) MC simulations Experimental data
IC GF
1×1 0.91 ± 0.05 0.89 ± 0.03 0.90 ± 0.05
3×3 1.10 ± 0.05 1.10 ± 0.03 1.09 ± 0.05
TABLE II: Scatter factors for one 50 µm-wide and 2 cm-high microbeam. The two sets of MC values and experi-
mental data agree well within the uncertainty bars. The uncertainties correspond to one standard deviation.
MC simulations Experimental data
PENELOPE Geant4 GF LAC
0.68 ± 0.04 0.75 ± 0.04 0.72 ± 0.07 0.72 ± 0.10
TABLE III: Comparison of the MC and experimental (films) farray values (GF) for some microbeams arrays. The
uncertainties correspond to one standard deviation.
Field size (cm2) farray MC simulations farray Experimental data
PENELOPE Geant4 GF
1×1 1.03 ± 0.02 1.03 ± 0.02 1.04 ± 0.08
2×2 1.05 ± 0.02 1.04 ± 0.02 1.05 ± 0.08
3×3 1.08 ± 0.02 1.05 ± 0.02 1.05 ± 0.08
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Introduction
The aim of this work consists of the assessment of several dosimetric features for forthcom-
ing preclinical studies in white-beam MBRT. The first part is related to the establishment of
a dosimetry protocol to ensure reproducibility in terms of dose for future MBRT biological
studies in rats. The protocol is based on absorbed dose to water and inspired by the recom-
mendations of the TRS 398 [IAEA-TRS-398 2005]. See sections 1.5.4.2 and 1.6.4. As in MRT,
determination of the absorbed dose under non-reference conditions is performed by means
of scatter factors, which were evaluated by MC calculations and verified experimentally.
The second part of this study deals with the experimental benchmarking of the MBRT
MC simulations (PENELOPE/PENEASY CODE, see section 1.5.4.1). To this end, part of the
ID17 photon source model previously defined for MRT was used (see section 2.5). The
validation was carried out by using HD-810 radiochromic films [ISP R© 2012] in homogeneous
and heterogeneous phantoms.
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Purpose: In the quest of a curative radiotherapy treatment for gliomas, new delivery modes are
being explored. At the Biomedical Beamline of the European Synchrotron Radiation Facility, a
new spatially fractionated technique, called minibeam radiation therapy (MBRT), is under develop-
ment. The aims of this work were to assess different dosimetric aspects and to establish a dosimetry
protocol to be applied in the forthcoming animal (rat) studies in order to evaluate the therapeutic
index of this new radiotherapy approach.
Methods: Absolute dosimetry was performed with a thimble ionization chamber (PTW semiflex
31010) whose center was positioned at 2 g cm2 depth. To translate the dose measured in broad
beam configuration to the dose deposited with a minibeam, the scatter factors were used. Those
were assessed by using the Monte Carlo simulations and verified experimentally with Gafchromic
films and a Bragg Peak chamber. The comparison of the theoretical and experimental data were
used to benchmark the calculations. Finally, the dose distributions in a rat phantom were evaluated
by using the validated Monte Carlo calculations.
Results: The absolute dosimetry in broad beam configuration was measured in reference condi-
tions. The dose rate was in the range between 168 and 224 Gy=min, depending on the storage ring
current. A scatter factor of 0.806 0.04 was obtained. Percentage depth dose and lateral profiles
were evaluated both in homogenous and heterogeneous slab phantoms. The general good agree-
ment between Monte Carlo simulations and experimental data permitted the benchmark of the cal-
culations. Finally, the peak doses in the rat head phantom were assessed from the measurements in
reference conditions. In addition, the peak-to-valley dose ratio values as a function of depth in the
rat head were evaluated.
Conclusions: A new promising radiotherapy approach is being explored at the ESRF: Minibeam
Radiation Therapy. To assess the therapeutic index of this new modality, in vivo experiments are
being planned, for which an accurate knowledge of the dosimetry is essential. For that purpose, a
complete set of measurements and Monte Carlo simulations was performed. The first dosimetry
protocol for preclinical trials in minibeam radiation therapy was established. This protocol allows
to have reproducibility in terms of dose for the different biological studies.VC 2011 American Asso-
ciation of Physicists in Medicine. [DOI: 10.1118/1.3608908]
Key words: synchrotron radiation, minibeam radiation therapy, dosimetry, Monte Carlo
simulations
I. INTRODUCTION
Conventional radiation therapy, a major treatment modality
for cancers, can prove ineffective at times. Its failure appears
to be primarily related to constraints on delivering a curative
radiation dose due to the critical morbidity of normal tissues.
Despite intensive research and development work in confor-
mal radiotherapy, there are still some radioresistant tumors,
like gliomas, for which a radical treatment is usually not
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feasible at hospitals. This limitation is especially severe in
children, due to the high risk of complications in the
development of the central nervous system. The manage-
ment of tumors close to an organ of risk, like the spinal cord,
is also restrained.
This is the motivation for the development of two new
radiotherapy techniques at the Biomedical Beamline of
the European Synchrotron Radiation Facility (ESRF):
microbeam radiation therapy (MRT) and, more recently,
minibeam radiation therapy (MBRT). These techniques
present two distinct features with respect to the conventional
radiotherapy methods that allow to shift the normal tissue
tolerances to higher doses:
(1) Submillimetric field sizes are used, exploring the limits of
what is called dose-volume effect: the smaller the field
size is, the higher the tolerances of the healthy tissues
are.1,2 The beam width range from 25 to 100 lm in the
case of MRT and from 500 to 700 lm in MBRT. The use
of those extremely thin beam widths, at least one order of
magnitude thinner than the ones used in radiosurgery,
may permit a rapid increase in healthy tissue tolerances.
(2) The dose is spatially fractionated: very high doses (100
Gy) are delivered in one fraction by using intense x-rays
parallel beams. The interbeam separation is 200 or 400
lm in the case of MRT and 600 lm in MBRT. The dose
profiles consist of a pattern of peaks and valleys, i.e., with
high doses in the beam paths and low doses in the spaces
between them.3 The minimum dose in the central region
between two beams is named valley dose and the dose in
the center of the beam is the peak dose. The different
widths and spacings in MRT and MBRT might lead to
dissimilar biological effects, which need to be evaluated.
In MRT the combination of submillimetric field sizes and
a spatial fractionation of the dose leads to an exceptional
normal tissue resistance to very high doses (100 Gy) in
one fraction.4–14 In addition, MRT rendered significant tu-
mor growth delay and, in some cases, complete tumor abla-
tion.15–21 This was despite the small fraction of the tumor
mass irradiated with the high dose microbeams, fact that
appear to challenge many of the current paradigms in con-
ventional radiation therapy. The preferential effect on malig-
nant tissues has been mainly attributed to selective effects of
microbeams on immature tumor vessels versus lack of
microbeam effects on the differentiated normal vascula-
ture,18 although other factors might be operative. Aimed
at the tumor volume, the microbeams interact in tissue,
delivering a lethal radiation dose to endothelial cells lying
directly in their path, i.e., peak regions. In normal tissue, the
well-preserved vasculature in the valley regions seemed to
ensure the rapid regeneration of directly irradiated blood
vessels. It is therefore essential that the valley dose is kept to
the minimum to ensure the preservation of normal tissue
architecture18 and the survival of sufficient cells needed for
healthy tissue repair. Based on these assumptions, the effec-
tiveness of MRT is determined by the peak-to-valley dose
ratio (PVDR). Therefore, PVDR is a relevant dosimetric
parameter in spatially fractionated techniques.3,18
The main drawback of MRT is that its widespread clinical
implementation is limited nowadays due to the requirement
of high dose rates, only available at synchrotrons. This is
due to the fact that since microbeams are closely packed, it
is important that the tissue=target does not move during the
irradiation due to the cardiosynchronous pulsations.22 The
thicker beams used in MBRT, a new radiotherapy approach,
overcome those difficulties. The dose profiles of minibeams
are not as vulnerable as the ones of microbeams to beam
smearing from cardiac pulsations, and therefore high dose
rates are not needed. Hence, it is conceptually possible to
extend this technique by using modified x-ray equipment,
creating an opportunity for its implementation at hospitals.
In addition, the use of higher beam energies in MBRT
(200 keV (Ref. 23)) than in MRT is feasible,24 resulting in
a lower entrance dose to deposit the same integral dose in
the tumor. Those advantages triggered the exploration of this
new radiotherapeutic approach.
Since the thicker beams and spacings employed in MBRT
in comparison with the thin microbeams may lead to
different biological effects than the ones observed in MRT,25
experimental studies are warranted to evaluate the possible
different tumor and normal tissue responses to MBRT with
respect to MRT and the other radiotherapy methods. Func-
tional tissue deterioration rather than direct cellular damage
in the beam path may be involved in MBRT.25 The results of
the first animal experiments performed at Brookhaven
National Laboratory indicate that the thicker beams used in
MBRT still provide a remarkable healthy tissue tolerances.14
This outcome paved the way to the implementation of this
novel technique at the ESRF ID17 Biomedical Beamline.26
MBRT might offer a good compromise between providing
a good healthy tissue sparing and having the possibility
of being extended outside synchrotron sources with a cost-
effective equipment. Preclinical studies with small animals
are being planned at the ESRF in order to assess the tumor
control and normal tissue complication probability curves
for this new therapeutic modality.
The precise knowledge of the doses in the preclinical
studies is crucial in order to extract valid conclusions for the
future possible clinical trials, like the assessment of dose-
response of healthy tissues or tumor control probability curves.
For that reason an extensive set of measurements and Monte
Carlo (MC) simulations were performed in different phantoms.
The agreement between the calculations and the experimental
data allowed the benchmarking of the MC dosimetry. Finally,
the first dosimetry protocol to be used in the preclinical trials
was established and it will be described, hereafter.
II. MATERIALS AND METHODS
II.A. Radiation source and minibeams patterns
generation
At ID17 Biomedical Beamline, the x-rays source consists
in two wigglers with 15 and 12.5 cm period, respectively,
and a maximum magnetic field of 1.6 T. In MBRT studies
only the first wiggler is used. It is located 40.5 m from the
patient positioning system and delivers high intensity
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kilovoltage energy x-ray beams. The x-ray energy spectrum
after filtering ranges from about 50 to 600 keV, with a mean
energy around 99 keV.27 The energy spectrum (Fig. 1) and
beam divergence at the sample position was assessed from a
complete modeling of the beamline and benchmarked with
experimental data.27
The animals or samples are placed in a three-axis Kappa-
type high-precision goniometer (Huber, Germany).28 See
Fig. 2. At that position, the maximum field dimensions
achievable are 2.5 mm in height and 41 mm in width,
approximately. Since the beam height is very thin, the ani-
mals or phantoms are scanned vertically through the beam.29
An original method was developed and tested at the
ESRF ID17 Biomedical Beamline to produce the minibeam
patterns. It utilizes a specially developed high-energy white-
beam chopper whose action is synchronized with the vertical
motion of the target moving at constant speed. Each opening
of the chopper generates a horizontal beam print. The
method offers an excellent reliability and allows for an easy
control of all the parameters which are essential for the
general safety of the treatment.26
A more detailed technical description of the beamline
layout can be found elsewhere.28
II.B. Monte Carlo simulations
The MC code PENELOPE 2008 (Refs. 30–32) and
penEasy,33 a structured general-purpose main program for
PENELOPE, were adopted to perform the calculations. In
this code, the coupled transport of photons and electrons and
its interactions in a wide energy range are considered. The
main advantage of this code is a careful implementation of
accurate low energy electron cross sections, which are of
particular importance in this work. The simulation algorithm
is based on a scattering model that combines numerical data-
bases with analytical cross section models for the different
interaction mechanisms and it is applicable to energies (ki-
netic energies in the case of electrons and positrons) from a
few hundred electron volts to 1 GeV. PENELOPE uses a
mixed simulation scheme in which hard interactions are
simulated collision by collision and small angular deflections
and energy losses are treated in a grouped manner (the
thresholds depend on the simulation parameters).
Since the working energy range is a few hundreds of kilo
electron volts the most relevant interactions are photoelectric
effect and Compton scattering. The photoelectric cross sections
used in PENELOPE are obtained by interpolation in a numeri-
cal table that was extracted from the Lawrence Livermore
National Laboratory (LLNL) evaluated photon data library
(EPDL).34 Regarding Compton scattering, PENELOPE consid-
ers bounding effects and Doppler broadening when simulating
Compton interactions. This code has been widely used in the
medical physics field, see for example Refs. 35, 36 and in par-
ticular for the dose distribution assessment in MRT and
MBRT.3,23,24,37,38
II.B.1. Simulation geometry and irradiation
configuration
Three geometries were considered in the simulations:
(1) A homogeneous RW3 (Goettingen White Water) solid-
water phantom (30 30 12 cm3).39
(2) A heterogeneous slab phantom (20 20 5 cm3) con-
sisting of one slab of bone equivalent material (1 cm
thick), two muscle equivalent slabs and two others of
RW3 (1 cm-thick each one).40
(3) A rat head phantom consisting in layers of skin (700
lm), bone (500 lm), and brain (2.6, 5.2, and 2 cm thick-
ness in lateral, anterior–posterior, and craneo-caudal
axis, respectively). See Fig. 3. Those thicknesses were
extracted from MRI images.23
Two irradiation geometries were investigated: a unidirec-
tional array (600 lm wide minibeams with a center-to-center
FIG. 1. Energy spectrum at the goniometer (patient) position at ID17 Bio-
medical Beamline, extracted from Ref. 27.
FIG. 2. Scheme of the irradiation setup. The samples
are positioned on top of a high-precision goniometer
whose vertical translation allows to cover the desired
field size.
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(c-t-c) distance of 1200 lm), and two orthogonal arrays,
one of them in the lateral direction (right to left), the other
in the craneo-caudal axis. The two arrays intersected in the
target position such that the peaks of one of them fill the
valleys of the other. This permitted to achieve a quasi-ho-
mogeneous dose distribution in the target. A beam width of
640 lm and a c-t-c distance of 1120 lm were found to pro-
vide a homogenous dose distribution in a rat head phantom.
Further details will be given in Sec. III B. In the rat, the tar-
get was the central plane of the tumor position. At the Bio-
medical Beamline (ESRF) the tumor is usually inoculated
at caudate nucleus (9 mm anterior to the ear-bars, i.e., at
bregma site, 3.5 mm lateral to the midline, 5.5 mm depth
from the skull).41,42
The dose computation was divided into two parts. The
absorbed dose distribution for a single minibeam in the
phantom was simulated first. Then, at each depth, the single
dose distribution was shifted and added to the total dose dis-
tribution in order to cover the irradiation field sizes: 1 1,
2 2, and 3 3 cm2. Only the 1 1 cm2 field size was
evaluated in the rat head phantom.
The absorption energy was set to 50 keV for electrons
and 5 keV for photons. The cutoff energies for the produc-
tion of hard inelastic events, WCC, and for the production of
hard bremsstrahlung, WCR were set equal to the absorption
energy for electrons and photons, respectively. The average
angular deflections between two consecutive hard elastic
events, C1, and the maximum average fractional energy loss
in a single multiple-scattering step, C2, were selected to be
0.1.
Doses were scored in voxels of 50 lm along the lateral
direction of the microbeams, 2 mm in the vertical direction
of the microbeam and 1 mm in depth. These dimensions
were reduced to 25 lm 1 mm 0.07 mm for the rat head
phantom as a higher spatial resolution was required.
The average statistical uncertainty in the simulations was
0.5% (two standard deviations).
II.C. Dosimetry protocol
This protocol describes a methodology for dosimetry in
MBRT preclinical studies. It is based on absorbed dose to
water and inspired by the recommendations compiled in the
IAEA TRS 398 Code of Practice.43 The main advantage of
this methodology is that biological studies can be made on
the basis of uniform dosimetry procedures. The different
points of this protocol are described hereafter.
II.C.1. Dosimetry equipment
Following the recommendations of the TRS 398 for
medium x-ray energies, the dose measurement in reference
conditions (see Sec. II C 2) was performed with a semiflex
PTW 30010 thimble ionization chamber (0.125 cm3).39 As
reported in Sec. II A, the maximum field dimensions
achievable are 2.5 mm in height and 41 mm in width. Since
the beam height is very thin, the animals or phantoms
are scanned vertically through the beam. It has been
demonstrated that the integration of the dose rate, while
scanning the ionization chamber with a constant and well
known speed is equivalent to measure the dose deposited
with a uniform irradiation.29
The experimental evaluation of the peak dose was per-
formed by using two altenative type of detectors:
• Gafchromic films HD 810,44 which provide a very high
spatial resolution and a wide dose range (from 10 to 400
Gy). This permits to measure peak and valley doses. A
widely used flat bed scanner (EPSON Perfection V750
PRO) was used to analyze the dose deposition in the films
following the methodology described in the work by Devic
et al.45
• A large Bragg Peak chamber (PTW 34070), also called as
large area chamber (LAC), with a diameter of 4 cm. The
collected charge corresponds to both primary and scatter
radiations.
Dose measurements were performed both in the homoge-
neous RW3 (Goettingen White Water) solid-water and the
heterogeneous phantoms39 described in Sec. II B. The use of
the RW3 instead of water to perform the dosimetry was due
to several practical aspects. First, very small misalignments
of any element of the beamline or beam emittance changes
can lead to differences in dose of up to 10%. Therefore the
dose must be measured before each experiment and=or refill
of the storage ring. An accurate setting of a water tank in the
experimental area at the Biomedical Beamline is very time-
consuming. Another reason to use a solid-water phantom is
that the handling and accurate positioning of the Gafchromic
films to be used in relative dosimetry is very delicate
in water. Since the MC simulations were performed in solid-
water phantoms and the correlation between the dose depos-
ited in the RW3 and the rat head phantom was established,
developing a protocol based on solid-water phantom meas-
urements does not lead to a lack of consistency. In addition,
the code of practice TRS 398 (Ref. 43) states that solid-water
phantoms could be used for routine measurements provided
that the relationship between dosimetry readings in water
FIG. 3. Coronal view of the rat head phantom. The thickness of the skin
(700 lm), the skull (500 lm) and the brain (2.6 and 5.2 cm in the lateral and
anterior–posterior directions, respectively) were extracted from MRI images
Ref. 23.
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and in the solid-water phantom has been established. A
5.7%6 0.1% higher dose deposition in water with respect to
RW3 was encountered both by comparing experimental
measurements and MC simulations. Consequently, to de-
velop a protocol for preclinical work based on measurements
in a solid-water phantom is justified.
II.C.2. Determination of absorbed dose under
reference conditions
The first step in this dosimetry methodology is to measure
the dose in reference conditions. Following the recommen-
dations of the TRS 398 (Ref. 43) for medium x-ray energies,
the center of the cavity volume of the ionization chamber
(reference point of the chamber) was placed at 2 g cm2
(reference depth). The reference field size was chosen to be
2 2 cm2. Since at the working range of energies the
average range of the electrons is less than 100 lm, the lateral
electronic equilibrium is guaranteed for that field size. The
phantom material was chosen to be RW3 for the reasons
explained in Sec. II C 1.
The absorbed dose in the solid-water phantom is then
obtained by using the following expression:
Dsw;Q ¼ MQND;sw;QoKQ;Qo (1)
where ND,sw,Qo is the calibration factor for the beam quality
Qo in water provided by the calibration laboratory,46 cor-
rected by the 5.7%6 0.1% difference in dose deposition in
water with respect to RW3. MQ is the reading of the dosime-
ter with the reference point of the chamber positioned at the
reference depth and corrected for the influence quantities
like temperature and pressure (KTP), ionic recombination
(Ks), polarity effect (Kpol), and electrometer calibration
(Kelec). KQ,Qo is a chamber-specific factor which corrects for
differences between the reference beam quality Qo and the
actual beam quality being used Q. Since the Bragg–Gray
theory cannot be applied in our case (the secondary electron
range is around 10 lm, much smaller than the detector
volume47), it is recommended to obtain KQ,Qo from measure-
ments. The calibration laboratory has provided us with the
calibration factor in 60 Co and some correction factors KQ,Qo,
around 4%, for different x-ray beam qualities close to our
spectrum. The KQ,Qo value for the closest spectrum (140 kV,
0.5 mm Cu) is 0.9536 0.031.
II.C.3. Determination of absorbed dose under
nonreference conditions
II.C.3.a. Peak dose: assessment of the scatter
factors. To translate the absolute dose measured in the broad
beam configuration to the dose deposited with a minibeam
(peak dose), the scatter factors were used. They take into
account the different contribution from the scattered radia-
tion as a function of the field size. Due to the low energies
used and the fact that the closest collimators are around 2 m
away from the patient, the collimator scatter factor is negli-
gible29 and only the scatter radiation originated in the phan-
tom will have a contribution. Therefore, the phantom scatter
factor Sp can be assumed to be equal to the total scatter fac-
tor. Sp was determined as the ratio of the dose deposited in
the central point of the irradiated field at 2 cm-depth in water
by the minibeam and the reference field. Hence, the peak
dose at 2 cm-depth in the solid-water phantom can be deter-
mined as:
Dpeak;2 cm ¼ Dreference  Sp  farray (2)
where Dpeak,2cm refers to the dose deposited by one mini-
beam (peak dose) at 2 cm depth in water, Dreference is the
absolute dose deposited by a 2 2 cm2 field size at the same
depth, Sp is the phantom scatter factor for one minibeam and
farray is a factor that takes into account the contribution of the
tails of the minibeams to the central peak when an array is
used. Sp and farray were assessed by using MC simulations
and verified experimentally by using two different methods:
• The ratio of the dose deposited at 2 cm-depth in the RW3
phantom with a 2 2 cm2 and a 600 lm 2 cm field was
assessed by using Gafchromic films.44
• The method described in the work of Sa´nchez-Doblado et
al.48 were followed by employing the LAC described in
Sec. II C 1.
II.C.3.b. Relative dosimetry: dose distributions. The
depth dose curves were assessed by placing Gafchromic
films in the central axis of the phantom which was previ-
ously aligned with the beam axis. The lateral profiles
were evaluated by irradiating films with different field
sizes at different depths. As it has already been stated in
the introduction, different biological studies suggest that
PVDR is a very relevant dosimetric parameter in spatially
fractionated techniques.3,18 Therefore, PVDR values were
studied.
II.C.3.c. Absorbed dose in the rat head
phantom. Absolute peak dose at 1 cm-depth (middle line of
the brain) in the rat head phantom (Dpeak,1cm,rat) is obtained
from the peak dose at 2 cm-depth in the solid-water phantom
(Dpeak,2 cm), see Eq. (2), by means of a precalculated (MC)
calibration factor (fswater,rat), as expressed by the following
equation:
Dpeak; 1cm; rat ¼ Dpeak; 2 cm  fswater; rat: (3)
The dose at any other point within the rat head phantom can
be evaluated by means of the percentage depth dose curves
(PDD) and PVDR values.
III. RESULTS
In this section, absolute dosimetry (reference conditions)
performed with the protocol described in Sec. II C and the
relative dose distributions will be reported. The comparison
of the experimental data with MC simulations was used to
benchmark the calculations. Dose distributions in the rat
head phantom will also be presented.
III.A. Absolute dosimetry
A value of _Dreference¼ 67:2Gy=s=mA was obtained for an
electron beam current in the storage ring of 189.41 mA. The
range of dose rate went from 168 Gy=min for a beam current
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of 150 mA to 224 Gy=min for a beam current of 200 mA,
that is to say, one order of magnitude higher than the 6
Gy=min achievable in Rapid Arc (Ref. 49) or VMAT
machines.50
The peak dose at 2 cm-depth in water was then obtained
from Dreference by using Eq. (2). Sp was assessed by using
MC simulations (0.806 0.04) and verified with experimental
data as described in Sec. II C. A value of 0.776 0.06 was
obtained by using Gafchromic films, whereas the LAC
chamber method provided a value of 0.826 0.08. Therefore
a good agreement was achieved. The correction factor farray
amounted to 1.096 0.02.
III.B. Relative dosimetry: dose distributions
In this section, the experimental dose distributions
obtained when the slabs phantoms (both homogenous and
heterogeneous) were irradiated with a unilateral array of
minibeams were compared with MC simulations. In addi-
tion, the quality of the interlaced configuration was assessed
by using Gafchromic films.
III.B.1. Dose distributions in solid-water phantoms
The PDD and lateral dose profiles were evaluated both
experimentally and theoretically (MC) for different field
sizes (1 1, 2 2, and 3 3 cm2).
Figure 4 depicts the PDD curves for the central mini-
beam of an array covering an area of 2 2 cm2. A good
agreement between calculations and experimental data was
obtained, the global difference being lower than 2%. A
satisfactory match was also achieved for the 1 1 and
3 3 cm2 field sizes. A small buildup (around 800 lm) in
the PDD was observed and consistent with the results of
Prezado et al.29
Figure 5 shows how the MC simulations reproduce the
experimental lateral dose profile at 2 cm-depth assessed by
Gafchromic films. Systematic comparisons of theoretical
and experimental PVDR values at different depths and
several field sizes for the homogenous phantom were
performed (see Table I).
Calculations and experimental data agreed within the
error bars (corresponding to extended uncertainty, k¼ 2).
PVDR values diminished as a function of depth, rapidly in
the first centimeter and very smoothly after 2 cm-depth. A
descend of PVDR values was also observed when the field
size (number of beams) augmented, in agreement with other
works.24,51 The smaller the field sizes were, the more impor-
tant the decrease in PVDR was, since the tails of the extreme
minibeams in the array contribute more to the central valley
than in larger field sizes.
Table II shows the satisfactory match of the theoretical
and experimental data in a heterogeneous phantom for
FIG. 4. Experimental (points) and MC PDD (dashed lines) curves for the
central minibeam of an array covering an area of 2 2 cm2.
FIG. 5. Experimental (points) and MC (dashed lines) lateral dose profiles at
2 cm-depth for a field size of 2 2 cm2.
TABLE I. Experimental (Exp) and theoretical (MC) PVDR values for different field sizes as a function of depth in a homogenous solid-water phantom.
Depth (cm)
PVDR 1 1 cm2 PVDR 2 2 cm2 PVDR 3 3 cm2
MC Exp MC Exp MC Exp
0.3 23.46 0.2 21.76 2.2 14.046 0.07 15.26 1.6 10.66 0.1 11.36 1.2
0.5 20.66 0.2 17.46 1.8 12.246 0.06 12.86 1.2 9.336 0.08 9.86 1.0
1.0 17.46 0.2 17.56 1.8 10.056 0.05 9.66 1.0 7.656 0.07 8.16 0.8
2.0 15.46 0.1 16.16 1.6 8.446 0.04 9.36 1.0 6.296 0.05 6.96 0.6
4.0 14.06 0.1 15.16 1.6 7.386 0.04 8.66 0.8 5.236 0.05 5.96 0.6
6.0 13.46 0.1 12.86 1.2 6.946 0.04 7.56 0.8 4.856 0.05 5.46 0.6
8.0 12.96 0.2 12.76 1.2 6.676 0.04 6.76 0.6 4.566 0.05 5.16 0.6
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several depths. Just after the bone (at 1 cm-depth), PVDR
values fell with respect to the homogenous case. Their
decrease was more important the smaller the field size was.
This PVDR reduction in bone is due to the increase of the
fluence of photons that are Compton scattered into the valley
region. These photons have a larger probability per unit
mass of undergoing a photoelectric absorption in bone since
its average atomic number is higher. This results in a higher
local dose deposition.3 The PVDR in depth (4 cm) were
similar to the ones obtained in the homogenous one (the
absolute peak doses being different in the two cases).
The general good agreement between calculations and ex-
perimental data achieved permitted to validate the simula-
tions, which showed their performance even in the presence
of heterogeneities.
In order to study, the quality of the interlacing at the
approximately the tumor position in a rat head phantom, the
dose distributions at 1 cm-depth in the solid-water phantom
were measured with Gafchromic films. Figure 6 shows
that the dose distribution fulfills the requirements to be
considered as homogeneous: the dose in the target fitted
within 95%–107% of the prescribed dose.52
III.C. Dose distributions in a rat head phantom
Absolute peak dose at 1 cm-depth in the rat head phantom
irradiated with an array of eight minibeams covering a 1 1
cm2 field size was determined by using Eq. (3). The dose at
any other point within the rat head phantom can be evaluated
by means of the PDD and PVDR values. Figures 7 and 8
depict the PDD curves and PVDR, respectively, as a func-
tion of depth. An enhanced dose deposition in the bone can
be clearly observed in the PDD due to its higher effective
atomic number. In parallel, the PVDR falls off rapidly in the
bone as it was explained in Sec. III B 1. In the central part of
the brain the PVDR remain almost constant. The same trend
was observed in other MRT studies.3
Regarding the interlaced configuration, it was determined
that a factor 1.12 higher dose in the target was obtained with
respect to peak dose in a unidirectional array at the same
position. This value was obtained by dividing the calculated
dose deposited in the central part of the dose profiles in the
interlaced and unidirectional configurations. This factor
(1.12) should be taken into account in the dose prescriptions.
IV. CONCLUSIONS
Minibeam radiation therapy is an innovative synchrotron
radiation therapy technique with potential of application out-
side synchrotron sources. Biological studies are planned to
evaluate the therapeutic effectiveness of this new approach.
For that purpose, a reliable and reproducible dosimetry pro-
tocol is essential. In this context, a complete set of measure-
ments and MC calculations were performed on solid-water
phantoms and in a rat head phantom for the first time. The
spatial dose distributions, depth dose curves and lateral
TABLE II. Experimental (Exp) and simulated (MC) PVDR values in a heterogeneous phantom, consisting in 1 cm of bone equivalent material, 2 cm of muscle
equivalent slabs, and 2 cm of RW3.
Depth (cm)
PVDR 1 1 cm2 PVDR 2 2 cm2 PVDR 3 3 cm2
MC Exp MC Exp MC Exp
1.0 12.026 0.09 11.06 1.1 7.456 0.07 7.46 0.7 5.946 0.06 5.96 0.6
2.0 13.66 0.1 13.96 1.4 7.506 0.08 8.16 0.8 5.546 0.06 6.46 0.6
3.0 14.16 0.2 13.86 1.4 7.596 0.09 7.86 0.8 5.596 0.06 6.26 0.6
4.0 14.56 0.2 14.06 1.4 7.86 0.1 8.16 0.8 5.666 0.07 6.26 0.6
FIG. 6. Dose distribution at 1 cm-depth for an interlaced configuration
measured by using the Gafchromic films. The dose distribution fits within
the recommended limits (Ref. 52).
FIG. 7. PDD for the central minibeam in the rat head phantom. An enhance-
ment of dose deposition is observed in the bone due to its high effective
atomic number.
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profiles, were evaluated. The satisfactory agreement between
theoretical and experimental values allowed to validate the
MC simulations, that had proven their performance not only
for homogenous medium but also in presence of heterogene-
ities. This permitted to establish the first dosimetry protocol
to guide the foreseen preclinical studies with small animals.
The reproducibility and reliability of this protocol is a rele-
vant feature to perform those biological studies aiming to
assess dose-response curves for normal tissue complication
probability (NTCP) and tumor control probability (TCP),
with the goal of determining the possible therapeutic win-
dow for this new radiotherapy modality.
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CHAPTER 3
Discussion and Conclusions
Synchrotron radiation is an innovative tool in the biomedical research field and, in particular,
for the treatment of some radioresistant tumours. Within this context, two spatially frac-
tionated radiotherapy techniques have been under development at the ID17 ESRF, namely,
microbeam radiation therapy and, more recently, minibeam radiation therapy. Both tech-
niques explore the limits of the dose-volume effect by the use of submillimetre field sizes in
combination with the spatial fractionation of the dose.
Preclinical trials in MRT performed during the last two decades showed an exceptional
healthy tissue tolerance accompanied by the eradication of some highly aggressive animal
tumour models. Thus, the next step in the development of the MRT program includes the
application of this therapy to pets as a safe intermediate step before treatment of human
beings.
This thesis has been mainly devoted to the assessment of several small (micrometre-sized)
field dosimetry features involved in the preparation of forthcoming MRT clinical trials by
means of Monte Carlo calculations and experimental measurements. The main conclusions
are:
• Safe irradiation protocols have been defined for forthcoming clinical trials in MRT. MC
studies in combination with radiobiological models showed that it is possible to deliver
a relatively large dose to the tumour (peak and valley doses of 55 Gy and 2.6 Gy, respec-
tively, for a centrally located tumour) and, at same time, keep the valley dose in healthy
tissue within tolerances. The increase in the dose deposited to the tumour with respect
to conventional radiosurgery (20–25 Gy) might probably lead to an enhancement of
the patient lifespan.
• The remarkable therapeutic index in MRT can be further improved by combination
with the enhanced absorption induced by contrast agents. The choice of the element
depends on the degree of cytotoxicity (not studied in this work), on the dosimetric pa-
rameter evaluated and on the irradiation modality. However, in general, three elements
stand out with respect to the others: Au, Tl and Lu. The use of these contrast agents
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in future clinical trials would lead to a reduction in normal tissue valley doses (on av-
erage 48% less with respect to the absence of high-Z elements) for a given dose to the
tumour.
• A MC-based treatment planning system calculation engine devoted to MRT has been
developed. The first part included the complete characterisation and modelling of the
ID17 synchrotron photon beam. The beam model was successfully validated for MRT
calculations with experimental measurements both in homogeneous and heterogeneous
phantoms. The second part consisted of the adaptation and optimisation of a MC code
for dose calculation at the micron scale in a CT voxelised model of the patient in a
reasonable amount of time (less than one day). Its performance has been proved with
a typical MRT clinical example. The development of this MC computation engine con-
stitutes a key tool for future MRT clinical trials in pets.
• For the first time, scatter factors for the MRT clinical trials settings were accurately and
systematically assessed. This important and challenging step would enable the absolute
dose measured in reference conditions to be converted to peak doses in MRT.
A new promising radiotherapy approach is being explored at the ESRF: MBRT. The larger
field sizes and associated c-t-c distances involved in this technique overcome the inherent
limitations of the clinical implementation of MRT, which nowadays can be only carried out in
synchrotrons. However, the different irradiation parameters can lead to dissimilar biological
effects with respect to MRT. In order to assess the therapeutic index of this new modality, in
vivo experiments are being planned at the ESRF.
Therefore, several dosimetric features were also evaluated in order to establish a MBRT
dosimetry protocol to guide the foreseen preclinical studies and to evaluate reproducibility in
terms of dose. The protocol includes the determination of the absorbed dose under reference
conditions, the assessment of the scatter factors and the final experimental verification of the
MC calculations.
The objectives achieved within the framework of this thesis have provided the dosimetric
tools for forthcoming MRT clinical trials in pets and MBRT preclinical trials in small animals.
Future perspectives
Future work could include the final integration of the MRT calculation engine into a user-
friendly graphical front-end. Some attempts have already been done in order to link the
132
programs developed during this PhD with the graphical front-end platform named VIR-
TUOS [Bendl 1993]. The commissioning of the whole system should be performed as well
[IAEA-TECDOC-1540 2007].
The methodology developed in this work allows the MRT TPS calculation engine to be
easily adapted with little or no programming to other MRT synchrotron sources, to be used
for dose calculation in presence of contrast agents or for MBRT.
Improvements in the accuracy of MC calculations would need to consider the inclusion
of the effects induced by the fine structure of biological tissues, which seems to have a non-
negligible effect [Felici 2005b, Felici 2007].
However, the most challenging work continues to be further development of dose detec-
tion systems and improvement of radiobiology knowledge. A more accurate measurement
(better than 3%) of the dosimetric magnitudes in MRT would enable complete dose charac-
terisation. Thus, intensive research is being carried out to find a detector with high spatial
resolution able to cope with the high dose rates and high doses used in MRT.
Additionally, a prerequisite to plan a radiotherapy session is to know the susceptibility to
radiation damage of the various kinds of normal cells. Due to the very distinct irradiation
features of MRT and MBRT with respect to conventional methods, there is no specific data on
healthy tissue tolerances and on radiobiological models for these kinds of techniques. Further
knowledge on these topics would allow an accurate assessment of the therapeutic index of
these innovative methods to be performed. These models could be implemented in the TPS
to perform a biological optimisation of the irradiations.
If the MRT clinical trials were successful (first in animals and then in humans), MRT could
be a good alternative in pediatric neurooncology [Dilmanian 1997, Laissue 2007], where
other kinds of treatments are unsafe and can cause unacceptable risks of long-term neuro-
logical disability [Rilliet 2000, Mueller 2009]. Additionally, other possible applications of
MRT are being explored; for instance, in the treatment of brain disorders [Anschel 2011,
Romanelli 2011] or vascular malformations [Dilmanian 2003a].
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